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SUMMARY
The aim of this research was to establish whether or 
not mouse interferon could reverse the phenotype of transformed 
cells so that they behaved in a more normal manner.
For this study, clonal isolates of transformed cells 
from two continuous cell lines and fibroblasts extracted 
from mouse embryos were used.
It was found that interferon could inhibit the growth
of both normal and transformed cells. With several transformed/clones interferon also reduced their saturation densities, 
which were normally several fold higher than those of the 
non-transformed parents. This suggested that interferon had 
induced a partial reversion to density-dependent growth control. 
Butyric acid also inhibited growth rate and acted additively 
with interferon when cells were treated with the two agents 
together.
Interferon had a variable effect on the ability of 
dispersed cells to form colonies on plastic substrate in 
liquid media, but had a consistently greater effect on the 
ability of transformed cells to form foci on a monolayer of 
normal cells, and to grow suspended in agar, two growth 
conditions specific to the transformed state. It was concluded 
that interferon had inhibited focus formation and growth in 
agar by a combination of its growth inhibitory activity and 
an effect specific for the transformed phenotype.
Interferon also affected the morphology of both normal 
and transformed cells. The cells became more spread-out, and 
in transformed cells there was a partial restoration of the 
microfilament bundle system. Despite these effects on the 
cytoskeleton, the extracellular matrix of fibronectin fibrils 
appeared to be little altered by interferon, except when 
added in conjunction with butyric acid. Under these 
circumstances, the fibronectin matrix became much more 
extensive.
These data increase the likelihood that interferon's 
in vivo antitumour activity involved a direct effect on the 
tumour cells themselves, such that these cells behave more 
normally.
1INTRODUCTION
In the Western World cancer is a major disease. For 
a number of years research has been conducted in order to 
understand the mechanisms of tumour formation, to learn 
how to detect and prevent the processes which lead to a 
tumour, and to find methods to cure patients in which 
tumours have already grown.
At present a number of cancers can be treated 
successfully by a range of techniques employing combinations 
of chemotherapy, radiotherapy and surgery, though such 
treatments can be toxic to the patient.
Interferon was originally identified as an antiviral 
agent, but in recent years has been shown to possess 
considerable potential for the treatment of a range of 
tumours, possibly with minimal side-effects. Experiments 
with animals, mainly mice, found that it could prevent the 
growth of transplanted tumours and has also caused some 
well-developed tumours to regress. Trials with people, 
however, have barely begun, having been used only in a 
few isolated cases, using small numbers of patients.
Full-scale clinical trials are now being planned
both in Europe and the U.S.A., but one of the major 
problems facing these trials is how to secure a sufficient 
supply of interferon. The past eighteen months have seen
A
some dramatic advances towards improving the supply, which, 
coupled with the planned trials and treatment of two 
young patients in Glasgow, has resulted in considerable 
publicity in the media .
To date almost all the interferon used in tests on 
people has been produced in batch processes by induction 
of leucocytes or lymphoblastoid cells grown in suspension. 
Such techniques are time-consuming, expensive and generate 
relatively small amounts of interferon. Genetic manipulation 
of human interferon genes into bacteria has resulted in 
isolation of clones which constitutively produce quite 
large amounts of interferon. This material has yet to be 
fully characterised and it is not known if it will be 
effective in humans. If it is found to be active it should 
then become possible to continuously produce vast 
quantities on a large industrial scale, thus overcoming 
the problems of costs and supply for clinical application.
These developments have placed interferon firmly in 
the vanguard of the 'revolution' in biotechnology and, if 
successful, may point the way towards enabling large-scale 
production of other biological agents for important medical, 
agricultural and environmental applications.
Before interferon can be successfully employed as an 
anti-cancer agent it is important to establish the 
parameters within which it will be effective, such as
5dosage, duration of treatment, mode of action, specificity 
for tumours and what might result from effects on growth 
and behaviour of normal tissues. Some of these can only 
be established through the clinical trials, but others, 
such as mode of action and effects on normal tissues can 
be studied in the laboratory. This thesis was initiated, 
as part of a programme in this laboratory, to study the 
ways in which interferon affects the transformed phenotype, 
and establish whether interferon can actually revert the 
transformed phenotype towards a more normal behaviour.
The following introduction is divided into two parts . 
The first discusses how the application of tissue culture 
has advanced our understanding of neoplasia over the past 
few years, and how in vitro transformation can be correlated 
with in vivo malignancy. The second part introduces 
interferon and surveys our present knowledge of its anti­
cellular and antitumour actions.
_PART I
TRANSFORMATION - AN IN VITRO MODEL FOR MALIGNANCY
4
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Section A Tissue Culture in the Study of Malignancy
The study of a range of tumour explants and normal 
cells which have been transformed in vitro has significantly 
advanced our understanding of the controls placed upon the 
growth of normal cells and of the process whereby cells 
free themselves from these controls to become tumourigenic 
(4, 128, 189, 197, 204) . However, tissue culture does have 
a number of limitations that stem from the way in which 
cells of different species and different tissue origin 
behave in widely differing fashions. This leads one to 
question how closely the properties of cells in culture 
reflect those prevalent in vivo. This problem of how 
relevant in vitro studies are to in vivo malignancy will be 
considered later. This section will discuss the basic 
properties and behaviour of different cell types grown in 
vitro. with a view to establishing which criteria need to be 
considered when selecting a cell system to study in vitro 
transformation.
1. Establishment of Cells in Vitro
The most direct way to study tumourigenic cells in 
vitro is to explant human or animal tumours and establish 
these in tissue culture. Usually they grow poorly, and
their use suffers from a number of disadvantages which are 
at least partly due to most tumours being a heterogeneous 
collection of different cell types (204) . One particular 
cell type may grow more vigorously than any of the others, 
and thereby come to dominate the culture, making it un­
representative of the original tumour (ref 204 p403), and 
indeed may not even be the malignant cell type. Moreover, 
rodent cells, for reasons discussed below, when in vitro 
often spontaneously undergo changes which may greatly alter 
their characteristics (ref 204 p403) . Finally, in a 
heterogeneous tumour it may be impossible to determine from 
which cell type the tumour originated and so there can be 
no normal cell type with whose behaviour it can be compared.
A more closely controlled experimental system can be 
established ¿n vitro by explanting normal adult or 
embryonic tissues and then transforming these. The trans­
formation process yields transformed cells whose properties 
can be directly compared with the normal parental line.
Apart from being diploid normal fibroblasts when 
explanted possess a number of characteristic behavioural 
properties;
1. they show contact inhibition of movement, i.e. migration 
of a cell in one particular direction is halted when contact 
is made with another cell, but movement in other directions 
is unhindered (3, 4).
2. their growth shows density dependent inhibition, i.e. 
when a confluent monolayer of cells is formed further
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growth is arrested (158, 241, ref 115 p451) .
3. their growth is anchorage dependent, i .e. they can 
only grow when attached to a solid substrate, not in 
suspension (242, ref 115 p452-3) .
These properties will be discussed in greater detail 
later.
Cells of human and avian origin retain these properties 
for between ten and over 100 cell doublings, after which 
time the cultures die out (ref 204 p402). Such cells are 
said to be stable, and possess finite growth potential (204) .
Cell cultures of rodent origin, however, frequently 
produce cultures which are aneuploid and have acquired 
infinite growth potential (ref 204, pp 402 & 409) - they 
will grow in culture forever. These cells are said to be 
of unstable species origin (204). The resultant aneuploid 
cultures invariably eventually transform spontaneously, 
and become tumourigenic in vivo (ref 204, pp402 & 408). 
However, it is possible to isolate by careful culture 
techniques lines which retain the phenotype of normal cells, 
even though they are aneuploid.
In this way the established 'normal' cell lines have 
been developed, such as the mouse 3T3's (2, ref 204 p409) 
and C3H 10T*5 (210) and the baby hamster kidney (BHK) cells 
(240) . These too tend to undergo spontaneous transformation 
after prolonged passage in culture (1, 204) .
72 . In Vitro Transformation
Ponten has defined transformation as the acquisition/
of permanent disturbance of growth and/or locomotion 
control (204) . Thus, transformed cells tend to lose 
density-dependent growth (241, ref 115 p451, ref 204 pp 406 
& 409), contact inhibition of movement (3, 4, ref 204 
pp405-6) and anchorage dependence (242, ref 115 pp 452-3) . 
The final and most fundamental criterion for tranformation, 
however, is tumourigenicity in vivo. The correlation 
between in vitro transformation and iji vivo tumourigenicity 
is not total, a problem that will be discussed later.
3 . Agents used for Transformation
Agents which have been used for in vitro transformation 
are all known to cause tumours in vivo. They fall into 
three main categories;
1) Ultraviolet or X-ray irradiation (50, ref 204 p410) ,
2) Chemicals such as polycyclic aromatic hydrocarbons, 
alkylating agents and nitrosamides (62, 117) .
3) Oncogenic viruses, such as the DNA viruses SV40 and 
polyoma, plus the RNA tumour viruses, or retroviruses 
(115, 204) .
Chemical and radiation-induced transformation probably 
occurs by mutagenesis . In vivo many carcinogenic chemicals 
must be activated by oxidases . When activated such 
chemicals bind quite strongly to DNA and RNA (62, 117) in
target cells, and it is possible to detect chromosome 
alterations a few cell doublings after treatment (20, 21, 181).
Onset of transformation, however, can vary from just 
a few up to 80 or more cell doublings following treatment. 
Rodent cell lines have proved to be the easiest to transform 
by chemicals and radiation, but only quite recently has it 
been possible to transform human cells (140, 148, 211) .
It has been suggested that resistance to chemical 
and radiation-induced tranformation by human cells may be 
due to a highly efficient DNA-repair mechanism (62).
Oncogenic viruses transform cells by introducing new 
genes into the cellular genome which code for transformation. 
The whole process of infection and transformation is quite 
rapid and c.an be completed within a few cell doublings 
(204). Retroviruses will readily transform murine and avian 
cells, but not human, for which SV40 is the usual trans­
forming agent (251-3) . Maintenance of the transformed 
phenotype requires the constant presence of the product(s) 
of the transforming gene. Studies with mutants of Avian 
Sarcoma Virus (ASV) and Kirsten Murine Sarcoma Virus (KiSV) 
temperature sensitive for transformation have found that 
transformed cells rapidly revert to normal upon shift from 
the permissive to the non-permissive temperature (228, 232, 
ref 115 p423) , thus suggesting rapid inactivation of the 
transforming gene's product(s).
The possibility that carcinogenic chemicals may transform
9cells by activating endogenous oncornaviruses has been 
discounted since no viral synthesis can be detected in 
chemically transformed cells, whilst agents which do 
activate endogenous viruses, such as iododeoxyuridine (IUdR), 
do not transform cells (117) .
The tendency for an established cell line to continue 
through a series of changes, progressing towards a more 
transformed state, from which clones of spontaneous trans­
formants can frequently be isolated (204), creates problems 
when comparing the behaviour of transformed clones with 
the 'normal' parental line, since the 'normal' line may 
itself be progressively becoming more transformed.
The use of cells of stable species (i.e. human and 
avian) may overcome these problems since their behaviour 
remains constant throughout and a culture of normal cells 
is more likely to be representative of its in vivo 
ancestors.
The study of human cancer should ideally use human cells 
in vitro, but, as already described, transformation of 
human cells by chemical carcinogens and radiation has only 
recently been achieved. Transformation of human cells by 
retroviruses is also difficult, and the only really successful 
agent routinely used is SV40 (234, ref 253 pp360-l). The 
ease with which avian and rodent cells transform with 
retroviruses has made these cells the choice system for many 
studies despite the problems of instability.
It could be argued that the study of viral transform­
ation is irrelevant to human cancer since no human tumour, 
with the exception of papillomas, has yet been found to 
be virus-induced. This argument is strengthened by three 
points:-
a) The initial stages of transformation by chemicals (the 
main human carcinogens) are different from those with 
oncogenic viruses,
b) The latent period before transformation by oncogenic 
viruses is complete is only a few days, but can be up to 
several weeks for chemicals (20, 21, 53, 140, 181, 211),
c) Some human tumour explants may still show some normal 
growth and movement control which is only lost when the 
cells are infected and transformed by oncogenic viruses
(ref 204 p411) ./
On the other hand, many naturally occurring animal 
tumours are caused by endogenous and exogenous retroviruses, 
and explants of animal tumours behave in a manner very 
similar to cells transformed by viruses in vitro (204) . 
Furthermore, though there have been considerably fewer studies 
of the transformed phenotype resulting from chemically- and 
radiation-induced transformation, the resulting phenotype 
seems to be quite similar to that of the virally transformed 
cells, suggesting that whatever the mechanisms of transform­
ation may be, the end result in terms of phenotype is 
essentially the same (20, 21, 50, 53, 62) .
■> w* '
Thus, in studies where only the behaviour of transformed 
cells is being studied, not the mechanisms whereby trans­
formation occurred, choice of transforming agent may not 
be so crucial. The next section describes the transformed 
phenotype using data drawn mainly from studies of viral 
transformation, though some data obtained from chemically 
transformed cells are also included.
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Section B The Transformed Phenotype
Upon transformation, either spontaneous or induced, 
cells acquire a number of characteristics which usually 
reflect the generally decreased control of growth and 
movement, such as loss of contact inhibition of movement, 
loss of density dependent growth control and loss of anchorage 
dependence.
Contact Inhibition
Contact inhibition was first described by Abercrombie 
and Heaysman (3) . As defined earlier, it is the property 
by which a normal cell tends to stop moving in a particular 
direction if it comes into contact with another cell, but 
is able to move away in other directions. This leads to 
confluent cultures becoming highly ordered with elongated 
cells running parallel to each other and forming complex 
whorls and fan-shaped patterns (ref 204 p405). In confluent
12
fibroblast cultures, at least, cell movement does not 
stop necessarily, but a continuous cell streaming occurs 
(204) .
Transformed cultures rarely show much order. Usually 
the cells grow in a random criss-crossed fashion, with cells 
piling up on top of each other.
It has been possible to quantitate contact inhibition, 
and generally it is found that transformed and tumour cells 
have greatly reduced contact inhibition, which may account 
for the disorder in transformed cultures (4) . Bell (22) , 
however, concluded that the criss-crossed pattern he 
observed with a culture of polyoma-transformed 3T3 cells was 
due to the random extension of pseudopodial arms from the 
cells, not loss of contact inhibition. However, it is 
probably partly loss of contact inhibition that enables 
transformed cells to grow and move on top of a monolayer of 
normal cells. This has enabled identification and selection 
of newly transformed clones from such foci growing amidst 
a background of normal cells (ref 115 pp418-420) . Efficiency 
with which dispersed transformed cells are able to grow to 
form foci on a normal monolayer is a simple quantitative 
assay for loss of contact inhibition and density independent 
growth.
Density Dependent Inhibition of Growth
Sparse cultures of normal cells grow at a rate only a
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little below that of transformed cells, but when a confluent 
monolayer of cells forms growth often abruptly ceases or 
slows greatly (158, 197, ref 115 p451, ref 204 pp406 & 409) . 
Transformed cells, on the other hand continue to grow 
rapidly until their density is 10 to 20 times greater than 
normal cells, forming cultures which may be several cell 
layers thick, even in the presence of only very low levels 
of serum (197, ref 204 pp409-410, ref 115 p451) .
It was at one time thought that contact inhibition 
prevented growth of normal confluent cultures (158, 159,
241, ref 115 p451); contact with cells on all sides inhibited 
a cell's further growth. However, many nontransformed cell 
lines may actually grow to quite high density if the supply 
of serum or growth factors is increased (ref 115 p451) . In 
such dense cultures of normal cells, unlike transformed 
cultures, the orderly arrangement, which is attributed to 
contact inhibition, is retained. Stoker and Rubin (241) 
proposed the term 'density dependent inhibition' to describe 
this growth control phenomenon, which may be somehow linked 
to the supply of serum growth factors (ref 115 p451) .
Folkman and Greenspan (72) proposed that cell shape may be 
important in determining a normal cell's ability to grow.
This was supported by Folkman and Moscona (73) who coated 
plastic Petri dishes with a nontoxic substance called poly 
(2-hydroxyethylmethacrylate) (poly(HEMA) ) at a range of 
concentrations. This had the effect of varying the adhesivity
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of the plastic so that on dishes bearing no poly(HEMA) 
normal cells spread well, whereas with increasing concen­
trations of poly(HEMA) cells became progressively more round. 
They found that the rate of DNA synthesis in any sparse 
culture was inversely proportional to the vertical thickness 
of each cell. In confluent cultures growing on untreated 
plastic the cells became more rounded, presumably due to 
cell crowding, and DNA synthesis slowed considerably, to a 
level very similar to sparse cells which were rounded by 
poly(HEMA) treatment.
SV40-transformed 3T3 cells grew equally rapidly on all 
treated and untreated plates, showing that their growth rate 
was not regulated with cell shape.
Folkman and Moscona suggested that sensitivity to serum 
growth factors in normal cells is controlled in some way by 
cell shape, possibly due to changes in surface area, so 
that flat cells are able to respond to serum and so grow, 
whereas rounded cells do not grow because they are less 
sensitive. Increasing the serum concentration should at 
least partially overcome this and allow the cells to grow. 
Cell shape and sensitivity to serum may be uncoupled by 
transformation and thus allow transformed cells to grow to 
very high densities regardless of morphology and serum 
concentration.
Anchorage Dependence
Stoker et al^ . (242) first applied the term 'anchorage
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dependence' to describe the property of rton-transformed cells 
whereby they are obliged to attach to a solid support in 
order to grow, unlike transformed cells which are able to 
grow freely in suspension. Macpherson and Montagnier (173) 
developed a method to grow single transformed cells into 
colonies suspended in semi-solid agar. This technique has 
proved very useful for isolation of transformed clones from 
a background of normal cells, and for quantitation of the 
degree of anchorage independence possessed by different 
transformed clones.
How cells lose anchorage dependence is not known but 
it may be explained by the coupling of cell shape to growth 
control, outlined above. Cells in suspension are spherical 
and therefore under the theory put forward by Folkman and 
Greenspan (72) normal cells will be unable to grow, possibly 
due to insensitivity to serum growth factors. Transformed 
cells will grow due to uncoupling of cell shape from growth 
control. A role of cell shape in growth control is supported 
by the observations that normal cells will grow suspended 
in agar if glass beads large enough for the cells to attach 
and flatten out are included in the agar. Silica particles 
to which the cells can anchor but are too small for them 
to spread out will not support their growth (72). This 
would suggest that anchorage per se is not sufficient for 
cell growth, rather that cell flattening may be.
Clearly these three basic features of normal cell
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behaviour are profoundly changed by transformation. These 
changes involve cell-cell communication, cell morphology 
and nutrient requirements, all of which are closely related 
to cell surface phenomena. It is not surprising, therefore, 
that many of the biochemical changes so far identified in 
transformed cells involve, either directly or indirectly, 
the cell surface. It is still not clear, however, which 
changes may be primary lesions causing the transformed 
phenotype and which are secondary changes occurring as a 
result of transformation.
The changes so far identified include rounded cellular 
morphology and partial dissolution of the cytoskeleton 
(197, 203, ref 115 pp444-447) , altered plasma membrane lipids 
and glycolipids (ref 189 pp5-6, ref 115 pp436-9), decreased 
cell surface fibronectin (259, 274, ref 128 pp78-82, ref 
189 pp7-8), collagen (ref 128 p85) and glycosaminoglycans 
(263, ref 189 p5), new cell surface antigens (150,ref 189 
pp34-43), increased cell agglutinability (ref 115 p443, 
ref 189 ppl9-34), increased uptake of certain amino acids 
(188, ref 189 pl4) and sugars (ref 115 pp441-3, ref 189 pl4), 
secretion of proteases (ref 115 p439) and other proteins 
(88, 226) and reduced levels of cyclic AMP (197, ref 115 
p447) .
Very few transformed clones possess all these character­
istics; usually only a few are expressed. Some properties 
may not be expressed immediately following transformation
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but may manifest themselves some time later, vivo
tumourigenicity is the ultimate test of a transformed 
clone. No single phenotypic marker for transformation 
correlates completely with iji vivo tumourigenicity, but 
some, such as growth in agar, are better indicators than 
others (75, 139) . This will be discussed in detail later.
Normal cells under certain conditions can actually be 
made to temporarily mimic the transformed state. For 
instance,cells in mitosis or when mildly treated with protease 
are rounded, have lost the microfilament system and cell 
surface fibronectin, and are more agglutinable (ref 189 pl2).
Morphology and Cytoskeleton
Normal fibroblasts usually have a well-spread flattened 
morphology and are firmly adherent to the substratum. Cell 
shape, adhesion and motility are largely controlled by the 
cytoskeleton (39, 149, 156), which consists of microtubules, 
intermediate filaments and microfilaments.
Microtubules, consisting principally of tubulin, and 
intermediate filaments, consisting of desmin, form two 
separate lattices throughout the cytoplasm (130, 193, 266,
267). Microfilaments, containing mainly actin, exist in 
two arrangements (149):
a) as single filaments dispersed throughout the cytoplasm, 
in the perinuclear region and associated with the leading 
ruffling edge of moving cells, and b) in well-spread cells,
as bundles (sometimes called stress fibres) running in 
straight parallel arrays along the lower surface of the 
plasma membrane ( 87, 155, 156, 203).
Upon transformation the cells usually become smaller, 
rounded and less adherent to the substrate. Some observations 
have suggested that the microtubule system may break down 
upon transformation (37, ref 115 pp444-7), but in the 
majority of cases at least, it now seems that the micro­
tubules remain intact (60, 192). Similarly, the intermediate 
filaments remain essentially unchanged (130) . The micro­
filaments, however, particularly the stress fibres in most 
transformed lines are either lost or at least greatly 
reduced . The total amount of cellular actin may or may not 
be reduced (70, 215, ref 128 p88), but is probably present 
in the cytoplasm in the monomeric form instead of the poly­
merised state (ref 128 p88) .
Loss of the stress fibres probably at least partially 
explains the rounded morphology and weaker adhesion (ref 
128 pl22) .
Cell Surface Components
Alterations in synthesis of various plasma membrane 
lipids, glycolipids, glycosaminoglycans and phospholipids 
have been reported but much of the data are conflicting 
and few generalisations can be drawn (115, 189, 262).
Some experimental evidence has suggested that the
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fluidity of the plasma membrane is increased after 
transformation, but the weight of evidence which has 
accumulated against this possibility now makes it seem 
unlikely (ref 115 p444) .
Normal cells secrete onto their outer surfaces a 
matrix which aids adhesion to the substrate (259, ref 128 
p70) . This matrix, or glycocalyx, is known to consist of 
at least three principal components; fibronectin, collagen 
and glycosaminoglycans (259), and seems to be involved in 
adhesion of cells to the substrate.
In transformed cells this glycocalyx is greatly reduced. 
The glycosaminoglycans are still produced and secreted in 
large quantities but they are not retained on the cell 
surface (ref 259 pl6) . Synthesis of collagen and fibronectin 
is reduced, and in addition, fibronectin which is synthesised 
and secreted is not retained on the cell surface as efficiently 
as on normal cells (191, ref 259 pl4 & 17).
Fibronectin, LETS (Large External Transformation- 
Sensitive protein) or CSP (Cell Surface Protein) as it may 
be known (amongst other titles), is a large glycoprotein 
with subunit molecular weight of 2.2 to 2.5 x 10^ daltons 
(259, 274, 275, 278).
Primary explants of both epithelial and fibroblastic 
cells synthesise and secrete onto their surfaces large 
amounts of fibronectin while established cell lines produce 
much lower amounts and transformed cells may have little,
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if any, fibronectin. Its absence was thought to correlate 
very closely with in vivo tumourigenicity (259, 274), but 
several tumourigenic transformed lines have recently been 
found to possess levels of fibronectin similar to the 
parental non-transformed line (274) .
Antisera raised to fibronectin of one species cross- 
reacts with fibronectin of a range of species, suggesting 
a conserved structure (2 79, 286) . Immunofluorescence using 
such antisera reveals several different patterns on cells 
of primary expiants (177, 274) . Confluent cultures possess 
a complex intercellular filamentous matrix running across 
the upper surfaces of the cells . Subconfluent cultures 
show mainly 'stitches' of fibronectin between adjacent cells, 
with very little matrix running across the cells. Extraction 
with NP40 allows the antisera to stain fibronectin beneath 
the cells which forms a filamentous network across each 
cell, with some intercellular connections (131, 177).
Addition of fibronectin to cultures of transformed 
cells often results in their adopting a more normal phenotype- 
flattened, more orderly alignment and containing micro­
filament bundles (6, 274, 277), and also increased cell 
motility (7) . Again, fibronectin from one species is 
active in a range of other species of cells (6, 277). There 
is no effect, however, on growth rate, saturation density 
or nutrient transport (6, 274, 277) .
Other data suggest considerable links between fibronectin
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and microfilaments. In normal cells immunofluorescent 
staining patterns for actin and fibronectin reveal con­
tiguous fibres with microfilaments inside the cells and 
fibronectin outside (131), treatment with proteases or 
cytochalasin B disaggregates both microfilaments and fibro­
nectin fibres, and mitotic cells too lack both structures 
(128, 189, 259) .
For interactions between the microfilaments and fibro­
nectin fibres to occur there must be a third component in 
the plasma membrane since neither actin nor fibronectin have 
yet been identified as intramembranous proteins . Evidence 
for such a component is increasing, though its identity is 
still a mystery (128, 131, 230) . Thus it seems probable that 
microfilaments and fibronectin together play a major role 
in facilitating cellular adhesion and controlling cell 
morphology, but apparently having little effect on control 
of growth.
Disruption of this microfilament-fibronectin complex 
in transformation would clearly result in considerable 
changes in cellular behaviour.
Increased Agglutinabilitv
Transformation is usually associated with increased 
agglutinability of suspended cells by lectins such as con- 
conavalin A (con A) and wheat germ agglutinin (WGA) (51,
195, ref 115 p443, ref 189 ppl8-34) . Normal cells during
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mitosis or when subjected to mild protease treatment mimic 
this increased agglutinability (ref 115 p443, ref 189 p24).
Transformed cells do not bind more lectin, rather cross- 
linking of bound lectin molecules with each other on the 
same and adjacent cells is somehow facilitated (51, 195, 
ref 189 p22). This facilitation is probably achieved by 
improved mobility of lectin-bound receptors within the plasma 
membrane. Control of mobility of surface receptors is thought 
to be by a structure called the Surface Modulating Assembly, 
consisting of microtubules, microfilaments and possibly 
fibronectin (65, 276, ref 128 pp95-99, ref 189 pp26, 29-31). 
Partial disruption of the SMA by transformation through loss 
of microfilaments and fibronectin would free the receptors 
from limitations on their mobility. No direct experimehts 
have proved the existence of the SMA, but experiments with 
drugs which disaggregate microtubules and microfilaments 
resulting in increased agglutinability argue strongly in its 
favour (65, 66, 178, 179, ref 189 p30).
A number of reports have shown that raised agglutin­
ability with con A, but not WGA, correlated quite well with 
in vivo tumourigenicity (ref 189 p22) . Recently a 100000 
dalton cell surface glycoprotein was found to bind proportion­
ally more con A, but less WGA, following transformation than 
before (273) . A range of transformed cells which showed 
this alteration were also tumourigenic in vivo, whereas those 
without it were not. WGA is toxic for transformed cells and
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so was used for selecting normal revertants . Such revertants 
showed decreased con A binding to this 100K glycoprotein, 
as well as being non-tumourigenic (273).
Induction of Cell Surface Antigens
Both chemically transformed cells and some human tumour 
cells express on their surfaces common embryonic antigens 
and tumour-specific transplantation antigens which vary with 
cell type and carcinogen (ref 115 p440, ref 189 pp34-36).
Retrovirus-transformed cells also express cell surface' 
antigens (CSA) which appear to be mainly virus-coded, 
consisting of, or at least associated with, precursor poly­
proteins of the gag and env structural genes (150, 235).
These CSA's of course make such cells antigenically 
distinguishable from normal cells and will thus elicit an 
immune response iji vivo which will limit the spread of 
tumours caused by these cells (150) .
Increased Nutrient Uptake
The uptake of glucose and its nonmetabolisable analogues 
2-deoxyglucose and 3-0-methylglucose as well as mannose, 
galactose and glucosamine are all stimulated following 
transformation, whereas the uptake of other carbohydrates 
is unaffected (ref 115 p442, ref 189 pl4). Similarly the 
amino acids glutamine, arginine glutamic acid and alpha 
aminoisobutyric acid are reported to be transported more
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readily (ref 189 pl4), though a recent report by Nakamura 
and Weber (188) found no differences in amino acid uptake 
between normal and chick embryo fibroblasts transformed by 
Rous Sarcoma Virus (RSV) unless they were starved of amino 
acids first.
The reduced requirement for serum by transformed cells 
may be attributable to increased uptake of nutrients from 
the medium, or perhaps to increased sensitivity to growth 
factors in the serum.
Secretion
Transformed cells and tumours both in vivo and in vitro 
secrete proteases which, it has been proposed, may be 
partly responsible for the transformed phenotype, for instance 
by cleaving away cell surface fibronectin (ref 115 p439, 
ref 128 pp91-92, ref 259 pll) .
One such protease is plasminogen activator which 
converts plasminogen (normally found in the serum in culture 
media) to plasmin, to which fibronectin is very sensitive 
(ref 128 p91). This may be one cause of the loss of 
fibronectin from cell surfaces, but the evidence so far 
suggests that it is at best only a minor cause (ref 128 pp91-92)
Senger et al^ . (226) have recently identified two classes 
of transformation-specific proteins, both with molecular 
weights of about 60000 daltons, and one of which is phosphory- 
lated. These proteins are secreted from cells of several
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different mammalian species transformed by a range of type 
C viruses. However, it is still not clear just how 
general these proteins are throughout the whole range of 
transformed and tumour cells, nor is their role in trans­
formation understood .
Cyclic AMP
Cyclic adenosine-3',5'-monophosphate (cAMP) has been 
implicated many times in the control of the growth of cells 
(197, ref 115 p447) . Several normal cell types, e .g.
Swiss 3T3 and NRK, when growing rapidly have quite low 
levels of cAMP, but as confluence is reached the amount 
present rises by about two fold or more (197) . In trans­
formants of these cells cAMP levels always remain low (197) . 
There are, however, several normal cell lines which do not 
show this fluctuation, such as BALB/c 3T3 and chick embryo 
fibroblasts (197), so the significance of cAMP is 
questionable.
The best evidence for a role of cAMP in control of 
cell behaviour comes from experiments on the effects of 
treatment of transformed cells with cAMP or dibutyryl cAMP. 
Transformed cells treated with dibutyryl oAMP became flatter, 
more adherent and arranged in orderly parallel arrays, 
cytoskeleton is restored, growth is slower and the cells 
are less agglutinable (197, 205, ref 115 p448). This effect 
can be potentiated by pretreatment with testosterone (205).
The physiological significance of results obtained 
with dibutyryl cAMP is in doubt since butyric acid has 
similar effects on morphology (8, 83, 85, 171, 271), though 
Storrie et al. (243) found that the effects were not 
identical. Butyric acid-treated transformed cells become 
flatter, have a restored cytoskeleton, raised intracellular 
cAMP levels and grow more slowly (as do normal cells in the 
presence of butyric acid) , but density dependent growth 
control is not restored (8) . Altenberg et al_. (8) found 
that butyric acid did not restore adherens junctions 
between cells, a type of junction which is common between 
normal cells . They proposed that this may be why growth 
control was not restored.
Corrélation of In Vitro Transformation with In Vivo 
Malignancy
Many of the observations regarding behaviour of 
transformed cells often apply well to cells of naturally 
occurring tumours explanted into tissue culture. They are 
small, rounded, generally lack a microfilament system and 
cell surface fibronectin, grow in agar, grow to high 
densities on a plastic substrate and are highly agglutinable. 
Thus it would seem that the in vitro transformed phenotype 
is a realistic equivalent to in vivo tumours. It is probable 
that certain of the i_n vitro properties correspond with 
specific in vivo features of tumours. Thus, loss of contact
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inhibition of movement in vitro may correspond to invasive­
ness ^n vivo (4, ref 204 pp405-6), loss of density 
dependent growth control to uncontrolled irregular growth 
in vivo (ref 189 p22, ref 204 p410) and anchorage independence 
to ability to metastasise (50).
Similarly the expression of a number of in vitro 
phenotypic characteristics of transformed cells have been 
shown to correspond quite well with their ability to form 
tumours in vivo. Such characteristics include growth in 
agar (50, 75, 139), loss of cell surface fibronectin (274), 
growth to high saturation densities (1, ref 189 p22, ref 
204 p410) and raised agglutinability by con A (272, 273, 
ref 189 p22). None of these correlates fully with in vivo 
tumourigenicity (23, 44, 137), but the combination of the 
four is generally sufficient to identify a tumourigenic clone.
Growth in agar is probably the most widely used method, 
reportedly correlating very closely with in vivo tumourigen­
icity (50, 53, 75, 139, 229). Loss of cell surface fibronectin 
was thought to correlate completely with in vivo tumourigen­
icity, but a number of exceptions have been discovered 
(274) . It is now thought to correlate more closely with 
the ability to metastasise in vivo or in vitro growth in 
agar (274) . Growth to high saturation density was probably 
one of the first phenotypes to be equated with in vivo 
tumourigenicity (ref 189 p22, ref 204 p410) . Many 
exceptions have been found (ref 204 p410). though it is still 
useful as a rough guide.
Con A agglutinability generally parallels loss of 
growth control (ref 189 p22), so its consequent correlation 
with tumourigenicity is not surprising. This may also 
relate to the 100000 dalton marker for malignancy mentioned 
earlier (273) . Agglutination by other lectins, such as 
soybean and wheat germ agglutinins, does not correlate 
with tumourigenicity.
In Vivo Tumourigenicity
The ultimate test to equate .in vitro transformation 
with in vivo carcinogenesis is to inoculate animals with 
transformed cells and watch for the growth of tumours.
The need for histocompatibility of cells and hosts 
restricts iji vitro work to use of cells explanted from 
inbred mice. Transformed cells can then be inoculated into 
syngeneic hosts . This limitation has been partly overcome 
by the introduction of nude mice which are athymic and so 
are unable to mount T cell-mediated immunity (196, ref 204 
p413) . These mice are able to take allogeneic grafts, 
including those from other species (207) . However, these 
mice can mount humoral immunity and Natural Killer (NK) cell 
activity which could destroy allogeneic grafts.
Due to the lack of T lymphocytes these mice are very 
susceptible to infections which may prove lethal, and so 
are very difficult to handle. It is at least partly for 
this reason that the majority of studies are still conducted 
using inbred syngeneic cells and animals.
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Section C RNA Tumour Viruses - 
Tools for Transformation
Since they transform many cell types with relative 
ease, RNA tumour viruses, or retroviruses, are the most 
widely used transforming agents. They have also been used 
in these studies .
The major class of retroviruses is the C-type viruses, 
which itself consists of two principal divisions: the 
sarcoma and leukaemia viruses. The former transform cells 
in vitro. whereas the leukaemia viruses can be divided 
into acute leukaemia viruses (ALV) which transform haema­
topoietic cells in vitro (and sometimes fibroblasts too). 
and lymphatic leukaemia viruses (LLV) which do not transform 
cells in vitro but do cause lymphomas in vivo. though only 
after a long latent period (ref 115 pp402-8) .
There is a further division into replication competent 
and replication defective viruses . In avian systems the 
sarcoma viruses and LLVs are competent, though there are 
some Avian Sarcoma virus (ASV) mutants which are replication 
defective (ref 115 pp402-8) . In mammals all sarcoma viruses 
are replication defective, while the LLVs are competent.
ALVs of both avian and mammalian origin are defective. 
Replication of defective viruses requires the presence of 
'helper' LLVs, so that all mammalian sarcoma virus and ALV 
stocks contain LLV.
By infecting cell cultures with virus at high dilution
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double infection with sarcoma and leukaemia viruses will 
be rare, so the majority of cells will be infected with 
just a sarcoma or a leukaemia virus. Transformed clones 
can then be isolated by focus formation or by culturing 
in agar. These will be infected with a sarcoma virus only, 
and so will show no viral replication. Such transformed 
clones which produce no virus are called 'non-producers' .
The sarcoma virus in these non-producers can be 'rescued' 
by superinfection with a L.LV, which will provide all the 
proteins necessary for virus production. The rescued 
sarcoma virus will be antigenically identical to the helper 
virus .
Initial infection of cells with sarcoma or leukaemia 
viruses follows essentially the same path. The viral RNA 
is transcribed by viral reverse transcriptase into DNA, 
which is circularised and then integrated into the host 
cellular genome (52, ref 115 pp410-414) . Integration and 
the subsequent initiation of transcription of the integrated 
provirus requires a cellular process, possibly some event 
late in G2 or mitosis (ref 115 pp414-5), the reason for 
which is obscure.
Replication competent viruses synthesise the full 
complement of structural proteins from the provirus, whereas 
the defective viruses are able to make only a few (235) , 
or in some cases none at all (235, 282) .
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Relationship between Mammalian Sarcoma and Lymphatic 
Leukaemia Viruses
The most closely studied mammalian viruses are those 
of the murine system from which a number of LLVs have 
been isolated. Several strains of sarcoma viruses have 
been experimentally derived from these LLVs by serial 
passage through animals. Both the Kirsten and Harvey 
sarcoma viruses were derived experimentally by passage ofI
LLV through rats, the former being derived from mouse 
erythroblastosis virus (MEV), which is now usually called 
Kirsten leukaemia virus (KiLV) (ref 282 p256) . Harvey 
sarcoma virus was derived from Moloney leukaemia virus 
(MoLV) (ref 282 p256), which was also passed through mice 
to give rise to Moloney sarcoma virus (MoSV).
The new viruses arose due to recombination of the 
leukaemia virus with the cellular genome, thus losing viral 
structural genes and gaining cellular genes (227, 228, 235, 
ref 115 pp426-8, ref 282 pp255-257). This is the cause of 
the defective nature of sarcoma viruses .
The proportion of leukaemia virus genome remaining in 
the different sarcoma viruses varies greatly. For instance, 
only 15% of the Kirsten sarcoma virus (KiSV) genome is 
homologous with Kirsten leukaemia virus (KiLV), whereas 
75% of the MoSV genome hybridises with MoLV (ref 282 p255) . 
The sarcoma virus-specific sequences are of cellular origin; 
in the case of KiSV and Harvey sarcoma virus (HaSV) much of 
it may be from a rat endogenous virus (235, 282) .
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Structure of the Genome
The genome of all C-type viruses is single-stranded 
RNA, present in the virion in diploid form, each copy 
having a sedimentation value of about 35s in the fully 
competent form, but only 30s in the replication defective 
mammalian sarcoma viruses (52, 282, ref 115 pp421-6).
Probably more is known about Rous sarcoma virus (RSV) 
than any other C-type virus. It is a fully competent, 
transforming virus of chickens . Its genome consists of 
four genes (52, ref 115 pp421-6), designated thus -
5 -I------ 1------f------ 1-------- 1--hpoly A 3
gag pol env src c
The gene gag codes for the viral core proteins, pol 
for the virion reverse transcriptase, env for the envelope 
glycoprotein(s) and src codes for the cell transformation 
protein(s). Towards the 3' end is a sequence designated 
'c' which is common to all type C viruses, with no known 
function. Right at either end of the genome are short 
homologous sequences which may be involved in integration 
of the DNA transcript into the host genome (ref 52 p5) .
The lymphatic leukaemia viruses, both avian and 
mammalian, possess the three structural genes, but not src.
Murine sarcoma viruses usually synthesise some of the 
gag viral proteins in nonproducer transformed cells, most 
often those nearest the 5* end, indicating that this region
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of the leukaemia virus is retained (150, 235) , However, 
both KiSV and HaSV express no viral genes because the 
leukaemia sequences at the 5' end are too short to code 
for any proteins (ref 282, p258) . In these two viruses 
most of the leukaemia-related sequences reside in the non- 
translated sequences at the 3' end of the genome (227, 282) .I J
Src Gene and Transformation by RSV
DNA complementary to the RSV src gene (cDNAsarc) 
hybridises to approximately 10 - 15% of the RSV genome 
(ref 115 p427) . This cDNAsarc not only hybridises to the
i
integrated proviral sequences in infected cells, but also 
to the DNA of uninfected cells (154,ref 115 p427) . The 
viral src and cellular sarc sequences in chicken cells are 
not completely identical. Hybridisation also occur between 
cDNAsarc and cellular sequences of other avian species 
(ref 115 p427) , though the degree of mismatching increases 
as the evolutionary distance between chickens and the
species being studied increases. No hybridisation occurs
( <
with LLV of avian or mammalian origin, nor with any mammalian 
sarcoma viruses .
These data suggest that the viral src of RSV and 
cellular sarc of a range of avian species had a common 
ancestral origin from which there has since been divergent 
evolution.
The gene product of src has been identified as a
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phosphoprotein of molecular weight 60000 daltons, designated 
s rcpp60 (42, 154, 225, 228), possessing protein kinase 
s rcactivity. The pp60 has to be constantly present in
order to maintain transformation (206, ref 115 p423).
Mutants of RSV temperature sensitive for transformation show
rapid transition between the transformed and normal state
on shifting between the permissive (36°) and nonpermissive
(41°) temperatures. Some changes occur within 30 minutes
of temperature shift, and transition is completed within
24 hours (206, ref 115 p432) . One of the earliest changes
to be seen on shifting to the permissive temperature is the
dissolution of the cytoskeleton (66, 179, 197, 262), so it
srchas been proposed that at least one of pp60 3 main actions
may be a direct effect on the cytoskeleton, causing the
microfilament system to breakdown (12 9, 179) .
s rcRecently it has been found that pp60 's protein 
kinase activity is independent of cyclic AMP (154), and 
instead of phosphorylating serine or threonineresidues, 
which are the normal substrates, it phosphorylates tyrosine 
(127, 154, 225). Levels of phosphotyrosine in RSV transformed 
cells are ten fold higher than the levels found in uninfected 
cells (129, 225), autophosphorylation and phosphorylation 
of two cellular proteins at 34K and 50K daltons apparently 
being the main targets (127, 154, 225).
In uninfected cells a phosphoprotein with a molecular 
weight of 60000 daltons has been detected (154), which
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s rccrossreacts with antisera to pp60 , and which phosphory­
lâtes tyrosine residues. The levels of this protein in
normal cells ^re 50-60 times lower than the levels of 
s rcpp60 in transformed cells. This protein is probably 
the product of cellular sarc genes, but its function is 
obscure.
Transforming Genes of Murine Sarcoma Viruses
Recently a phosphoprotein of molecular weight 21000 
daltons, designated p21, has been identified in cells 
transformed by KiSV and HaSV. Antiserum raised in rats 
bearing tumours induced by syngeneic inoculation of HaSV- 
transformed normal rat kidney (NRK) cells precipitated
p21 from both KiSV and HaSV-transformed cells and p21
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translated in vitro from KiSV mRNA (227) . KiSV mutants,
temperature sensitive for transformation, produce thermolabile
srcp21, suggesting that this protein, analagous to pp60 
of RSV, may be the transforming protein for at least these 
two murine sarcoma viruses (228) .
Neither Kirsten nor Moloney leukaemia viruses systhesise 
this protein, so it is probable that the rat cellular 
sequences in the sarcoma viruses code for it. This 
possibility is strengthened by the antigenic identity of 
p21 from KiSV and HaSV transformed cells. Whether these 
sequences have a role in rat cells is not known.
It would seem that the transforming genes so far
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identified, src for RSV and p21 for KiSV and HaSV, are
all derived from cellular sequences. It is still not
known what function, if any, these cellular genes might
normally have, or why they do not cause transformation in
uninfected cells . It was noted earlier that the levels 
s rcof viral pp60 in transformed cells are 50-60 times
higher than the levels of the sarc protein in normal cells',
so transformation may be the result of excessive quantities
of a protein normally present in very small amounts. It
has been suggested that the sarc protein has an important
role in regulating growth, and hence the conservation of
its gene sequence throughout avian species . Transformation 
s rcby pp60 could be due to its much higher concentration 
upsetting this normal control, by perhaps overactivating 
a normal process (154) . One possible candidate is the 
control of binding of Epidermal Growth Factor (EGF) .
Binding of EGF to the cell surface is accompanied by 
phosphorylation of tyrosine residues of a cell surface protein, 
possibly the EGF receptor (154) .
Even if phosphorylation of tyrosine residues is 
important in transformation by RSV, it does not appear to 
be universal. Mouse cells transformed by KiSV, MoSV or 
SV40, chick embryo cells infected with avian myelocytomatosis 
virus MC29, rat or hamster cells transformed by polyoma 
virus, and at least three chemically transformed lines show 
no increase in phosphotyrosine levels (225) .
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PART 2
INTERFERON'S POTENTIAL AS AN ANTITUMOUR AGENT
Section A Historical Perspective
For a considerable period before interferon was discovered 
it was known that virus infection of a tissue could prevent 
subsequent infection with a second virus. This was first 
observed in 1935 by Hoskins (ref 236 p2) who termed it 
'viral interference'
It was not until 1957 that Isaacs and Lindenmann clearly 
demonstrated a diffusible agent, produced by virus-infected 
cells which could interfere with virus replication (132, 133) .
They took chick chorioallantoic membranes and infected them
\
in vitro with heat-inactiyated influenza virus . After 20 
hours they removed the supernatant fluid and added it to 
uninfected membranes These were then challenged with live 
influenza virus, which failed to replicate. They concluded 
that the inactivated virus had stimulated the infected cells 
to synthesise and secrete a substance which rendered the 
uninfected membranes resistant to live virus. This substance 
they called the 'interferon'.
Interferon was found to be a glycoprotein, stable at 
pH2, though an acid labile form was later found, whose 
production could be stimulated by a range of substances other 
than viruses. It would protect a range of tissues against 
infection by many different viruses, but interferon from any
one species was active only in cells of that species - its 
activity was said to be species-specific.. This restriction is 
now known not to be rigid and the term ’restricted host 
range' is more appropriate. This will be discussed in more 
detail later.
For a number of years interferon was considered to be 
a purely antiviral substance with no effects on the host cells' 
metabolism, despite effects on cell morphology reported by 
Gresser in 1961 (89), and inhibition of DNA synthesis 
reported by Paucker et al. in 1962 (198). Such effects were 
generally considered to be due to impurities in the interferon 
preparations (19, 160, 182, ref 236 p238) .
However, it was found that the growth of tumours in vivo 
could be inhibited, initially virally induced tumours where> i
the inhibition was attributed to interferon's antiviral 
activity (94), but subsequently it was shown that growth of 
transplantable tumours which were not virus induced could 
also be inhibited (91, 99, 102) . These findings paralleled 
further reports that in vitro cell growth was slowed by 
interferon (100, 101, 172) .
The mechanisms by which interferon inhibits tumour growth 
in vivo and cell growth in vitro are still unknown, but the 
antiviral mechanism is now quite well understood (11, 13, 15, 
17, 113, 123, 142a, 208, 218, 270). These mechanisms will 
be discussed in more detail later.
Interferon has been used on a number of occasions to
WÊÊKÊÊÊÊÊ
treat cancer sufferers but always only very small numbers 
of patients have been treated in each test and none have been 
double-blind controlled. The most frequently quoted trial
has been treatment of a rare bone tumour, osteosarcoma,i
which involved some 30 patients in Sweden (94, ref 236 pp320-l). 
Though beneficial effects were seen, the trial was not double­
blind controlled.
One of the major stumbling blocks to clinical trials is 
the shortage of supply of interferon. Present doses used 
are up to several million units per week. The bulk of the 
world's supply of human interferon has been produced from 
buffy coats by the Finnish Red Cross, and more recently from 
lymphoblastoid cells by Wellcome Research Laboratories, but 
these are only sufficient for a limited number of small trials.
Increased supplies may eventually be available from 
constitutive production of large quantities of human interferon 
following manipulation of the human interferon genes into 
Escherichia coli (187) .
I
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Section B Properties of Interferon 
Types of Interferon
The concept of restricted host range of activity implies 
that interferons of different species have different structures, 
so that the term 'interferon* represents a whole range of 
closely related glycoproteins.
The most closely studied interferons are those of mice 
and humans. There are at least three major classes of 
human interferon, called under a new classification system, 
alpha, beta and gamma. Alpha and beta are the classic 
virally induced pH 2 stable leukocyte and fibroblast inter­
ferons respectively, formerly called type 1, while gamma 
corresponds to the pH 2 labile immune or type 2 interferon 
induced in lymphocytes and macrophages by antigens and 
mitogens (9) . Purified alpha interferon appears on poly­
acrylamide gels as two bands at 15-18000 daltons and 21-22000 
daltons (36, ref 236, ppl65 & 174). Removal of the 
carbohydrate moiety by periodate treatment or allowing 
cellular synthesis to proceed in the presence of tunicamycin 
converts all alpha interferon to the 15000 dalton form 
(36, 239, ref 236 pp 167 & 180), suggesting that if there 
are different primary amino acid sequences, they are all 
closely related.
Purified beta interferon appears on polyacrylamide gels 
as just one band at 19-20000 daltons. Deglycosylation of 
this interferon has little effect on its mobility (24, 145, 
249, ref 236 pl81) .
Using highly purified material the amino terminal 
sequences of human beta (147), lymphoblastoid (285), and 
mouse Ehrlich Ascites (245) interferons have been determined, 
and the entire sequences of human alpha and beta interferons 
have been deduced by sequencing the cDNAs used to clone the
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genes into E. coli (61, 250) . The results show that alpha 
and beta interferons have different sequences, but the 
genes are closely related, and presumably have diverged 
from a common ancestor. Lymphoblastoid interferon which 
is produced by established human lymphoma lines appears to 
consist principally of alpha interferon with a few amino 
acid changes (250, 284) .
Interferon from mouse Ehrlich Ascites cells exists 
in three forms, A, B and C, with molecular weights at 35- 
40,000 daltons, 26-33000 daltons and 20000 daltons respect­
ively (45, 245) . The partial sequence data have shown that 
A and B probably have an identical sequence which is closely 
related to human beta interferon. C has a sequence which 
is related to human alpha interferon. Therefore A and B 
are classed as beta and C as alpha interferons.
Interferon from mouse L cells consists of just two 
forms, at 35-40000 daltons and 22-28000 daltons. Deglyco- 
sylation converts both to one smaller form at 18000 daltons, 
and though it has yet to be sequenced, it is thought to be
principally beta type interferon (58, 134) , though Yamamoto/
and Kawade (280) and Trapman (257) recently found the two 
forms to be antigenically distinct.
Gamma interferons consist of all the type 2 interferons 
that have so far been identified in different species.
Mouse gamma IFN was first identified in mice that developed 
antiviral resistance following injection of certain antigens.
TNo alpha or beta interferons could be detected in the serum 
of these animals, but eventually an acid-labile interferon­
like substance was identified (ref 236 ppl45 & 8). Mouse 
and human gamma interferons are heterogeneous glycoproteins
stable at pHs down to about pH4 (ref 236 ppl45 & 8).)
All three interferons, alpha, beta and gamma have 
both antiviral and anticellular activities, but the facts 
that gamma is not induced by viruses and may have more 
potent anticellular activities, and that human beta in vivo 
is more quickly removed from serum than human alpha, suggest 
that the different interferons may have rather different 
roles in the body (ref 236 pl82) .
Some Characteristics
Restricted host range Interferons do not show strict 
species specificity (ref 236 ppl35-145) . Both human alpha 
and beta interferons are active on monkey and rabbit cells 
(ref 236 ppl36-7) both in vivo and in vitro. but only alpha 
IFN is active on bovine and cat cells (ref 236 pp 136-7) . 
Similarly mouse IFN shows some activity on rat cells, but 
is actually more active on guinea pig cells than on mouse 
cells (ref 236 pl42) .
The reverse is not necessarily true, however - monkey 
IFN is active on human cells, but rabbit IFN is not (ref 236
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pl38) .
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Acid stability As already described, alpha and beta 
interferons are stable at pH 2, which has proved very 
useful in an initial purification step, but gamma interferon 
is stable at pH 4 but not in more acid solutions (ref 236 
pl45) .
Stability to reducing agents and detergents Interferons 
are generally labile to boiling, repeated freezing and 
thawing, and physical agitation. Sodium dodecyl sulphate 
(SDS) protects interferon against such treatments. 
Mercaptoethanol and urea alone or with SDS have varying 
effects on different interferons. For instance human alpha 
interferon is protected by SDS or mercaptoethanol alone, 
but is only partially protected by the two together. The 
response of human beta interferon, however, is completely 
the reverse (ref 236 pl75) .
Section C Production and Purification 
Inducers
A whole array of substances induce interferon production 
in vitro and/or in vivo. Viruses of every major class
induce interferon, including many inactivated 
viruses (ref 236 p34) . Synthetic double-stranded RNAs may 
also be potent inducers, particularly poly rl .poly rC 
(ref 236 pp46 & 49).
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Various bacterial products, such as statolon from 
Penicillium stoloniferum induce interferon, because of 
the double-stranded RNA viruses they contain. Double- 
stranded RNA appears to be the active component in many 
inducers, but there are many others which are structurally 
unrelated, such as bacterial endotoxins, radioprotective 
chemicals, synthetic polyanions, e,g. pyran copolymer and 
low molecular weight substances such as tilorone hydro­
chloride. Many of these only induce in vivo, and no common 
molecular structure can be found which may suggest a common 
induction mechanism (ref 236 pp52-54) .
Yields
Cell type and inducer must be closely matched in order 
to achieve maximum yields since different inducers and cell 
types vary in their potency and sensitivity towards each 
other. As a result routine production of IFN is generally 
conducted in a-very limited number of ways, such as mouse 
L cells with Newcastle Disease Virus (NDV) or human diploid 
fibroblasts with poly rl .poly rC.
Yields can be greatly increased in some inducer-cell 
type systems by pretreating the cells with small amounts 
of interferon before induction, a process called priming 
(ref 236 p233) . Superinduction is often used coupled to 
poly rl.poly rC induction. This involves the application 
of cycloheximide and later actinomycin D to induced cells.
This treatment increases the maximum yield, and duration of 
production of interferon (ref 236 pp97-100).
Purification
Purification to homogeneity has only recently been 
achieved for mouse and human alpha and beta interferons 
(24, 45, 58, 145, 147, 216, 224, 249, 284) . The procedures 
usually involved concentrating large volumes of crude inter­
feron to a manageable size and then purification was achieved 
by various combinations of gel filtration, affinity 
chromatography and polyacrylamide gel electrophoresis . Most 
of the multistep procedures developed give yields of 1-10% 
of the crude starting material (24, 134, 141, 145, 147, 249) , 
whereas some two-step methods may give 50-90% yields . In 
this respect one of the most successful procedures for 
purifying mouse interferon is that described by de Maeyer- 
Guignard et al^ . (58) . Crude interferon from mouse C243 
cells was purified by affinity chromatography on poly U- 
Sepharose followed by chromatography on anti-interferon 
antisera coupled to an agarose column. In this way 90% of 
the starting material was recovered in two fractions . The 
first fraction carried a few contaminants, but the second
was pure as judged by polyacrylamide gel electrophoresis.
9The specific activity of the pure material was 2.3 x 10 
international units per mg protein.
Section D Cellular Actions of Interferon
Antitumour Activities in Vivo
Interferon was first shown to have an antitumour effect 
due to its ability to prevent viral induction of tumours 
in hamsters and mice (94) . The interferon had to be 
administered prophylactically presumably to induce an anti­
viral state in the target tissues. Interferon treatment 
after virus inoculation was generally ineffective, except 
with RNA tumour virus inoculation, the most closely studied 
of which was Friend virus inoculation (95, 96, 97, 98, 220) . 
This virus normally infects the spleen and causes rapid 
growth and multiplication of the spleen cells, the virus 
itself undergoing multiple rounds of replication, the 
progeny virions infecting previously uninfected cells . 
Repeated intraperitoneal interferon injection following 
infection could successfully block splenomegaly (95, 96), 
even if treatment was not started until several days after 
virus inoculation (96, 97) . Virus titres and the numbers 
and size of foci of Friend cells in spleens of IFN-treated 
mice were greatly reduced, suggesting that the replication 
and spread of the virus was prevented, although Gresser 
and his colleagues did also suggest that foci might be 
reduced in size due to an inhibition of cell growth as well 
as spread of virus (96, 98) .
Gresser and his colleagues subsequently confirmed that 
interferon could block the growth of tumours by inhibiting
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cell growth (91, 99, 102). They found that BALB/c, DBA/2
and C57BL/6 mice could be protected against inoculation of
a range of tumour cell types, none of which were virus
producers, provided interferon treatment was continued for
several weeks after tumour cell inoculation. Prophylactic
treatment was ineffective. Interferon was most effective
in BALB/c mice inoculated with 103 Ehrlich Ascites (EA)
cells, where almost all interferon-treated mice survived
beyond 60 days post-inoculation, whereas no control mice
lived more than 30 days. Furthermore an inoculum of one
to ten EA cells constituted one LD50 in control BALB/c mice,
4 5but 10 -10 EA cells were required for one LD50 for 
interferon-treated mice (91) .
Injection of interferon inducers could be just as
effective as interferon itself at preventing splenomegaly
in Friend disease and tumour growth following RC19 cell or
L1210 cell inoculation, presumably by inducing endogenous
interferon (90, 268, 269, 283) . Levy et al. (161) found
that the interferon inducer poly(rl)poly(rC) was able to
delay the growth of several tumours in mice if administered
repeatedly after cell inoculation. A reticulum cell sarcoma
and human adenovirus 12 transformed mouse cells were the
most sensitive of the transformed cells tested. Even if
these tumours were allowed to grow to a palpable size before poly 
(rC)(rl).poly^ treatment commenced tumour regression still 
occurred. The sarcoma regressed completely and did not
<
return even after treatment ceased, whereas the adenovirus
tumour regressed only temporarily despite continued poly (rl)
It was generally found that interferon was most effective
if injected by the same route as tumour cell inoculation
and intravenous injection was generally quite ineffective
effective despite subcutaneous inoculation of cells
Inoculation of Lewis lung carcinoma cells subcutaneously
into mice, followed by repeated intravenous interferon
injections, commencing 24 hours or 6 days later, inhibited
growth of both the primary tumour and pulmonary métastasés
Both the size of the tumours and the number of
tumour-bearing mice were reduced. This result is especially
significant since this tumour is generally resistant to
most anti-tumour drugs
Spontaneous Tumours
95% of AKR mice in their sixth month develop lymphomas
due to the activation of endogenous Gross virus . Treatment
of AKR mice with interferon for one year from birth extended
the survival time of the mice and decreased lymphoma
incidence to 65% (106) . Presumably this effect is due at
least partly to interferons antiviral activity
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Inhibition of Growth of Normal Cells in Vivo
Regeneration of liver following partial hepatectomy 
in mice (74, 135) and growth of allogeneic lymphocytes or 
syngeneic bone marrow cells injected into irradiated DBA/2 
mice (46) were all inhibited by interferon treatment. Large 
doses of interferon (8 x 105 units) injected daily into 
newborn mice caused extensive liver damage which led to 
death (109) . If treatment was stopped after 6 to 9 days 
the liver repaired itself and the animal appeared healthy, 
but in succeeding months developed glomerulonephritis and 
died (94, 110). This could of course have major implications 
for interferon's clinical application to children.
Clinical Trials
The discovery of interferon's antitumour activity 
raised the possibility of interferon's use in cancer treat­
ment. Numerous small tests have been conducted, but all 
with very small numbers of patients who usually already had 
a heavy tumour load.
Strander and his colleagues have been conducting a 
trial since 1971 on interferon's efficacy against osteosarcoma, 
a rare malignant bone tumour which afflicts mainly young 
people. With conventional treatment 70% of patients 
developed metastases and 65% died within 2*5 years of 
diagnosis. Twenty-eight newly diagnosed patients, who were
free of metastases were given daily injections of 3 x 10^
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units of alpha interferon, coupled with excision or X- 
irradiation of the primary tumour, followed by three inter­
feron injections per week for 17 months . After 2*s years 
36% of patients had developed métastasés and 28% had died 
(94) . Although these results are encouraging, this trial 
has been severely criticised because it was not double-blind 
controlled, the control group that was used consisted of 
patients receiving treatment at hospitals scattered over 
Sweden, whereas all members of the interferon group have 
been treated at the Karolinkska Institute in Stockholm, 
and the numbers of patients involved are so small that the 
results are not statistically significant.
Mechanisms of the Antitumour Activity
It is still not clear how interferon exerts its anti­
tumour effect, but there is evidence to suggest that a 
direct inhibitory effect on the growth of tumour cells, or 
a stimulation of the host's immune systems, or a combination 
of the two may be involved.
The observation that interferon is generally most 
effective when administered via the same route as the tumour 
cell inoculum suggests that close contact between interferon 
and tumour cells is required for optimal activity, arguing 
for a direct effect on their behaviour. When Gresser et al. 
(103) incubated mouse L1210 cells with interferon .in vitro
they found that these cells were less able to grow in agar\
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in the absence of interferon and were less tumourigenic 
when injected into animals. Gresser and Bourali (91) further 
suggested that interferon's inhibition of Ehrlich Ascites 
tumour formation in BALB/c mice was due to a direct effect 
on cell growth since such cells grew much more slowly in 
the peritoneal cavity of IFN-treated than control mice.
However, experiments utilising the interferon-resistant 
subline L1210R (108), suggest that a direct effect may not be 
interferon's only antitumour mechanism. Gresser et al.
(105) found that interferon could protect mice against 
L1210R as well as L1210S tumour cells, suggesting some in­
hibitory effect mediated by some indirect mechanism. L1210S 
cells were , however, rather more sensitive than L1210R cells, 
so it is possible that interferon had some direct inhibitory 
effect. The difference may not have been significant 
however since such small numbers of mice were used (nine 
for each subline) .
Evidence that the immune system may be involved comes 
from smears taken from P388 and L1210 leukaemias (246) and 
Ehrlich Ascites (EA) tumours in mice (91).
Samples taken from interferon-treated mice showed 
tumours heavily infiltrated with well-differentiated macro­
phages and phagocytosis of tumour cells was frequently seen. 
Samples of tumours from control mice showed few macrophages, 
which actually degenerated as the tumours grew, and phago­
cytosis of tumour cells was not observed (91).
In vitro and iji vivo studies have shown that interferon 
can directly stimulate cytotoxicity and phagocytosis by 
lymphocytes and macrophages and activity of natural killer 
cells (84, 116, 212, 258) . This is discussed in more detail 
later.
Other experiments suggest that there may be no involvement 
of the immune system. Interferon still inhibited growth of 
L1210 and EA tumours in mice that had been treated with 
antilymphocyte serum (ALS), X-irradiation (to inactivate 
lymphocytes) or silica (to inactivate macrophages), though 
the latter treatment reduced IFN's antitumour activity a 
little (93) . Growth of L1210R, as well as L1210S, cells in 
treated mice was inhibited by interferon, so this suggests 
that either the ALS, X-ray and silica, treatments did not 
fully suppress lymphocyte and macrophage activity, or some 
other host-mediated mechanism was not affected. The most 
likely candidate for the latter is natural killer cell 
activity.
Yokota et al. (281) have provided strong evidence that 
interferon may directly inhibit in vivo growth of tumours. 
Tumour formation by HeLa cells or human bladder carcinoma 
cells in nude mice was inhibited by human interferon, but not 
mouse interferon. Conversely tumour formation by mouse 
sarcoma 1§0 cells in nude mice was inhibited by mouse inter­
feron, but not human. Similar experiments have been conducted 
by Taylor-Papadimetriou and Balkwill which generally support 
the findings of Yokota £t al. ( 293),
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Thus much evidence implicates both direct inhibition 
of tumour cell growth and a stimulated immune system, but 
the relative importance of each in different tumours and 
animals is still not known.
Inhibition of Growth in vitro
As already mentioned, interferon was, for some time, 
considered to be a purely antiviral substance, and effects 
on cellular behaviour were attributed to contaminants in 
the interferon preparations (19, 160, 182) . Effects on cell 
morphology (89), cell growth (197) and RNA synthesis (233) 
were reported in the early 1960s, but it was not until the 
late 1960s and early 1970s that such effects were studied 
seriously, at about the same time as effects on tumour growth 
were observed.
Gresser and his colleagues demonstrated beyond reasonable 
doubt that interferon could indeed inhibit growth of cells . 
They used mainly L1210, a murine leukaemia line. Growth 
rate and maximum density of these cells , in suspension 
(101, 103, 104, 107, 172), was inhibited by a number of 
interferon preparations from different sources induced by 
different agents . In subsequent experiments with L1210 cells 
(100) they were the first to suggest that the growth inhibition 
may be cell cycle dependent. Cells seeded at high density 
were less sensitive to interferon than those seeded sparsely, 
and they found that the degree of growth inhibition was
directly proportional to the number of population doublings 
a control culture needed to go through to reach saturation 
density at the time of interferon treatment of test cultures.
Further proof for cell cycle dependence came from 
Macieira-Coelho et al. (172) who found that interferon 
decreased the rate of entry of newly subcultured L1210 cells 
into S phase, although all cells eventually entered it. Thus 
they concluded that the doubling potential of interferon- 
treated cells was reduced.
A subline of L1210 selected for resistance to interferon's 
antiviral action was found to be resistant to cell growth 
inhibition as well, thus strengthening the argument that 
interferon can inhibit cell growth . Many also found that 
the maximum cell density reached was reduced (5, 54, 81, 100, 
119, 120, 121, 151, 152, 157, 166, 170, 172, 175, 190, 198,
244). Some studies have found that transformed cells were 
more sensitive than normal ones (143, 157, 166). For instance 
Knight (143) found that saturation densities of L cells and 
SV40- and polyoma virus-transformed 3T3 cells were greatly 
reduced, while those of nontransformed 3T3 and mouse embryonic 
fibroblasts were unaffected. On the other hand, others 
have found little correlation between sensitivity to growth 
inhibition and transformation (190) .
Interferon also inhibited the ability of dispersed 
macrophages to grow into colonies in agar (180), and the 
phytohaemagglutinin (PHA)- or allogeneic cell - stimulated 
growth of lymphocytes (167) .
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With few exceptions, studies that have measured cell 
viability have found that interferon is not toxic to cells 
(54, 100, 143, 166) , However, Tovey and Brouty-Boye (254), 
using L1210 cells growing in a chemostat, found that the 
growth rate could be closely controlled by the rate of 
medium flow. Below a certain growth rate mortality increased 
and the culture died out. Interferon treatment (6400 U/ml) 
slowed growth of cultures by 1.8 fold, regardless of initial 
doubling time. The faster growing cultures showed no increase 
in mortality, but those growing more slowly started to die 
following interferon treatment. They proposed that inter­
feron was not toxic per se, but cells will die if it reduces 
their growth rate below a sustainable level.
Whilst it remained impossible to completely purify 
interferon it was in doubt whether the growth inhibition was 
actually due to the interferon itself or to some contaminant. 
Gresser et al^ . found that in several mouse IFN preparations 
the ratio of antiviral to anticellular activities was 
constant, and in dose response curves,thermal inactivation 
curves and appearance and rise of activity in supernatants 
above NDV-induced L cells, antiviral and anticellular 
activities paralleled each other, showing that the two were 
inseparable (107) . However, Lindahl-Magnusson et al. (166) 
found that mouse interferons from different sources could 
vary in their growth inhibitory potency, requiring differing 
numbers of antiviral units to cause a 50% inhibition of growth
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of a given cell type.
Other experiments found that anticellular and antiviral 
activities of mouse and human IFNs were present in a constant 
ratio in different preparations when tried on neonatal 
foreskin fibroblasts (146) and Daudi lymphoblastoid cells 
(119, 120) . The two activities were also inseparable by 
polyacrylamide gel electrophoresis (190), or by rigorous 
dénaturation and renaturation by boiling in SDS (238) .
However, Borecky et al. (34) were able to separate the anti­
viral and anticellular activities of human interferon by 
electrophoresis. Dahl and Degre (55, 56) claimed to have 
separated human interferon into a protein component with 
antiviral activity, which bound to albumin, and a glycolipid 
with molecular weight of 3200 which contained the growth 
inhibitory activity. It was proposed that this glycolipid 
is actually held within the folded structure of the interferon 
protein molecule which has made it difficult to separate 
the two activities.
Purification of interferons to homogeneity has now ruled 
out the possibility that a contaminant is responsible for 
cell growth inhibition, since all purified interferons so 
far tested possess both antiviral and anticellular activities 
(58, 82, 174), though the possibility of a tightly-bound 
component as proposed by Dahl and Degre cannot be excluded.
Growth Inhibition Studied in Synchronised Cultures
Following suggestions that the growth inhibition may be
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cell cycle dependent, a number of studies were conducted to 
identify whether any particular part of the cell cycle was 
more sensitive than the rest. Data so far obtained using 
3H-thymidine incorporation into cells synchronised in Go 
by density dependent growth control or serum starvation 
(18, 54, 170, 231), at the Gl/S boundary by thymidine block 
(79, 194), or in mitosis by colcemid (79), provide evidence 
suggesting that interferon treatment arrests cells in late 
Gl, possibly at the Go-Gl boundary, but probably not as late 
as the Gl-S boundary (170, 194, 231, 264). Some reports 
also suggest that there may be a block in G2+S phases in some 
cells (18, 54, 79, 175) . It is quite possible that interferon 
may arrest different cell types at different stages of the 
cell cycle.
Other Effects on the Cellular Phenotype
a) Morphology Gresser's observation of a change in 
morphology of human amnion cells from epithelial to fibro­
blastic when exposed to interferon for three days, was one 
of the first non-antiviral effects observed (89). Chany and 
Vignal (48) isolated from a MSV-transformed BALB/c 3T3 line 
a revertant subline with normal morphology by cultivating in 
the presence of interferon for 200 passages. However, since 
the transformed line was a virus producer it is likely that 
interferon acted by inhibition of virus growth. More recently 
Fuse and Kuwata (78) found that transformed human RSa cells
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changed from a fibroblastic to an epithelial morphology.
This they equated with the observation that cells in S phase 
tended to be epithelial, while those in Gl were fibroblastic. 
Using cultures synchronised by thymidine they found that 
onset of the first S phase following release was not delayed 
by interferon, but mitosis started five hours later than in 
controls (27, 93). They concluded that the increase in 
epithelial-like appearance was due to the cells being delayed 
in S phase. However, the second S phase following release 
was almost completely abolished, suggesting that there was 
a major interferon-induced block in Gl following mitosis.
Since then there have been few reports of a change in 
cell morphology, though recently Pfeffer et^  al_. (201-2) found 
that normal human fibroblasts became flatter, larger and 
organisation of the cytoskeleton and fibronectin matrix 
increased. In addition Bal de Kier et al^ . (14) found that 
interferon had no effect on mature mouse neuroblastoma cells, 
but stimulated immature cells to grow long processes from the 
cell body and take on the appearance of fully differentiated 
neuroblastoma cells . Linked to the morphology studies is 
the finding by Brouty-Boye and Zetter (39) that both mouse 
and human interferons could inhibit motility of homologous 
normal and transformed cells .
b) Alterations to biosynthesis High doses of interferon 
can cause a general inhibition of RNA and protein synthesis,
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up to 50% (ref 236 p242) , but more significantly there are 
effects on synthesis of specific products, which may be 
stimulated, inhibited or even both. Low doses of interferon 
can stimulate its own production following viral induction 
(priming), and can also stimulate haemoglobin synthesis in 
DMSO-stimulated Friend erythroleukaemia cells (63, 214).
High doses inhibite synthesis of both (213, 214, ref 236 p236) . 
Similarly very low doses of interferon can stimulate, while 
higher doses inhibit , antibody production.
Histamine synthesis by leukocytes exposed to ragweed 
antigen E or anti IgE is stimulated by interferon (ref 236 
p249), and it can also stimulate synthesis of prostaglandin 
E by human synovial and foreskin fibroblasts (ref 236 p248).
Production of several enzymes is inhibited; for instance 
dexamethasone-induced tyrosine amino transferase in rat 
hepatoma cells (ref 236 p243) .
The physiological significance, if any, of all these 
changes is unknown, though fever, a side-effect of interferon 
treatment, may be due to production of histamine and pro­
staglandin E.
c) Cell surface changes Interferon has a whole host of 
effects on cell surfaces ranging from effects on overall 
morphology to the expression of certain specific antigens.
The transport of various nutrients may be changed. Tovey 
and his colleagues (38, 255) found that uptake of H-thymidine
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into the acid soluble pool of L1210 cells grown in a chemostat 
could be inhibited within two hours of initiation of inter­
feron treatment, whereas cell growth rate remained unchanged
until 18-22 hours later. O'Shaughnessey et al. (194) also
14 3recorded that uptake of C-amino acids and H-thymidine 
into L cells was inhibited by interferon. Secretion of 
plasminogen activator (PA) from SV40-transformed 3T3 cells 
was inhibited by IFN by 58% without having any effect on 
intracellular PA levels (223) . High IFN doses did inhibit 
PA synthesis, but only in line with a general reduction in 
RNA and protein synthesis. This report is especially 
significant since it is one of the few which clearly demon­
strates an inhibitory effect on a transformation-specific 
phenomenon, and a phenomenon which, as outlined earlier, may 
be important to the transformed phenotype.
Binding of ^Ni-Con A to the surfaces of L1210 cells 
is stimulated by interferon treatment (124), but there are 
no reports of an effect on the agglutinability of transformed 
cells. Increased binding may be due to increased expression 
of surface antigens. The expression of histocompatibility 
antigens on L1210 cells in vitro is stimulated, as is expression 
on mouse splenic lymphocytes and thymocytes in vivo (164,
165, 168,ref 236 p249). Expression of carcinoembryonic anti­
gen (CEA) on surfaces of human colon carcinoma cells is also 
enhanced by interferon (10). Such enhancement of expression 
may aid the host defences to recognise foreign cells. In
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addition to these increases in antigen expression, Chang 
et al. (47) using freeze fracture techniques, observed that 
interferon induced an increase in the density of intra- 
membranous particles in mouse AKR cells .
Immune Effects of Interferon
a) Antibody production Interferon generally inhibits 
antibody production, but under some circumstances its synthesis 
may be stimulated. For instance, 80 units/ml inhibited 
antibody production by mouse lymphocytes when exposed to 
sheep red blood cells (SRBC) - a T cell-dependent antigen - 
but 0 .8 units/ml stimulated antibody synthesis. ¿n vivo 
injections have had a similar effect (ref 236 pp254-256).
Production of antibody in mice in response to the B 
cell-dependent antigen, Salmonella typhimurium lipopoly­
saccharide, could also be inhibited by interferon injection 
(ref 236 p255) .
b) Lymphocyte cytotoxicity Incubation of sensitised 
lymphocytes with interferon for a few hours can greatly 
enhance their cytotoxicity towards specific target cells 
(116, ref 236 p250) . This specific cytotoxicity is mediated 
by T lymphocytes. Non-specific or spontaneous cytotoxicity 
towards foreign cells, to which the immune system has not 
previously been exposed, is mediated by Natural Killer (NK) 
cells. These are non-B non-T lymphocytes which are equally
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active in athymic nude mice as in normal mice (84, 112, 212) . 
Both ¿n vitro and in vivo interferon has had a direct 
stimulatory effect on NK cell cytotoxicity (64, 84, 116), 
possibly by recruitment of previously inactive pre-NK cells 
(217) .
Interferon treatment of the target cells instead of the 
lymphocytes does not stimulate specific nor spontaneous 
cytotoxicity, but may actually render the cells resistant to 
the lymphocytes (64, 67, 183, 184) . Trinchieri and Santoli 
(258) found that while treatment of normal cells with 
interferon rendered them resistent to lymphocytes, interferon- 
treated transformed cells remained sensitive.
c) Macrophage activity Interferon, in vivo or ¿n vitro, 
can increase cytotoxicity of macrophages to any allogeneic 
cells and syngeneic tumour cells. It can also increase 
macrophage phagocytosis of carbon particles and latex beads 
(ref 236 p251) . The clearance of injected leukaemia cells 
and antibody-coated erythrocytes from the serum of mice is 
also greatly enhanced by interferon treatment (114, ref 236 
p251) .
Furthermore, in vitro macrophages will spread out more 
on a glass surface if treated with interferon than will un­
treated controls (221, ref 236 p252).
Neither the mechanisms nor the physiological significance 
of most of IFN’s effects on fibroblasts, epithelial cells and
immunological cells is at present understood. Clearly, from 
these experiments, interferon has considerable effects on 
cell-mediated immunity which could be important in cyto­
toxicity and phagocytosis of foreign cells. Effects on both 
normal and transformed cells _in vitro involve increasing 
antigenicity of both, which could presumably aid immune 
recognition, and slowing cell growth and division which in 
vivo would be most effective against rapidly growing tumour 
cells. Some further evidence, such as effects on morphology, 
saturation density and secretion of plasminogen activator, 
suggests that interferon may also partially revert the 
transformed phenotype.
Current knowledge of the mechanisms of growth inhibition 
and effects on the transformed phenotype are discussed below.
Possible Mechanisms for Interferon's Cellular Activities
The lack of understanding concerning the mechanisms of 
interferon's cellular activities contrasts sharply with that 
of the antiviral effect which is now quite well understood. 
There is still some question as to whether the effects on 
cellular metabolism could be mediated by the same or a 
similar mechanism to the antiviral effect, though most evidence 
would suggest not. However, a brief outline of the antiviral 
mechanism will be given here as a background to some of the
anticellular studies.
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a) The antiviral mechanism The kinetics of the development 
of the antiviral state following interferon treatment vary 
greatly between different cell lines, but generally speaking 
a one hour interferon treatment usually leads to the antiviral 
state being detectable three to four hours after treatment, 
peaking at eight to twelve hours, lasting for fourteen to 
twenty-four hours and declining slowly, tailing off for up 
to seventy-two hours until no viral resistance remains 
(ref 236 ppl96-200) .
There is evidence that interferon can inhibit virus 
replication at several stages of the infectious cycle, most 
viruses apparently being sensitive at at least one stage.
The initial establishment of infection, particularly by 
retroviruses, can be blocked (71, 185, 200), as can assembly, 
maturation and release of these and other viruses from7
infected cells (25-27, 63, 76, 77) . Some viruses, most 
notably SV40 and vesicular stomatitis virus (VSV) are sensitive 
to transcription inhibition (ref 236 p209).
The main block in replication appears to be in the 
translation of mRNA, and it is this which has been most 
extensively studied. vitro a protein was identified in
extracts of interferon-treated cells, but not controls, which 
could be activated by double-stranded RNA and ATP to synthesise
a small molecule which itself activated an endonuclease and
I
a protein kinase (11, 12, 13, 15, 16, 69, 142a, 208, 222, 270, 
ref 236 p214) . This small molecule was identified as a novel
oligonucleotide pppA2'p5’Ap51A (abbreviated to 2.5A) . Thus 
the protein which synthesises 2 .5A is termed 2 .5A synthetase. 
It remains inactive until virus infection in vivo or dsRNA 
treatment jin vitro (11, 16, 17, 123, 142) .
The protein kinase, activated by 2.5A, phosphorylates 
at least two proteins - the alpha subunit of elF 2 ( a protein 
synthesis initiation factor) and a ribosomal protein (218,
219). This may inhibit the formation of the met,tRNA-mRNA-40s 
ribosomal subunit complexes prior to start of translation 
(162, ref 236 p216) . This presumably frees the mRNA into the 
cytoplasm where it can be digested by the 2 .5A-activated 
endonuclease. Both cellular and viral mRNAs are digested 
by this endonuclease, though reovirus mRNA is digested more 
efficiently than cellular mRNA (69, ref 236 p214) .
The limited host range of interferon activity is 
determined at the cell surface, not by the 2 .5A-activated 
system which has been found to be identical in a number of 
species (16). This is strengthened by observations by Blalock 
and his colleagues (28-31, 125), that once the antiviral 
state has been established in some cells it can be transferred 
between cells in the absence of interferon and even in the 
presence of interferon antiserum. This transfer can not 
only occur between homologous cells but also between cells 
of heterologous species. These observations argue for the 
transfer of a common antiviral agent between cells via
6-)
intercellular connections .
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b) The cellular phenotype Serum arrested or density 
inhibited cells are thought to rest in Go phase (or the A- n
state) . The observations that interferon apparently arrests 
cell growth in this phase has led to speculation that its 
role may be to make cells more sensitive to a normal growth 
control mechanism (121, 172, 201) . That increasing the 3
serum concentration inhibits interferon's action (100), as 
well as stimulating serum starved or density inhibited cells 
to grow, strengthens this possibility. The mechanisms 
whereby these controls act are not known, let alone how 
interferon might affect their expression. Most studies of 
interferon's growth inhibitory mechanism have to date 
concentrated on trying to determine whether or not the anti­
viral mechanism may be involved in any way.
Numerous reports have implicated cyclic nucleotides as 
being activated by cell surface bound interferon to trigger 
both the antiviral and anticellular activities (80, 256,
265, ref 236 pl94). The most popular candidate is cyclic 
AMP, though its involvement has been refuted. Tovey et al.
(256), using L1210 cells grown in a chemostat found that 
interferon treatment was followed by a rapid rise in intra­
cellular cyclic GMP, but cAMP levels did not rise until 
several hours later, more as a consequence than a cause.
Fuse and Kuwata, however, did observe a correlation between 
increased cAMP levels following interferon treatment of 
human RSa cells and inhibition of cell growth (80).
Even if both activities do use a common second messenger 
it does not necessarily imply that they share a common mechanism; 
the second messenger may activate a cascade phenomenon 
affecting a whole range of processes. There have been a 
number of studies to identify whether the ratio of the 
anticellular and antiviral activities of interferon preparations 
on a range of cell types, is constant or varies. If it 
remains constant this would suggest that the mechanisms may 
be similar, but a variable ratio suggests independent 
mechanisms. Virtually all studies have found that the anti­
cellular activity, usually measured as growth inhibition, 
is less potent than the antiviral activity, and that the 
ratio remains constant for different preparations on the same 
cell type, suggesting that the growth inhibition is at least 
a specific interferon activity (as discussed earlier) (107,
119, 120, 146, 238). However, when it comes to studying 
any one preparation on different cell lines there is dis­
agreement . Some find that the ratio always remains constant 
(119, 237) , while others find that the ratio varies (151, 152, 
157, 166, 176, 186), so no clear-cut answer to this question
has been possible./
Several interferon-resistant sublines have been selected. 
Both the L1210R subline, selected for resistance to inter­
feron's antiviral activity (100, 101, 105, 108), and the 
transformation revertant of MSV-BALB (48), selected for 
resistance to the growth inhibitory activity, were resistant
4
to both antiviral and anticellular effects. The major 
difference between the two was that L1210R cells did not 
bind interferon on their surfaces, and so presumably were 
resistant for that reason, whereas the MSV-BALB revertant 
bound normal amounts of interferon and thus must have been 
resistant due to some intracellular mechanism. A third sub­
line isolated by Kuwata et al. (151) was resistant to the 
growth inhibitory action, but was still as sensitive as the 
parental line towards antiviral activity.
Hovanessian and Wood (122) recently treated cells with 
2 .5A at concentrations of 10-100 nanomolar. At low concen­
trations transient inhibition of DNA, RNA and protein synthesis 
was observed, but at high concentrations the effects were more 
persistent and were accompanied by cell growth inhibition.
This high concentration also inhibited viral replication by 
90-100%, but the physiological relevance of these amounts 
of extracellular 2 .5A to intracellular levels normally 
synthesised as a response to interferon treatment and virus 
infection is not known.
An argument against the anticellular activity using the 
same mechanism as the antiviral activity is that of kinetics. 
The antiviral state takes only a few hours to develop after 
a very short exposure to interferon, whereas anticellular 
activities, including cell growth inhibition may take 20 hours 
or more to appear with continuous interferon treatment.
6 a
However, it cannot be ruled out that the anticellular effect
69
may be the result of the cell being in a prolonged antiviral 
state.
Genetic studies, using human x mouse hybrids identified 
some time ago that human chromosome 21 determines sensitivity 
to both antiviral and anticellular activities of alpha, beta 
and gamma interferons (248, ref 236 pl85) . The equivelent 
mouse chromosome has only recently been identified as
chromosome 16 (163) . The gene(s) appears to code for the
the behaviour of the L1210R sublirn cell surface receptor (209), and/is presumably due to a
defect in the gene(s) on chromosome 16, whereas that of the
MSV-BALB revertant is due to a change in the genes coding for
the intracellular mechanisms.
Reversion of the Transformed Phenotype
Most evidence presently available, which has been 
discussed in Part 2, indicates that interferon's antitumour 
activity may act principally by two routes, viz direct cell 
growth inhibition and stimulation of the immune system.
Scattered evidence also suggests that interferon may cause 
transformed cells to behave in a. more normal manner, but little 
attention has so far been paid to this possibility. Most of 
the experiments that have brought forward such evidence have 
already been mentioned in the context of interferon's general 
growth inhibition and effects on cell behaviour, but they 
are all brought together here simply to illustrate how sparse 
the presently available data are.
Knight (143) found that saturation densities of L cells 
and polyoma- and SV40-transformed 3T3 cells were reduced by 
interferon treatment to levels similar to the normal 3T3's. 
Saturation density of the 3T3's was unaffected. These 
results suggest that the transformed cells regained some 
density dependent growth inhibition. Several other reports 
have found that transformed lines may be more sensitive to 
growth inhibition by interferon than are normal cells (86,
157, 244). Bourgeade and Chany (35) found that sodium 
butyrate enhanced the antiviral and cell growth inhibitory 
activities of interferon on MSV-transformed mouse BALB/c 
and Syrian hamster cells, but not on normal cells . They 
suggested that this may be due to the elaboration of the 
microfilament and microtubule systems induced by butyrate 
in transformed cells.
Gresser et _al. (103) was able to inhibit tumour formation 
in vivo or colony formation in agar by L1210 cells by pre­
treating them in vitro for several days with interferon.
This may be due to a reversion of their phenotype, but it 
could also be due to residual growth inhibition.
The most clear-cut effect on a transformation-specific 
phenotype is that observed by Schroder et aJL. (223) where 
interferon inhibited secretion of plasminogen activator 
from SV40-transformed 3T3 cells.
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All these observations, though they suggest that 
interferon may actually revert the transformed phenotype, 
are far from unequivocal proof. No systematic study has 
yet been undertaken to assess whether reverse transformation 
by interferon is possible, despite the fact that such an 
effect could have profound implications for our understanding 
of the antitumour activity. The aim of this project, 
therefore, is to carry out such a systematic study and 
establish whether or not interferon really can cause reverse 
transformation.
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MATERIALS AND METHODS
MATERIALS
General chemicals that are commerically available were 
usually of 'Analar' grade, and were supplied by BDH, 
Fourways, Atherstone, Warwickshire, and by Fisons of 
Loughborough, Leicestershire. Named reagents were supplied 
as follows:
BDH Chemicals. Fourways, Atherstone. Warwickshire 
Ethylenediaminetetraacetic acid (EDTA)
Fluorescein isothiocyanate (FITC)
Beta-mercaptoethanol
Sigma (London) Chemical Co. Ltd.. Poole. Dorset 
Bovine serum albumin (BSA)
Concanavalin A
Cyclohexylaminopropanesulphonic acid buffer (CAPS)
Deoxyribonuclease 1
Gelatin
Fisons. Loughborough, Leicestershire 
1,4-Dioxan (spectroscopic grade)
Folin and Ciocolteu's phenol reagent
Aldrich Chemical Company Ltd., Gillingham. Dorset
Butyric acid
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Collaborative Research. Waltham. Massacheusetts, U.S.A. 
Human fibronectin
Rabbit anti-human fibronectin antiserum
Wellcome Reagents Ltd,, Hither Green Lane, London SE13 
FITO conjugated goat anti-rabbit IgG
Gibco Bio-Cult Ltd., Washington Road, Paisley, Scotland 
Freund's complete and incomplete adjuvants
Pharmacia Fine Chemicals. Uppsala, Sweden 
Poly U-Sepharose 4B 
Blue-Sepharose CL6B 
Sephadex G25 and G50
Cyanogen Bromide-activated Sepharose
Bio-Rad Laboratories Ltd.. Holywell Industrial Estate, 
Watford. Herts.
Affi-gel 202
George T. Gurr, Searle Scientific Services. High Wycombe, 
Crystal Violet
Flow Laboratories Ltd., Irvine. Ayrshire 
Newborn calf serum
Dulbecco's and Glasgow's modifications of Eagle's medium 
(DMEM and GMEM)
Versene
GMEM, ten times concentrated
Bucks
Glutamine
Difco Laboratories. East Molesey, Surrey
Noble Agar
Glaxo Laboratories Ltd., Greenford, Essex 
Penicillin and streptomycin
Radiochemical Centre. Amersham, Bucks.
3H-uridine (26 Ci/mMol)
3H-thymidine (25 Ci/mMol)
3H-leucine (342 Ci/mMol)
35S-methionine (740 Ci/mMol)
Packard Instrument Co. Inc. U.S.A.
Insta-gel scintillation cocktail
Eastman-Kodak, Rochester. New York. U.S.A.
N,N,N',N'-Tetramethylethylenediamine (TEMED)
Panatomic-X 35mm film roll
Tri-X Pan 35mm film roll
Photo Flow wetting agent
X-omat-H X-ray film
Kodafix fixer
Ilford Ltd., Basildon. Essex 
Ilfospeed multigrade filters 
Ilfospeed multigrade printing paper 
Ilfospeed multigrade developer
Hypam rapid fixer
Paterson Products Ltd., Boswell Court. London
Aculux and Acutol film developers
METHODS
Cells
Normal mouse fibroblasts used were continuous lines of 
C3H and NIH mouse embryo fibroblasts, COHIOT^ cl8 (210) and 
NIH 3T3cl4E (289, 290), and primary cultures of NIH and C3H' 
mouse embryo fibroblasts (MEF) prepared in this laboratory.
The established lines, although aneuploid and capable of 
indefinite growth in vitro, were nevertheless normal by the 
criteria of anchorage dependence and failure to form tumours 
in syngeneic hosts .
Kirsten Sarcoma Virus-transformed clones were derived 
from C3H10T>J, NIH 3T3 4E and NIH MEF? MSV C3H2 and 6 (from 
C3H10T>s) ? CC1 and cAl2 (from NIH 3T3 4E) and MSV MEF2 and 4 
(from NIH MEF) . These transformed cells were non-producers 
with the exception of MSV C3H6 which produced both KiSV and 
KiLV.
All cell types were cultured in Dulbecco's modification 
of Eagle's medium supplemented with 10% new-born calf serum.
Confluent cells were passaged by trypsinisation with
0.2% trypsin plus 0.02% EDTA and recultured at 1:8 dilution 
so that each passage was equivelant to roughly three population
doublings .
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After approximately 20 passages the caHlOT1* cl8 and NIH 
3T3 4E cells were discarded and new vials of early passage 
cells thawed from liquid nitrogen, since after that many 
passages spontaneous transformation started to occur.
Despite disadvantages of mouse cells caused by their 
instability and tendency to spontaneously transform, there 
were several reasons for choosing to use cells of this species
a) clones of mouse fibroblasts transformed by Kirsten 
Sarcoma virus were already being studied in this laboratory
I
to establish numbers and locations of proviral integration 
sites . Thus several clones were immediately available and 
transformation by KiSV to produce further clones was possible;
b) most of the early studies of interferon's anticellular 
and antitumour activities had been conducted in mice and it 
was therefore appropriate to extend these observations;
c) mouse interferon was available in much larger quantities 
than human interferon, since L cells grew more readily and 
were much more prolific producers of interferon than any 
human cells that were available;
d) it would be possible to transplant mouse cells into 
syngeneic hosts for in vivo tumourigenicity studies if 
necessary.
Interferon Production and Purification
Initially a series of studies was conducted to improve 
yields of crude interferon and the final purity of that
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interferon following purification steps . Those studies 
are described in chapter one of the Results. Here is 
described the final method adopted for production of inter­
feron .
Mouse interferon was produced routinely from confluent 
monolayersof L cells by induction with Newcastle Disease Virus 
(NDV) . The cells were grown in roller bottles in Glasgow's 
Modification of Eagle's medium supplemented with 10% new-born 
calf serum. When confluence was reached fresh medium was 
added. Twenty-four hours later the medium was removed and 
5 mis of NDV (HAU: 10^ units/ml) added to each bottle for 
one hour. After this period excess virus suspension was 
removed and 50 mis of serum-free GMEM added.
The cells were incubated for 16 hours and then the
interferon-containing medium was harvested and acidified by
HCl to pH 2 . The crude interferon was left at pH 2 at 4°C
for 7 days. Each batch yielded roughly 500 mis of crude
7 8interferon containing 5 x 10 to 5 x 10 units. After seven 
days the solution was dialysed against lOmM Tris-HCl, pH 7 .5 
for 48 hours . The dialysed interferon was then applied to a 
column of Blue-Sepharose CL-6B which had been equilibrated 
with the same buffer. After passing the crude solution 
through, the column was washed with lOmM Tris-HCl, pH 7.5, 
and the interferon then eluted with the same buffer containing 
1M NaCl and 8M urea. The IFN-containing eluate was then 
dialysed against 10 mM Tris-HCl, pH 7.5 for 24 hours and
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applied to poly U-Sepharose 4B, equilibrated with the same 
buffer. After application of the interferon and washing 
of the column, the interferon was eluted with lOmM Tris-HCl 
pH 7 .5 containing 1M NaCl.
Final yields of IFN were usually approximately 50-80% 
of starting material in about 5 mis of eluate. The specific
activity of batches obtained by this technique varied
7 8between 5 x 10 units/mg of protein and 2 x 10 units/mg of
protein.
Assay of Interferon Titres
Interferon was assayed in L cells by the viral RNA 
synthesis reduction assay (286), using Semliki Forest Virus 
(SFV) as challenge, or by plaque reduction, using Encephalo- 
myocarditis (EMC) virus as the challenge virus. Titres for 
the same interferon sample were roughly equal when assayed by 
the two methods.
One unit in these assays was equal to one international 
reference unit.
Measurement of Protein Content
The standard procedure used was the method described by 
Lowry et al. (169), though during experimental studies to 
improve interferon purification (chapter one of Results), an 
assay using fluorescamine, described by Bohlen et al. (33) ,
was often used.
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Bohlen et ¿1 claimed that the fluorescamine assay was 
accurate at protein concentrations in the nanogram range. 
Fluorescamine reacts with primary amines to form fluorescent 
complexes . The reaction proceeds at room temperature in 
aqueous solution at pH 8-9 with a reaction half-time in 
milliseconds. Unreacted fluorescamine is broken down to 
water-soluble products. Fluorescamine itself is insoluble 
in aqueous solution eo it has to be dissolved in an organic 
solvent which gives minimal absorbance, such as acetone or 
spectroscopic grade 1,4-dioxan.
The manual procedure described by Bohlen et al_. was 
followed, except that 1.0 ml of the fluorescamine solution 
was used instead of 0.5 ml. It was found that the former 
gave more reproducible results . The procedure was as follows. 
Fluorescamine was dissolved in 1,4-dioxan at a concentration 
of 30 mg/100 mis. 100 uls of the protein sample was made up
to 1.5 mis with 0.05 M sodium phosphate buffer at pH 8 . 1 ml
of fluorescamine was then added, while the sample was shaken 
on a vortex mixer. The mixture was then left for 5 minutes 
for fluorescence to reach its maximum, which was then measured 
in a Perkin-Elmer MPF3 spectrofluorimeter with excitation at 
390 nm and emission at 475 nm. Using bovine serum albumin 
as standard a linear relationship between fluorescence and 
protein concentration was obtained in the range 20-100 ng/ml. 
Below 20 ng/ml reproducible results could not be obtained.
a o
Measurement of Antiviral and Anticellular Activities in 
Different Clones
Sensitivities of CSHIOT^ cl8 , NIH 3T3 4E and several 
KiSV-transformed clones towards interferon's antiviral activity 
were measured using the viral RNA synthesis reduction assay
with SFV as challenge virus. Transformed cells were seeded
5 4at 2 x 10 cells per vial and normal cells at 5 x 10 cells
4per vial. Interferon doses used were in the range of 10 to
10  ^units/ml. Sensitivity was determined from the dose
response curves as the interferon dose required to inhibit
viral replication by 50% (V150) .
To measure the sensitivities of these cells to cell growth
inhibition 2000 cells were seeded per well of a 96 well micro-
titre tray and incubated for 24 hours in DMEM supplemented with
newborn calf serum. Fresh medium was then added containing
4 -3interferon at concentrations ranging from 10 to 10 units/ml. 
After a further 72 hours, the cells were incubated for 3 hours 
in the presence of H-thymidine (10 nCi/ml). Radioactivity 
in the acid insoluble material was then determined by solubil­
ising cells in 1 M NaOH, neutralising in 1 M HCl and mixing an 
aliquot in instagel scintillation cocktail, and then counting 
in a Packard liquid scintillation counter at 12% gain. Sensi­
tivity was determined from the dose response curves as the 
dose of interferon that would inhibit cell growth by 50% (G150).
DNA Synthesis at Different Cell Densities
Cells were seeded into wells of microtitre trays at a
range of densities, 500-23000 cells per well in DMEM supple­
mented with 10% newborn calf serum. After 24 hours incubation
4interferon at 10 units/ml was added to half the wells. In 
some experiments butyric acid was added to half the wells to 
measure its effects on DNA synthesis alone and in the 
presence of interferon.
3After a further 24 hours H-thymidine (10 p,Ci/ml) was 
added for three hours, and radioactive incorporation into 
the acid insoluble material determined.
Growth Curves and Saturation Density 
43 x 10 cells were seeded per 35 mm Petri dish in DMEM 
supplemented with 10% newborn calf serum. After 24 hours
4interferon (10 units/ml) was added to half the cultures.
Fresh medium and interferon were added every day to ensure 
growth was not nutrient-limited. At intervals pairs of 
dishes were trypsinised and cells counted with a haemocytometer. 
The means of cell numbers in each pair of dishes were recorded.
In some experiments butyric acid (0.5 mM) was also 
present to determine its effects on growth curves and satura­
tion density when alone and in the presence of interferon.
Focus Assay
102 transformed and 105 normal cells of the parental cell 
type were seeded together in 50 mm Petri dishes in DMEM 
supplemented with 10% newborn calf serum. Twenty-four hours
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later this medium was replaced with DMEM supplemented with
45% heat-inactivated newborn calf serum. IFN (10 U/ml) was 
added to half the dishes at this point. Thereafter, fresh 
medium and IFN were added every third day until foci formed 
by the transformed cells were clearly visible on the control 
plates at which time foci on all plates were scored, usually 
at about 10 days.
Anchorage Dependence ed
103 transformed cells suspended in DMEM supplemented with 
20% newborn calf serum and 0.25% agar were overlaid onto a 
base of this same medium containing 0.4% agar (173) in 50 mm
Petri dishes. For IFN treated cultures, IFN was added to) 4both the overlay and the base layer at 10 U/ml. Colonies 
were counted, after 28 days incubation, on a low power micro­
scope .
Cloning Efficiency in Liquid Medium 
210 cells were seeded per 50 mm Petri dish in DMEM
supplemented with 20% newborn calf serum. After 24 hours IFN 
4at 10 units/ml was added to half the dishes, and thereafter |
fresh medium and IFN were added every third day until colonies 
were clearly visible. The plates were then fixed in methanol 
and stained with crystal violet, and the colonies counted 
on a low power microscope.
a3
Concanavalin A Agglutination
Cells were grown in 50 mm Petri dishes in DMEM supple­
mented with 10%  newborn calf serum i interferon until 
saturation density was reached. The cultures were then 
rinsed and cells removed by 0.02% EDTA in phosphate buffered 
saline (PBS) . Trypsin was not used since trypsinisation of 
cells increases their agglutinability. The cells were 
centrifuged and then resuspended in PBS at 10 /ml. Two 
millilitre aliquots of this suspension were added to siliconised 
glass flasks. Concanavalin A (100 jig/ml) was added to half 
the flasks, which were then put on a shaking water bath at 
37°C. Samples were taken at intervals and cells not agglut­
inated were counted with a haemocytometer.
Morphological Studies
Cells were grown in 35 mm Petri dishes with DMEM 
supplemented with 10% newborn calf serum for up to a week
4with or without interferon up to 10 units/ml. Normal cells 
were usually fixed at or just before confluence, and trans­
formed cells were fixed while they still formed a single 
layer over most of the dish. In some experiments butyric acid 
(0.5 mM) was also added to observe its effects on morphology 
when alone and whan in the presence of interferon. Three 
parameters were studied;
i) Cell and culture morphology Cells grown in 35 m m  Petri
dishes were fixed for 20 minutes at room temperature w i t h
Concanavalin A Agglutination
Cells were grown in 50 mm Petri dishes in DMEM supple­
mented with 10% newborn calf serum ± interferon until 
saturation density was reached. The cultures were then 
rinsed and cells removed by 0 .02% EDTA in phosphate buffered 
saline (PBS). Trypsin was not used since trypsinisation of 
cells increases their agglutinability. The cells were 
centrifuged and then resuspended in PBS at 10^/ml. Two 
millilitre aliquots of this suspension were added to siliconised 
glass flasks. Concanavalin A (100 jig/ml) was added to half 
the flasks, which were then put on a shaking water bath at 
37°C. Samples were taken at intervals and cells not agglut­
inated were counted with a haemocytometer.
Morphological Studies
Cells were grown in 35 mm Petri dishes with DMQ1 
supplemented with 10% newborn calf serum for up to a week
4with or without interferon up to 10 units/ml. Normal cells 
were usually fixed at or just before confluence, and trans­
formed cells were fixed while they still formed a single 
layer over most of the dish. In some experiments butyric acid 
(0.5 mM) was also added to observe its effects on morphology 
when alone and when in the presence of interferon. Three 
parameters were studied;
a3
i) Cell and culture morphology Cells grown in 35 mm Petri
d i shes w e r e  fixed for 20 minutes at room temperature with
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3.5% formaldehyde in PBS and then stained with crystal violet. 
The cultures were examined at low power on a Leitz Diavert 
inverted microscope.
ii) Microfilament system Cells grown on glass coverslips 
were fixed for 20 minutes at room temperature with 3 .5% 
formaldehyde in PBS and then treated with methanol at -20°C 
for 15 minutes to make the plasma membranes permeable. The 
coverslips were washed repeatedly with PBS and then stained 
with deoxyribonuclease I to which was coupled fluorescein 
isothiocyanate (FITC) for 45 minutes at 37°C. DNase I binds 
specifically to actin (32), as well as DNA, and thus FITC- 
DNase gives a quick and simple method to label the actin 
microfilament system (118, 261). The stained coverslips were 
washed in several changes of PBS for 1*5 hours and then 
mounted on slides in PBS-glycerol (1:9) . The cells were 
examined under a Reichert Zetopan UV fluorescence microscope.
iii) Fibronectin pattern Cells grown on coverslips were 
fixed with formaldehyde as above, but since fibronectin is a 
surface protein the cells were not permeabllised with methanol. 
In some experiments live cells were treated with 1% NP40 in 
PBS for one hour immediately prior to fixation. This treatment 
removed the cells but the matrix between cell and substrate 
remained.
Rabbit anti-fibronectin antiserum was applied to all 
coverslips for 30 minutes at 37°C. The antiserum used was 
either a commercial preparation (Collaborative Research)
directed against human cell-surface fibronectin, or a 
preparation made in this laboratory directed against fibro­
nectin purified from newborn calf serum.
After labelling with anti-fibronectin the coverslips 
were washed with PBS and then stained for 30 minutes at 37°C 
with sheep anti-rabbit IgG conjugated with FITC. Stained 
coverslips were then washed in PBS for 1^ hours and then 
mounted on slides in PBS:glycerol (1:9) . The Reichert 
fluorescence microscope was again used .
Conjugation of FITC to DNase I
The conjugation procedure used was similar to that 
described by Johnson and Holborrow (136) . Basically, dry 
FITC was added to a solution containing 10 mg of DNase I per 
millilitre of buffer, in the ratio of 20-40 itg FITC/mg of 
DNase. The buffer in which the DNase I was dissolved was 
0 .15 M NaCl and 10% by volume of carbonate buffer (5.8 ml of 
5.3% Na^CO^ and 10 mis 4.2% NaHC03> adjusted to pH 9.5). The 
mixture was then shaken gently for 2 hours at room temperature 
during which time the FITC slowly dissolved in the solutions 
and ensured a slow binding of FITC to DNase, decreasing the 
of risk over-labelled DNase molecules. Conjugated FITC-DNase I 
was then separated from free FITC by gel filtration on 
Sephadex G50 medium grade, the conjugated material being 
washed through by PBS ahead of the free FITC.
Usually, 10-50 mg DNase I were conjugated at any one time,
V
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and this could be collected in a final volume of PBS of
2-10 mis and then stored at -20 C. These FITC-DNase I
fractions could usually be diluted up to 1:2 with PBS before
Coupling of Affinity Adsorbents to CNBr-Activated Sepharose 4B
Bovine Serum albumin (BSA) and gelatin were coupled to
purification and the purification of serum fibronectin from
newborn calf serum respectively. In each case the method
and then washed for 15 minutes in ImM HCl. This treatment
lactose which are added to the Sepharose to preserve its
activity when freeze-dried. One gram of powder gave approx
Immediately after swelling, the protein to be coupled
of 5-10 mg/ml gel, dissolved in an alkaline coupling buffer
(0.1 M NaHCO pH 8.3, containing 0 .5 M NaCl) . The alkaline
pH maintains the amino groups in the unprotonated form and
thus apparently aids binding of the protein to the Sepharose
which thus also aids coupling to the Sepharose
The coupling was allowed to proceed for 2 hours at room
temperature, and then excess active groups on the Sepharose
S7
gel were blocked by suspending the gel in 1 M glycine or 
tris buffer for 2 hours at pH 8 .
The final gel was then washed alternately four or five 
times with acetate buffer (0.1 M, pH 4), and carbonate buffer 
(0.1 M, pH 8), each containing 0.5 M NaCl.
This washing procedure removes excess non-covalently 
bound protein and any other contaminating agents, but does 
not affect covalently bound material.
The BSA-Sepharose 4B and gelatin-Sepharose 4B were then 
stored at 4°C in PBS containing sodium azide until use.
Fibronectin Purification
Serum fibronectin was purified from newborn calf serum 
by the method described by Engvall and Ruoslahti (68). 
Basically, serum which had been dialysed for 48 hours against 
PBS, pH 7.2, containing 0.01 M sodium citrate was applied to 
a column of gelatin-Sepharose equilibrated in the same buffer. 
Adsorbed material was then eluted with 8 M urea in 0.05 M 
tris-HCl at pH 7.5. The fibronectin was removed immediately 
and could be collected in 2 x 2 ml fractions . Protein 
content in the fractions was estimated by absorption at 280 nm 
and the Lowry method. Polyacrylamide gel electrophoresis, 
using Collaborative Research human fibronectin as marker, 
showed this fibronectin to be contaminated by several smaller 
proteins, most of which could be removed by gel filtration on 
Sephadex G200 . One protein which ran slightly slower than 
fibronectin remained just visible.
w *
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Preparation of Antiserum to Fibronectin
Purified serum fibronectin was used to prepare antisera 
from New Zealand White rabbits. For the first injection 
0.5 mg fibronectin, dissolved in 0.5 mis PBS (pH 7.2) was 
mixed with an equal volume of Freund's complete adjuvant, 
and then injected subcutaneously. Further injections of 0.5 mg 
fibronectin with incomplete adjuvant were given every 2 weeks 
thereafter. The rabbit was first bled from the ear six weeks 
after the first injection and fortnightly thereafter.
Appreciable amounts of antisera were produced eight weeks after 
the first injection.
The antiserum was tested, along with Collaborative 
Research anti-human fibronectin antiserum against purified 
human cell and calf serum fibronectin and the sera of calf, 
horse, mouse and chick, by Ochterlonie diffusion immuno­
précipitation .
Attachment of Cells to Glass
Cells were grown in Petri dishes until dense as described 
above, and were then fed medium containing H-leucine (5 |iCi/ 
ml) for 24 hours, followed by a five hour period with no 
radioactive leucine. At the end of this time the cells were
5trypsinised and resuspended at 10 cells/ml in serum-free 
medium. 0.5 ml aliquots were then added to glass scintillation 
vials which had previously been soaked for 2 hours with 0.5 ml
of PBS or fibronectin purified from newborn calf serum (10ty,g/m!l),
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After one hour the cell suspensions were removed, the vials 
lightly rinsed once with PBS and then instagel scintillation 
cocktail added to measure radioactivity which was proportional 
to the number of adsorbed cells.
Polyacrylamide Gel Electrophoresis of Cell Lysates
4Cells were seeded in 35 mm Petri dishes at 3 x 10 cells 
per dish in DMEM supplemented with 10% newborn calf serum.
4Twenty-four hours later interferon (10 U/ml) was added to 
half the dishes. After several days incubation, but while 
still subconfluent, the medium was removed and replaced with 
methionine-free medium with or without interferon, and 
incubated for a further six hours. At the end of this period 
half the dishes were trypsinised and cells counted with a 
haemocytometer, while in the other half the medium was removed, 
cells washed with PBS and 100 nl PBS containing 100 nCi 
35S-methionine added to each dish . After 45 minutes incubation 
the radioactive methionine was removed, dishes washed with 
PBS and cells solubolised by 2% SDS and 1% mercaptoethanol 
in 5 mM tris buffer (pH 9) . 2 nl aliquots were removed from
each sample and washed on scintered glass filters with 5% 
trichloracetic acid, followed by ethanol and diethyl ether, 
and then air dried. The dried filters were put in glass
scintillation vials, solubolised with toluene/PPO scintillation
35cocktail and the S-methionine incorporated counted.
Of the remaining 98 nl of each sample, 40 ill was taken
and diluted to 50 p,l with the same buffer as was used to 
solubolise the cells, containing bromophenol blue. 5 x 105 
counts per minute of each sample were applied to polyacrylamide 
gels, as described by Laemmli (153), with a 4% stacking gel 
and 8%  resolving gel.
X-Omat H film was used to visualise the protein bands .
Fibronectin and actin were then quantitated by cutting out
the respective bands in the gels, extracting the protein into
3 mis of a scintillant, at 37°C for 48 hours, and counting 
35S in a liquid scintillation counter. The scintillant 
consisted of (in a 2 litre volume) : NCS tissue soluboliser 
(180 mis) , liquifier ( 8 g PPO + 160 mg POPOP in 84 mis of 
toluene), toluene (1716 mis) and water (20 mis) .
Immunoprécipitation of p21
In this experiment cell cultures were handled by myself,
35but labelling of cultures with S-methionine and immuno­
précipitation were conducted by Dr. Frank Cooke.
45 x 10 cells were seeded per 50 mm Petri dish in DMEM 
supplemented with 10% newborn calf serum. After 24 hours
4interferon (10 U/ml) was added to half the dishes. When
35confluent, cultures were labelled with 250 nCi S-methionine 
per dish in 0 .8 mis Earle's saline for 2 hours and then 
washed with ice-cold PBS . In cultures grown in the presence 
of interferon, IFN was also present in the radioactive saline. 
Cell lysis, immunoprécipitation and gel electrophoresis
i
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were carried out as described by Shih et al. (227) . Anti­
serum to p21 was prepared byScolnick from rats bearing
tumours induced by transplanted cells transformed by Harvey/
Sarcoma Virus (HaSV) .
Quantitiation of the p21 of each cell type with and 
without interferon, present in bands revealed by gel electroph­
oresis was attempted by removing the portion of the gels 
containing the p2 1 , and then extracting and dissolving the 
protein in scintillant. The radioactivity (counts per 
minute) in the p21 were then determined. The ratio of these 
cpm to three parameters were calculated - total protein 
content of the cell lysate (determined by Lowry), total cpm 
of the lysate, and the cpms of three other proteins which 
were apparently unaltered by interferon treatment.
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RESULTS
CHAPTER ONE
PRODUCTION AND PURIFICATION OF INTERFERON
At the time that this project commenced most studies of
interferon activity, both anticellular and antiviral, had
been conducted with interferon of specific activity routinely 
6 7around 10 to 10 U/mg of protein. As discussed in the 
introduction, this raised the possibility that many observa­
tions may be due to contaminants and not to interferon at all. 
Thus, as techniques for purification were improved, so it 
became essential to routinely use preparations of higher 
purity.
Initially techniques available in this laboratory were
7able to yield up to 2.5 x 10 units of crude L cell interferon
from ten roller bottles, which was then concentrated
approximately ten fold by ammonium sulphate precipitation
at pH 2. This also purified the interferon roughly ten fold
0to a specific activity of 10 U/mg protein, but there were 
no further purification steps.
Studies with two main aims were thus initiated?
1) To maximise the yield of interferon in the crude material,
but without increasing the volume if possible.
\
2) To improve the purification procedures so that interferon
8of close to 10 units/mg of protein could be routinely
produced. This should be achieved without too great a loss
\
of interferon during the purification steps.
I
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A) Production of Interferon
Monolayers of L929 Cells The routine procedure followed
initially was to induce 10 rollers of confluent L cells with
4 o5mls of NDV per roller (HAU:10 /ml) for one hour at 37 C,
after which the virus suspension was removed and replaced
by 25mls of serum-free medium. The interferon-containing
medium was harvested 16 hours later. As mentioned above
7this procedure yielded up to 2 .5 x 10 units of interferon 
in 250mls .
Several modifications were introduced to increase this 
yield.
1) Twenty-four hours before induction of confluent L cells, 
fresh medium was added to each roller bottle to initiate a 
further round of cell division, thereby increasing cell 
density to the maximum possible without the cells stripping 
off the glass due to overcrowding.
2) Twenty-five roller bottles were induced instead of ten.
3) Only ten millilitres of serum-free medium were added to 
each roller bottle after induction instead of 25mls.
These three changes ensured that the final volume of
the crude remained at 250 mis, but the total interferon
9 8yielded rose to about 2.5 x 10 units (10 units per roller
7bottle), with a specific activity of up to 10 U/mg of 
protein.
Suspension L Cells Induction of suspension L cells was
attempted as a potential method to produce very large
quantities of interferon but with less labour than is required
with roller bottles. Cultures were maintained in GMEM
supplemented with 10% new-born calf serum, at a concentration 
5 6of 7 x 10 to 1.5 x 10 cells per ml. Doubling time in 
agitated cultures was approximately 24 hours . Though these 
cultures were incubated in a warm room with no C0 2 buffering, 
it was found that the cells generated sufficient acid them­
selves to buffer the medium, provided their density did not
5fall below 7 x 10 /ml and culture volume was not less than 
60% of the total flask volume. It was not possible to 
continuously grow these cells simply by diluting the cells 
one to two with fresh medium every day. At least once a week 
the entire culture had to be sedimented by centrifugation and 
the cells resuspended in completely fresh medium, suggesting 
the build-up of a growth inhibitor in the conditioned medium.
For interferon induction the culture size was increased 
to two litres . Six hours prior to induction the cells were 
sedimented by centrifugation and resuspended at 10^ cells/ml 
in fresh medium. For induction the cells were again sedimented
4and resuspended in a suspension of NDV (2 x 10 HAU/ml) for 
one hour at 37°C. This suspension, unlike the cell maintenance 
cultures, was not stirred. After one hour the cells were 
sedimented from the virus suspension and resuspended in serum- 
free medium at 10^ cells/ml. After 16 hours incubation the 
cells were sedimented once more and the interferon-containing
medium harvested.
3b
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Titres of approximately 106 units/ml were obtained,
9thus yielding 2 x 10 units per two litre batch.
Larger yields could easily be increased by inducing a 
larger culture, the only limitations here being size of 
flasks and centrifugation facilities available.
However, interferon produced by L cell monolayers was 
the method eventually chosen for routine production, since 
although maintenance of a suspension L cell culture was very 
simple, the number of centrifugation steps and the volumes 
involved, during the induction process made this procedure 
very time consuming and put a strain on available centrifugation 
facilities. Routine production of interferon was taken over 
by Mr. Robert Bird, and the method he finally adopted after 
some further studies was that described in Materials and 
Methods .
All batches of crude interferon were acidified to pH 2 
with hydrochloric acid immediately after harvesting and 
stored at 4°C for three to five days before purification by 
the methods described below.
B) Purification
The strategy adopted in studies of purification was to 
test the effectiveness of several methods already published 
in the literature and adapt the most successful technique
to our own uses to give a product with specific activity of 
0about 10 units/mg of protein.
Carter and his colleagues had already tested a number 
of affinity adsorbents for their potential in affinity 
chromatographic purification of interferon (287, 288), and 
so two of their most successful adsorbents were tested - 
BSA-Sepharose 4B, and Affi-gel 202.
BSA-Sepharose 4B Huang et al. (288) first demonstrated the 
use of this adsorbent to purify human fibroblast interferon, 
binding the interferon in phosphate buffer at pH 7.2 and 
releasing it with ethylene glycol, but were unable to purify 
mouse interferon by this method. Davey et al. (287) modified
the technique to bind interferon in acetate at pH 5 and so
4 5purify 4 x 10 units of crude L cell interferon from 10 U/mg
Qof protein to 10 U/mg protein in a single step with 90% 
recovery. The method they employed was as follows:
Crude interferon was dialysed for 24 hours against 0.05 M 
sodium acetate, pH 5.0, and then applied to the BSA-Sepharose 
column which was equilibrated with the same buffer. The pH 
of the column was then raised to 7.4 by washing extensively 
with 0.02 M disodium monohydrogenphosphate. Interferon was 
then eluted by a sodium chloride gradient of 0 to 0.5 M in 
the 0.02 M phosphate buffer, with the interferon eluting in 
the early part of the gradient.
The method adopted in our studies was essentially the 
same except that ammonium sulphate-precipitated interferon 
was used instead of crude, and a much higher titre was applied
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to the column - a total of 2 x 10^ units. Furthermore a 
sodium chloride gradient was not applied to elute the 
interferon, just a fixed concentration of either 1.0 M or 
0 .1 M NaCl dissolved in the buffer.
Figure one and Table one show the results of the first 
experiment, in which 1.0 M NaCl was used to elute the inter­
feron. As can be seen, the vast bulk of the protein ran 
straight through in the acetate breakthrough, but this only 
contained 0.05% of the interferon. Washing with phosphate 
buffer at pH 7.4 released approximately 1% of the interferon. 
These results were in accord with those observed by Davey 
et al.. but the results of the salt elution were rather 
disappointing. Only 50% of the interferon was released and 
the highest specific activity attained showed just a four 
fold purification of the starting material.
It seemed possible that use of a lower salt concentration 
might release less non-interferon protein bound strongly to 
the BSA, so the experiment was repeated, but this time the 
interferon was eluted initially by 0.1 M NaCl and then 
followed by 1.0 M NaCl.
Figure 2 and Table 2 illustrate that interferon purity 
was indeed improved by eluting with a lower salt concentration. 
0 .1 M NaCl eluted the interferon, though with only 30% yield,
7the highest specific activity attained being 10 U/mg protein, 
while 1.0 M NaCl released no more interferon but doubled the 
release of protein.
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Fraction Volume
(m is )
Tota l
In te r fe ron
(U n its )
Tota l
P ro te in
(mg)
S p e c if ic
A c t iv i t y
(U/mg)
B' ttirough 1 10 794 0 ‘ 67 l* 2 x l0 5
B'through 2 10 214 0*11 2 -0 x l0 5
Washings 10 l*4 x l0 4 0*14 l*0 x l0 4
Sa lt 1 10 lx lO 6 0*24 4*8x l06
Sa lt 2 10 l»6 x l0 4 0*14 1 -lx lO 5
Sa lt 3 10 2*9xl04 0*14 1*8x10^
TABLE 1 P u r if ic a t io n  o f  In te r fe ro n  by A f f in i t y  Chromatography 
on BSA-Sepharose 4B (Experiment l )
KEY TO TABLES 1 TO 4 
B -  BREAKTHROUGH 
W -  PHOSPHATE BUFFER WASHINGS 
1 to 9 -  SALT ELUATB FRACTIONS
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INTERFERON
SPECIFIC
ACTIVITY
(UNITS/mg)
— Q - -O ------
107
Bi B2 W  1 2 3
FRACTION
FIGURE 1 P u r if ic a t io n  o f  In te r fe ro n  by A f f in i t y
Chromatography on BSA-Sepharoae 4B (Experim ent l )
KEY TO FIGURES 1 TO 4
BREAKTHROUGH _  b 
PHOSPilATE WASHINGS -  W
SALT WASHINGS -  1 to 5
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Fraction Volume
(n ils )
Tota l
In te r fe ron
(U n its )
Total 
. F ro te in
(e g )
S p e c if ic
A c t iv i t y
lU/mg)
B1 through 1 10 0 0-59 0
B'through 2 10 0 0*07 0
Washings 1 10 3*2xl05 0*11 3xl04
Washings 2 10 l«0 x l0 5 0-39 2 *6x l03
S a lt  1 10 5*6x10^ 0*05 l * l x l0 7
S a lt 2 10 3-5xl04 0*05 7*0x l05
S a lt  3 10 5xl04 0*07 7*1x10^
S a lt  4 10 100 0*07 l- 4 x l0 3
S a lt  5 10 0 0*11 0
TABLE 2 P u r if ic a t io n  o f  In te r fe ro n  by A f f in i t y  Chromatography 
on BSA-Sepnarose 4B (Experiment 2)
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Bi B2 W i W 2 1 2 3  4  5
1 0 7
INTiKFEHO:«
SPECIFIC
ACTIVITY
(UNITS/mg)
-D---□—
1 0 2
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FRACTION
FIGURE 2 P u r if ic a t io n  o f  In te r fe ro n  by A f f in i t y
Chromatography on BSA-Sepharoae 43 (Experiment 2)
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Subsequent experiments with crude interferon were less 
successful. In one typical experiment 100% of the interferon 
bound, but 5% was released in the washings and only 10% was 
eluted by salt.
Affi-gel 202 This is a commericially produced hydrocarbon-
coated agarose which Davey et al. (287) used to purify crude
mouse interferon from 105 U/mg of protein to 108 U/mg of
protein, with 95% yield in a single step, using exactly the
same conditions and buffers as for BSA-Sepharose.
Table 3 and figure 3 illustrate the results of the first 
gtest using 10 units of interferon which had been partially
purified by ammonium sulphate precipitation. Only a total of
20% of the starting material was recovered, 9% of it being
in the breakthrough and washings, and the remaining 11% in
the 1 M NaCl eluted fractions. However, despite the low yield,
the purity of the interferon was raised twenty fold from 
7 81 .6 x 10 U/mg of protein to 3 .8 x 10 U/mg protein, a consider 
able improvement on the BSA-Sepharose method. Subsequent 
experiments failed to show such encouraging results. Close 
to 100% of the interferon bound to the column, but NaCl failed 
to elute any. Application of up to 50% ethylene glycol also 
failed to remove the interferon.
Poly U-Sepharose De Maeyer-Guignard et al. (57) first 
observed that mouse interferon could bind to polynucleotides,
Fraction Volume
(m is )
Tota l
In te r fe ro n
(U n its )
Tota l
P ro te in
(raff)
S p e c if ic
A c t iv i t y
(U/mg)
S ta rtin g
IFN 40 1*1xlO9 70 l * 6x l07
B'through 40 2 * 5x l07 53 *6 4*5*10'*
Washings 30 6 *6* 10 7 6-0 l * l x l 07
S a lt wash 1 .2 5* 0x l 05 0*06 l * 0x l07
i i  i t  2 2 2 *0x l05 0*1 2 *0x l06
i i  n  5 2 l * 0x l 08 0*26 3*8x l 08
»» •» 4 2 3*6x l 06 0*032 1 *1 * 10 8
TABLE 3 P u r if ic a t io n  o f  In te r fe ro n  by A f f in i t y  Chromatography
104
FRACTION
FIGURE ;  P u r if ic a t io n  o f  In terferon , by A f f in i t y  Chromatography
on Affi-Cel 202
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and this was used as a method to elute interferon from Blue 
Dextran-Sepharose . Later, however, they purified interferon 
to homogeneity on a Poly U-Sepharose column followed by an 
anti-interferon antiserum-agarose column (58) . The results 
of a typical experiment with crude interferon using conditions 
exactly as described (58) are shown in Table 4 and figure 4.
As can be seen a fifty fold purification was possible in one 
step, with 100% yield.
Consistent results have always been obtained with Poly 
U-Sepharose and each column can be used several times. It 
is also equally effective at purifying suspension L cell 
interferon as monolayer interferon.
Coupling Several attempts were made to couple affinity 
chromatography on Poly U-Sepharose with BSA-Sepharose and 
Affi-Gel 202. Such attempts proved unsuccessful due to the 
failures of the BSA-Sepharose and Affi-gel methods which have 
already been described.
Linking ammonium sulphate precipitation with chromatography/
on Poly U-Sepharose was a little more successful. Essentially 
100% of interferon activity could be recovered from ammonium 
sulphate precipitation yet up to 90% (or one log) of activity
was often lost, especially when large interferon samples
9 .were used (more than 10 units) between the precipitation 
and the chromatography. This presumably took place during 
dialysis of the interferon into lOmM Tris-HCl for the chroma-
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Fraction Volume
(m is)
Tota l
In te r fe ro n
(U n its )
Tota l
P ro te in
(mg)
S p e c if ic
A c t iv i t y
(U/mg)
S ta rt in g
IFN 50 l * 25x l 07 25*0 5*0xl05
S a lt Wash 1 2 8*0x l06 0» }6 2*2xl07
h h 2 2 4*4x l06 0 -16 2*75*107
TABLE 4 P u r if ic a t io n  o f  In terferon , by A f f in i t y  Chromatography 
on Pol.y U-Sepharose 4B
PROTEIN
PER
FRACTION
(mß)
FIGURE 4
p
107
FRACTION
P u r ific a t io n  o f  In te r fe ro n  bv A f f in i t y  Chromatography
on Poly  U-Sepharoae 4B
tography. This was observed repeatedly with interferon from 
both monolayer and suspension L cells by both myself and 
Mr. Robert Bird.
Further studies by Mr. Bird led to the development of 
the routine procedure described in Materials and Methods of 
sequential affinity chromatography of crude interferon on 
Blue-Sepharose CL6B followed by Poly U-Sepharose 4B. Initially, 
elution of interferon from Blue-Sepharose was accomplished 
by 1 M NaCl, giving yields of 30-70%. Use of 8 M urea 
improved yields to over 70%. The entire procedure now
7routinely yields interferon with specific activity of 5 x 10
g
to 2 x 10 U/mg protein.
C) Stability
Highly purified interferon appeared to be unstable when 
in dilute solution. We found that interferon samples with a
gspecific activity of over 10 U/mg protein lost as much as 
one log of activity during storage,even at -70°C. Possibly 
interferon needs other proteins present in order for it to 
retain its conformation and thus its activity, so purer 
preparations become less stable. Certainly crude mouse 
interferon remains stable for weeks at 4°C.
An initial attempt to overcome this was made by adding 
BSA at concentrations up to 3 mg/ml to purified samples, 
which appeared to be at least partially effective. Later 
batches, purified by Blue-Sepharose and Poly U-Sepharose, were
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found to be quite stable if kept in DMEM supplemented withi
10% new-born calf serum and stored in liquid nitrogen.
D) Discussion
Huang et al. (288) found it was necessary to use ethylene 
glycol treatment to release human interferon bound to BSA- 
Sepharose at neutral pH, thus suggesting that the interferon 
was hydrophobically bound. Davey fît al. (287), however, were 
able to bind mouse interferon to BSA at pH 5 and release it 
at pH 7.2 with salt only. This suggested that electrostatic 
interactions may be more important in interferon binding.
If hydrophobic interactions were playing a major role 
in our experiments, then the use of ethylene glycol may have 
released the bound interferon. However, hydrophobic bonding 
is almost certainly very important with Affi-gel 202, yet 
ethylene glycol failed to release bound interferon.
Binding of interferon to polynucleotides in general 
and poly U in particular is probably electrostatic in nature, 
being easily reversed by the addition of salt. The physio­
logical significance, if any, of such a specific binding as 
this is still unknown. The fact that double-stranded poly­
ribonucleotides are inducers of interferon both in tissue 
culture and in animals has led some to suggest that the 
polynucleotide-interferon binding is important in the induction 
of interferon (236) .
At the start of this study experiments by most workers
routinely used interferon of specific activity around 10 - 
107 units/mg protein, though several laboratories had 
claimed to have purified various interferons to homogeneity. 
Knight (144) in 1975 purified mouse interferon by a four 
step procedure to give a preparation containing 10-11 poly­
peptides, apparently all with interferon activity, with total
Q
specific activity of 2.5 x 10 U/mg protein. Subsequent
studies since 1978 (45, 58, 134, 141, 245) have purified
gmouse interferon to more than 10 U/mg protein containing 
only two active polypeptides . All such preparations possess 
both antiviral and anticellular activities.
The drawbacks with most of these techniques which purify 
interferon to homogeneity are that most have several steps.
This makes the process extremly time-consuming and gives very 
low yields at the finish. For instance, Iwakura e_t al. (134) 
purified interferon from mouse L cells to a specific activity
9of 2 .6 x 10 units/mg protein in a process that used eightI
steps but gave a yield of less than 1% of the starting material. 
Similarly, with purification of human alpha and beta interferons, 
multistep procedures have purified interferon to homogeneity 
but have often only obtained low yields (24, 145, 216, 249,
284, 285) .
Due to the problems of obtaining large quantities of 
pure interferon the majority of studies on interferon's 
activities are still conducted with material of specific 
activity in the range of 107-10^ units/mg protein since large
0
I l l
quantities of interferon of this purity can be routinely 
achieved. A few purification techniques have, however , been 
developed which give highly purified interferon in high 
yields, e.g. the two-step procedure developed by de Maeyer- 
Guignard et al. (58) for mouse interferon using Poly U-Sepharose 
and anti-interferon antiserum, and purification of human 
fibroblast interferon by Knight et al. (147) by Blue- 
Sepharose and polyacrylamide gel electrophoresis, which suggests 
that it may soon become possible to routinely employ pure 
interferon in many more studies .
Using interferon purified by Poly U-Sepharose and anti­
body agarose, De Maeyer-Guignard and her colleagues have 
recently published the results of studies employing homogeneous 
mouse interferon (58, 59, 82) .
In summary, the results presented in this chapter show
the efficiency of various agents in acting as affinity
adsorbents for the purification of mouse interferon and
described the development of a technique which can routinely
7 8achieve specific activities of 5 x 10 to 2 x 10 units/mg 
protein with at least a 70% recovery of the initial crude 
material. This procedure, whilst obtaining interferon which 
is at best 10% pure, compares favourably with methods used 
by others to produce interferon used routinely in studies of 
interferon's antiviral and anticellular activities.
CHAPTER TWO
EFFECTS OF INTERFERON ON GROWTH OF CELLS
On a number of occasions interferon has been reported 
to inhibit the growth of both normal and transformed cells, 
and several studies (8 6 , 143, 157, 166, 244) have found 
that interferon may affect the two types of cells differentially.
The series of experiments described in this chapter 
studied the effect of interferon on various parameters of 
cell growth in an attempt to establish if differences between 
the responses of normal and transformed cells to interferon 
do exist.
A) Senstivities to Antiviral and Cell Growth Inhibitory 
Activities
Inhibition of SFV replication (as measured by ^H-uridine 
incorporation in AMD-treated cells) and cellular DNA systhesis
(as measured by 3H-thymidine incorporation) by a range of
4 - 3  -.1 •interferon doses (10 to 10 units/ml) in several cell lines
is shown in the dose response curves of figures 5 and 6 .
The data presented in Table 5 show that the sensitivities
to interferon's antiviral activity vary widely, a range of
about 1000 fold being seen in just these eight cell lines .
By contrast, sensitivities to cell growth inhibition are
remarkably similar, varying by only 15 fold. However, since
these cells were incubated for three days in the presence
i
3of interferon, before labelling with H-thymidine, the
V
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LECSfD TO FIGURE 5
H^-Uridine incorporation measures only viral replication. 
Cellular RNA synthesis is inhibited by the presence of 
actinomycin D.
Dotted lines represent the following - 
a - lOO^ i virus replication (virus control) 
b - 5Q?o virus replication, 
c - 0 virus replication (cell control)
d - Interferon dose that would reduce viral replication to 
50^ of virus control (VI50).
This experiment was conducted by the same method as
that employed for routine interferon assays (266). Basically,
2 5cells were seeded in glass vials (area of base 1cm ) at 10 
cells per vial, and incubated for 24 hours in lmlof DMEM 
supplemented with 10£« new-born calf serum. At the end of 
this period the medium was removed and replaced with 1ml 
medium containing 2% new-born calf serum and a range of 
doses of interferon. After a farther 24 hour incubation 
this medium was replaced by 0*25ml DMEMplus 2Jti new-born 
calf serum containing actinomycin D (lpig/ml) and Semliki 
Forest Virus(SFV). The AMD inhibits the cellular DNA-directed 
RNA synthesis, but not the viral RNA-directed RNA synthesis. 
After-a 3 hour incubation 0*25 mlDMEM containing 2% new-born 
calf serum, AMD and ^-uridine (lfiCi/ral) was added to each , 
vial for a further 2£ hours. Incorporation of 5H-uridine 
intothe acid precipitable material was then recorded in order 
to measure SFV replication.
*FIGURE 5
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LffiE.D TO KI GURK 6
''h-  Thymi d ine in co rpora tion  measured the le v e l  o f  DNA 
synthesis in  the cu ltu res .
Dotted lin e s  represen t the fo llo w in g  -  
a -  5Q. in h ib it io n  o f  c e l lu la r  DNA syn thesis, 
b -  In te r fe ron  dose causing Vbo in h ib it io n  o f  c e l lu la r  
DNA syn thesis .
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Sensitivity of Cell Lines to the Growth Inhibitory 
Activity of Interferon
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observed reduction in H-thymidine incorporation at high
interferon doses was due not only to a slower rate of DNA
synthesis, but also to lower cell numbers. The dose-response
curves were, therefore difficult to interpret. A 24 hour
3interferon treatment before labelling with H-thymidine 
would have avoided the complication of reduced cell numbers 
so that reduced rate of DNA synthesis only was measured.
Such data are presented in paragraph C of this chapter, though 
only with one interferon dose . These results will be 
compared in the Discussion.
The maximum effect on DNA synthesis in these experiments
4was observed at an interferon dose of 10 units/ml, so this 
dose was used in most subsequent experiments .
B) Growth and Saturation Densities
4Growth curves were determined with and without 10 units/ml
of interferon for various cell lines (fig. 7). CSHIOT^,
NIH MEF and C3H MEF cells without interferon showed the growth
characteristic typical of normal cells whose growth is
subject to density dependent inhibition, i .e. rapid initial
4 2growth to a saturation density of 1-3 x 10 cells per cm .
In the presence of interferon the growth of CSHIOT^ and C3H MEF 
cells was very severely inhibited, but growth of NIH MEF
cells was unaffected. In the absence of interferon, the MSV/
transformants of the C3H10T*5 and NIH MEF cells grew initially 
at a rate very similar to normal cells, but they reached
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densities ten to twenty times greater than their non- 
transformed parents. These cells had, thus, lost density- 
dependent inhibition of growth . An exception were MSV C3H2 
cells, which at early passage post-transformation retained 
density-dependent inhibition of growth, and had a saturation 
density very similar to the CSHIOT^ cells. At later passages, 
however, these cells too lost growth control and then grew 
to very high densities . The early passage MSV C3H2 cells 
responded to interferon in a manner very similar to CSHIOT^ 
cells, growth being severely inhibited. Those cells that 
had lost growth control, including late passage MSV C3H2 
cells, responded to interferon very differently. Growth of 
cells in the logarithmic phase seemed to be only a little 
inhibited by interferon, but, with the exception of MSV MEF4 
cells, growth was strongly inhibited at densities similar to 
the saturation density for control CSHIOT^ cells. This 
suggested that interferon may have imposed a degree of growth 
control onto these cells . MSV MEF4 cells appeared to be 
resistant to this property of interferon, continuing to grow 
to a density similar to that of untreated cultures.
There was a possibility that the cessation of growth 
by MSV C3H2 and 6 and MSV MEF2 at a low cell density may be 
due to a delayed toxic effect of interferon, in which case 
if interferon-treated cells were reseeded at very low density, 
still in the presence of interferon, no new growth should 
occur. This was tested with MSV MEF2 cells by repeatedly
i
r
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passing the cells in the presence of interferon. At each 
passage the untreated controls grew to a density 5 to 10 fold
higher than that of the interferon-treated cultures (15 to
6 6 2 20 x 10 versus 2 to 4 x 10 cells per 25cm flask), thus
demonstrating that a delayed cytoxicity is not the cause
of the growth inhibition. Similar results with a wide range
of other cell lines have been obtained by Dr. A. Morris.
The NIH 3T3 4E cells and their transformants, CCl and
cA12, appeared to be less sensitive to interferon's activity.
The nontransformed NIH 3T3 4E cells grew to almost as high
a density as the CCl and cA12, but interferon treatment did
reduce it somewhat, as well as reducing the growth rate.
Interferon reduced the growth rate of the cA12 cells but not
the CCl cells, and conversely the saturation density of CCl
cells was reduced, but that of cA12 was barely affected.
Interestingly, in interferon-treated cultures of NIH 3T3,
CCl and cA12 cells the saturation densities were all very 
5 2similar - about 10 cells per cm .
Despite the fact that both CSHlOT^s cl8 and NIH 3T3 4E 
cells were used in these experiments at early post-cloning
passages (less than 15 passages), it is clear that they/
behaved very differently, the CSHlOTh cl8 cells being much 
more tightly growth controlled and growth rate being much more 
severely hindered by interferon. The NIH 3T3 cells had a 
tendency to undergo spontaneous transformation after about 
20 passages in culture, and even at the earliest passages the
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cells were smaller and the microfilament stress fibre system 
was less extensive than in early passage C3H10T*5 cl8 cells, 
in addition to the higher saturation density (results not 
shown) . It is quite possible that this state of partial 
transformation may have been partly responsible for the 
different behaviour of these cells.
When growth curves for C3H 10Th cl8 cells at later 
passage (passage 30) were measured, the results were very 
different from those obtained with early passage cells 
(figure 8) . These cells showed at least a partial loss of 
density-dependent inhibition of growth, and reached a saturation 
density several fold higher than that observed for early 
passage CIHIOT^ cl8 cells. In addition cell size was also 
reduced. This would suggest that these cells may be under­
going progressive spontaneous transformation. The response
I
of these cells to interferon treatment was also very similar
to that seen with the density-independent MSV-transformed
cells . The logarithmic growth phase was only inhibited a
little by interferon, but growth was strongly inhibited at a
density very similar to early passage CSHIOT^ cl8 cells - 
4 2about 2 x 10 cells/cm . These data, plus those obtained 
with the MSV C3H2 cells, suggest that the way in which MSV- 
transformed cells respond to interferon is not due to MSV
transformation per se, but is determined more by the degree
/
of growth control shown by a cell type.
It was possible that, due to the impure mouse interferon
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cells were smaller and the microfilament stress fibre system 
was less extensive than in early passage C3HlOT*s cl8 cells, 
in addition to the higher saturation density (results not 
shown). It is quite possible that this state of partial 
transformation may have been partly responsible for the 
different behaviour of these cells.
When growth curves for C3H lOT^ cl8 cells at later 
passage (passage 30) were measured, the results were very 
different from those obtained with early passage cells 
(figure 8) . These cells showed at least a partial loss of 
density-dependent inhibition of growth, and reached a saturation 
density several fold higher than that observed for early 
passage CIHIOT^ cl8 cells . In addition cell size was also 
reduced. This would suggest that these cells may be under­
going progressive spontaneous transformation. The response 
of these cells to interferon treatment was also very similar 
to that seen with the density-independent MSV-transformed 
cells . The logarithmic growth phase was only inhibited a 
little by interferon, but growth was strongly inhibited at a
density very similar to early passage CSHlOT^s cl8 cells - 
4 2about 2 x 10 cells/cm . These data, plus those obtained 
with the MSV C3H2 cells, suggest that the way in which MSV- 
transformed cells respond to interferon is not due to MSV 
transformation per se, but is determined more by the degree 
of growth control shown by a cell type.
It was possible that, due to the impure mouse interferon
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preparations used, some unknown contaminant may be responsible 
for the growth effects observed. Several preparations were 
therefore tested on heterologous rat cells . Figure 9 shows 
the results obtained with one preparation on Normal Rat 
Kidney (NRK) cells and MSV-transformed (KNRK) cells. Inter­
feron preparations had little effect on growth of these 
heterologous cells, confirming that the growth inhibitory 
activity was species restricted, and therefore almost certainly 
due to interferon itself.
Overall the data show that mouse interferon affected the 
growth of mouse cells in two ways:
a) increased population doubling time of cells in logarithmic 
growth phase, and
b) lowered saturation density.
Cells showed sensitivity to one, both or neither of these 
activities. The cells which were strongly growth controlled 
were very sensitive to the inhibition of logarithmic phase 
growth, e.g. C3H MEF, early passage CSHlOT^ and early passage 
post-transformation MSV C3H2, while those which had lost, or 
were losing, growth control were usually less sensitive to 
the effect of interferon on logarithmic phase growth, but
showed reduced saturation densities, e .g. MSV C3H6, MSV MEF2,)
late passage post-transformation MSV C3H2, NIH 3T3 and late 
passage C3HlOT*s. Other cell types were insensitive to both 
effects, e.g. NIH MEF and MSV MEF4.
FIGURE 9
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C) Effects of Cell Density on Interferon's Inhibition of 
DNA Synthesis
The observations that interferon had differential effects 
on growth of growth-controlled and uncontrolled cell lines 
suggested that interferon added to cells at different densities 
might inhibit DNA synthesis by varying degrees. Thus, inter­
feron treatment of cells showing no growth control would 
cause a dramatic inhibition of DNA synthesis in cells seeded 
at high density but not in sparsely-seeded cells. The reverse 
would be true for growth controlled cells in which growth 
of sparsely-seeded cells would be dramatically inhibited by 
interferon, but at high density neither control nor interferon- 
treated cultures may be growing.
3This was tested by measuring the incorporation of H- 
thymidine into early passage ClHlOT^ cl8 cells and three 
MSV-transformed cell clones, seeded into wells of microtitre 
trays (96 wells per tray) at varying densities. As can be 
seen in Table 6 the C3H10T% cl8 cells incorporated much less
3H-thymidine per cell at high than at low density for these 
cells . Interferon had proportionally greater inhibitory 
activity at the lower cell density, where rapid growth would 
normally occur, than at the higher densities where control 
cells had ceased growing due to density dependent growth 
inhibition.
The transformed cells, in the absence of interferon, 
incorporated roughly the same amount of radioactive thymidine
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TABLE 6
CELL
LINE
IFN
U/ml
Incorporation of 
Material mean cpm
^H-Thymidine into acid-insoluble
per culture xlO ^
No. of cells per well
500 2000 10000 20000
(1000/cm2) (4000/cm2) (20000/cm2) (40000/cm2)
0 2-9 (6:1) + 0-5 (4.1) 3*3 (1*3) NP
CJK lOTj ^ .  •• *
104 1*9 (4sl) 7*2 (3*5*1) 2*7 (1*4) NO
0 NP 7*1 (3-5*1) 29*7 (3*1) 50*8 (2*5:1)
KSV CJH2
104 NP 7*1 (5*5*1) 22*0 (2*2:1) 33*6 (1*6:1)
0 NP 8*0 (4:1) 32*0 (3*2:1) 48*8 (2*5:1)
MSV C3H6
104 NP 5-8 (3:1) 22*6 (2*2:1) 22*2 (1*1:1)
0 NP 8-3 (4:1) 43*8 (4*4:1) 57*6 (2*8:1)
MSV MEF2
104 NP 7-1 (3*5*1) 56*2 (3*6:1) 53*9 (1*7*1)
Effect of Interferon on DNA Synthesis at Different Cell 
Penalties
+Nos* in brackets indicate the ratio of cpm per cell.
Not Pone i NP
1 3 0
per cell throughout (3 to 4 x 103 cpm per cell at 2000 cells/ 
well, falling only to 2.5 to 2.8 x 103 cpm per cell at 20000 
cells per well) . Interferon had a proportionally greater 
inhibitory effect at the higher cell density, the thymidine 
incorporated per cell being virtually unaltered at 2000 cells 
per well, but roughly halved at 20000 cells per well (1.1 to 
1.7 x 103 cpm per cell). Nevertheless, DNA synthesis in the 
transformed cells at high density was still quite high, 
whereas the complete inhibition of growth seen in the growth 
curves of figure 7 would suggest that DNA synthesis should 
be reduced to zero. There are several possible explanations 
for this contradiction, the two most likely being (i) cells 
that are already crowded are much less sensitive to the 
addition of interferon than cells which are initially sparse 
at the time of interferon addition, or (ii) interferon takes 
more than 24 hours to cause maximal inhibition of DNA 
synthesis. These possibilities will be discussed in detail 
later.
D) Focus Formation
The ability of dispersed transformed cells to form 
discrete foci on top of a monolayer of normal cells is a 
growth property peculiar to the transformed phenotype, made 
possible by the lack of contact inhibition of movement and 
density dependent inhibition of growth in such cells. The 
effects of interferon on the ability of transformed non-
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per cell throughout (3 to 4 x 103 cpm per cell at 2000 cells/
well, falling only to 2 .5 to 2 .8 x 103 cpm per cell at 20000
cells per well) . Interferon had a proportionally greater
inhibitory effect at the higher cell density, the thymidine
incorporated per cell being virtually unaltered at 2000 cells
per well, but roughly halved at 20000 cells per well (1.1 to 
31.7 x 10 cpm per cell) . Nevertheless, DNA synthesis in the 
transformed cells at high density was still quite high, 
whereas the complete inhibition of growth seen in the growth 
curves of figure 7 would suggest that DNA synthesis should 
be reduced to zero. There are several possible explanations 
for this contradiction, the two most likely being (i) cells 
that are already crowded are much less sensitive to the 
addition of interferon than cells which are initially sparse 
at the time of interferon addition, or (ii) interferon takes 
more than 24 hours to cause maximal inhibition of DNA 
synthesis. These possibilities will be discussed in detail 
later.
D) Focus Formation
The ability of dispersed transformed cells to form 
discrete foci on top of a monolayer of normal cells is a 
growth property peculiar to the transformed phenotype, made 
possible by the lack of contact inhibition of movement and 
density dependent inhibition of growth in such cells. The 
effects of interferon on the ability of transformed non-
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producer cells to form foci was studied to assess interferon's 
®ffici®ncy in inhibiting growth under transformation-specific 
conditions . It was found that focus formation was inhibited 
by widely varying degrees, ranging from complete inhibition 
to only 50% reduction (Table 7) . MSV C3H6 cells were not 
used in this experiment since they produce MSV/MLV and so 
form foci by spread of virus rather than by simple growth of 
cells, and since interferon inhibits MSV/hLV production (291) 
it would be difficult to dissociate this from an effect on 
cell growth. As with the growth curves, MSV MEF4 cells were 
the least sensitive to interferon, focus formation being 
reduced by only about 50%. However, CCI cells which were 
also quite insensitive to interferon's growth inhibitory 
activities, were clearly quite sensitive to its focus forming 
inhibitory activity, the numbers of foci formed being reduced 
by 96%. This would
suggest that interferon's growth inhibition and inhibition 
of focus formation may occur by different mechanisms.
Experiments designed to distinguish between cell growth 
inhibition and a transformation-specific effect by interferon 
are described in section F .
E) Anchorage Independence
Transformed cells, having lost the requirement to attach 
to a solid substrate in order to grow, are able to grow 
quite freely when in suspension. Thus, growth of single
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TABLE 7
C ell
type
IFN
(U/inl)
C loning 
in  l iq u id
ji Focus 
formation
R atio  o f  
fo c i/ c lon es  
e f f ic ie n c y
}i A;<ar 
co lon ies  
formation
R a tio  o f  
a^-ar cols/ 
c lon es
NIH 3T3 0 36± 3*7 1 - - - -
4E 104 35±5*8 - - - -
C3H lOTV
0 6 l± . l l * 5 - - - -
i o 4 25 ±  2»7 - - - -
HSV C3H2 0
35±9 *0 32± 3-0 0*91 8*0 ±1*2 0*23
104 35±10*4 0 0 3*3 ±0*2 0*10
M3V C3H6 0
27 ±1 1 *0 - - 21*2d> 1*6 0*79
104 18 ± 7 *0 - - 12*7± 1*3 0*70
KSV MEF2 0 59 ±12*1
40 ±3 *0 0*68 14*0± 1*3 0*24
104 49 ±10*0 12 ±1 *2 0*24 4*0± 0*6 0*08
0 42 ±6 *7 46 ¿4 *2 1*09 43*04: 3*8 1*02
MSV MEF4
104 30±5 *2 22 ±  2*1 0*73 20*7± 3*4 0*69
CCI 0
74 ± 5 *8 52 4:1*6 0*70 37*1± 5*5 0*50
104 50 ±11*2 2 ±2 *5 0*04 15*5± 5*2 0*27
cA12 0
57 ±12*2 26±8*8 0*46 34*9± 5*5 0*61
104 27 ±10*7 11 ±4 *2 0*40 13*3± 6*5 0*49
E ff  act o f  In te r fe ro n  on Clonlnfe E ffic ie n c y  in  L iqu id  I'edium. on?. Focus 
Formation and on Growth in  S o ft Agar o f  Two Normal and Six M3V- 
Transformed C e ll Clones
 ^ The data presented in th is ' Table a re  the means o f  resu lts  from nine
P e tr i  dishes which rece iv ed  the seme treatment in  3 separate experim ents.
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cells to form colonies suspended in agar is a property 
specific to the transformed state. The effects of interferon 
on this parameter were, therefore, studied to assess its 
ability to inhibit growth under these transformation-specific 
conditions.
The ability of transformed cells ,to grow in agar varied
widely, ranging from only 8% efficiency for MSV C3H2 to 4336
for MSVMEF4. Several of the transformed clones, e.g. MSV C3H2
and MSV MEF2, were unable to grow in agar at all at early
passages post-transformation, but they were all able to grow
in agar by passage 20 (292) . The effects of interferon on
efficiency of growth in agar were measured between the
twentieth and thirtieth passages . It was found that interferon
reduced the efficiency of growth by between 40% for MSV C3H6 
MEF2
and 71% for MSV/ Even with such a large inhibition, the 
efficiency of growth in an interferon-treated culture of CCl 
cells was still greater than growth in a control culture of 
MSV C3H2 cells, the efficiencies being 13.5% and 8% respect­
ively (Table 7).
In addition those colonies that did grow in the presence 
of interferon were greatly reduced in size, compared to those 
in control cultures, and necrotic colonies were most frequently 
seen.
These data do not give an indication of the mechanism 
by which interferon inhibited focus formation and growth in 
agar. It is possible that the inhibition was due solely to
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interferon's antiproliferative activity, but it is also 
possible that there may be a specific effect on the trans­
formed phenotype. Experiments described in the next section 
clarify this possibility.
F) Cloning Efficiency in Liquid Medium
Growth of dispersed cells to form colonies on a solid 
surface in liquid medium is a property not specific to the 
transformed state and so inhibition of colony formation by
interferon treatment under these conditions is likely to
/ /
involve only the non-specific growth inhibitory activity. 
Experiments were conducted to measure the efficiency of 
cloning on plastic, and these data were then used to identify 
a transformation-specific effect of interferon on focus 
formation and growth in agar by transformed cells.
Table 7 shows that interferon had variable effects on 
the cloning efficiency of normal and transformed cells, 
ranging from a 59% reduction for C3HlOT*s cells to little or no 
change for NIH 3T3 and MSV C3H2 cells. In most cases the 
sizes of the colonies which did form were also somewhat 
reduced by interferon.
When the efficiency of cloning of transformed cells on 
plastic was compared to their growth in agar and focus form­
ation, it was found that interferon did have a greater 
inhibitory effect on these two transformation-specific parameters 
This was measured by calculating the ratios for efficiency
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of focus formation or growth in agar to the efficiency of 
cloning on plastic.
For focus formation interferon treatment reduced the 
ratio by a variable degree, ranging from 33% for MSV MEF4 
cells, to a reduction to zero for MSV C3H2 cells due to the 
total inhibition of focus formation in these cells. With 
growth in agar the reductions in the ratio were a little less 
dramatic, ranging from 11% for MSV C3H6 cells to 67% for 
MSVMEF2 cells .
These data indicate that the two transformation-specific
properties of anchorage independence and focus formation were
\
inhibited by interferon by at least two mechanisms - a non­
specific growth inhibition, and an additional activity which 
was highly variable but accounted for a considerable proportion 
of the inhibitory activity against focus formation and growth 
in agar. Since xnterferon was much more active at inhibiting 
growth of transformed cells under conditions selective for 
the state than it was under non-selective conditions, it 
would seem very likely that the additional activity in trans­
formation-selective conditions was due to an effect aimed 
specifically against the transformed phenotype.
G) Effects of Serum Concentration on Interferon Activity
Kading et al. (138) reported that lowering the serum
concentration enhanced interferon's inhibition of cloning in
4 4liquid media. However, using 10 U/ml and 3 x 10 U/ml of
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TABLE 8
Serum 
Con ten t
1 FN
(U/ml)
Cloning E f f ic ie n c ie s  
liq u id  Medium (;t))
in
o f  Medium
( * )
CC1 cA12 DA4
0 59 51 27
20
10 4 48 59 55
3x 104 42 53 20
0 ND 54 22
10
10 4 ND 50 19
3xio4 ND 42 20
0 28 54 20
5
10 4 35 57 18
orHXN"> 24 26 17
Effects of Serum Content of Medium on Interferon's Inhibition 
of Cloning on. Plastic
Not Done * ND
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interferon no change in interferon1s effect on cloning could 
be observed on these cells when the serum concentration was 
lowered from 20% to 5% (Table 8) .
However, when growth curves for early passage CSHIOT^ 
and MSV C3H6 cells were repeated in medium containing 50% 
serum several changes were observed (figure 10). The CSHlOT^ 
cells grew to a much higher density, as expected, but inter­
feron had no effect on the growth rate or saturation density 
of these cells . The MSV C3H6 grew to the same density as in 
medium containing 10% serum, while interferon treatment only 
had a small effect on initial growth rate and final saturation 
density was only reduced by half.
H) Conclusions
The results presented in this chapter show that interferon 
can reduce the growth rate of cells, whether they are normal 
or transformed, but also causes the transformed phenotype to 
become a more normal one. Thus, it was found that interferon?
a) reduced the saturation density of transformed cells, 
suggesting that density dependent growth inhibition was at 
least partially restored?
b) inhibited ability of single transformed cells to form foci 
on top of a confluent monolayer of normal cells, which even 
after growth inhibition is taken into account, suggests at 
least partial restoration of contact inhibition of movement, 
and density dependent inhibition of growth?
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c) reduced the ability of transformed cells to grow suspended 
in agar, which again even when growth inhibition has been 
accounted for, suggests that partial restoration of anchorage 
dependence occurred.
Serum factors may influence these actions of interferon, 
overcoming its growth inhibitory activity at very high 
concentrations but having little effect on interferon1s 
inhibition of colony formation at lower concentrations.
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CHAPTER THREE
INTERACTIONS BETWEEN BUTYRIC ACID AND 
INTERFERON IN GROWTH INHIBITION
It has been known for some time that sodium butyrate 
could inhibit the growth of many cell types and could also 
cause partial reversal of the transformed phenotype (8 , 83,
85, 171). Transformed cells become flatter, grow in more 
orderly arrays and possess a near-normal microfilament system 
(8 , 171, 243), but do not show density-dependent inhibition 
of growth (8 , 83) .
Bourgeade and Chany (35) recently reported that sodium 
butyrate could enhance interferon's antiviral and growth 
inhibitory activities on MSV-transformed cells, but not on 
normal embryonic fibroblasts .
This chapter describes studies on the effects of butyric 
acid on interferon's growth inhibitory activity, while 
chapter 4 looks at the effects on cell morphology.
A) Effects of Butyric Acid on Growth Curves
Figure 11 shows the growth curves obtained as a result of 
treatment with interferon and butyric acid on CSHlOT^, MSV C3H2 
and MSV C3H6 cells . The greatest effect of 0.5 mM butyric acid 
both on MSV-transformed and normal cells was to greatly delay 
initiation of growth, but once the logarithmic phase started, 
growth appeared to have been almost as rapid as in controls. 
This inhibition was even more severe when butyric acid and
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FIGURE 11
CELLS PER
Effects of Butyric Acid, in the Presence or Absence of 
Interferon, on the Growtn of Cells.
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interferon were added together.
Butyric acid appeared to have had little effect on the 
saturation density of MSV C3H2 cells, but small reductions 
can be seen with MSV C3H6 and C3H10T^ cells . However, it 
is not clear if such small reductions are significant.
The general conclusions that can be drawn from fig 11 
suggest that the growth inhibitory effects of butyric acid 
and interferon are additive, one effect superimposing upon 
the other but neither being enhanced.
B) Effects of Butyric Acid on 3H-thymidine Incorporation 
into Cellular DNA
4Using interferon at 100 and 10 units/ml and 0.5 mH 
butyric acid in experiments conducted essentially as in 
chapter two paragraph C, the results shown in Figure 12 were 
obtained.
These data broadly confirm those shown in Figure 11?
not synergistic, but either
that the effects of butyric acid and interferon together are/ 
or less than additive
additiv%£ With the exception of MSV MEF4 cells, every cell 
type tested, whether normal or transformed, was inhibited by 
0.5 nM butyric acid and 100 units/ml interferon at most cell 
densities . The two agents usually inhibited ^H-thymidine
4incorporation by as much as 10 units/ml interferon alone.
MSV MEF4 cells appeared to be almost completely resistant to 
butyric acid, but did show some sensitivity to interferon 
(though less than any of the other cell types tested) .
KICJRK 12 Effect of Interferon and Butyric Acid on DNA
Synthesis of Cells at Different Densities
KEY
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FIGURE 12 cont/d.
C) Conclusions
The data presented in these two sections show that 
interferon and butyric acid can act additively to inhibit 
growth of both transformed and normal cell types (in contrast 
to the findings of Bourgeade and Chany (35) ) . Thus growth 
of sparse cells was severely inhibited by the additive effects 
of interferon and butyric acid, but saturation density was 
affected only by interferon. This clear distinction between 
butyric acid and interferon activities, and their lack of 
synergism when added together, suggests that the two agents
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act by different means.
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CHAPTER FOUR
EFFECTS ON CELL SURFACES AND MORPHOLOGY
Cell-to-cell and cell-to-substrate interactions are 
very important in the control of cell behaviour, organisation 
and growth both in vivo and in vitro. Transformed and 
tumour cells show many changes at their surfaces which may 
be linked to the loss of some characteristics of normal cells 
such as a well-spread flattened morphology, strong adhesion 
to the substrate and density dependent inhibition of growth,.
A series of experiments were conducted to assess whether 
interferon's transformation-specific activity could be 
attributed to some effects on the cells' surfaces, resulting 
in a more normal behaviour. Agglutinability by concanavalin A, 
and adhesion to glass surfaces were briefly examined, but 
the majority of the studies concentrated on observing the 
overall cellular morphology, intracellular microfilament 
system and the cell surface fibronectin distribution. Butyric 
acid's combined effect with interferon on these parameters 
was also studied.
A) Agqlutinability by Concanavalin A
A number of experiments were conducted in which the 
agglutinability of CCI cells grown in the presence or absence 
of 10^ U/ml interferon was compared with that of NIH 3T3 cells. 
Table 9 shows the results of the first experiment in which 
the CCI cells grown in the presence of interferon were clearly
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TABLE 9
% C e lls  not Agglu tinated
a ft e r  Time (mins)
CELL LINE IFN Con A
(U/ml) (pg/ml) 0 mins 13  rains 30 mins
NIH 3T3 4E 0
0 100 100 94
100 100 38 34
0 100 100 100
0
100 100 22 7
CC1
10 4
0 100 100 100
100 100 66 94
Agglutinability of CC1 and NIH 3T3 4E Cel la b.y Con A after Growth 
in the presence or Absence of Interferon
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much less agglutinable than those grown without interferon, 
or even than NIH 3T3 cells. Several subsequent experiments 
gave much less clear-cut results, only a two-fold reduction 
in agglutinability being seen (results not shown) . These 
variable results were attributed at least in part to the 
technical problems involved in this experiment (such as 
preventing cells adhering to the walls of the vessel) , and 
so these studies were not continued. Nevertheless, the data 
presented in Table 9, and general observations of the 
behaviour of trypsinised cells strongly suggest that inter­
feron-treated transformed cells are less agglutinable than 
those grown in the absence of interferon.
B) Morphology
The majority of transformed cell types show a different 
morphology from their normal parents, being small and rounded, 
and the cultures do not possess the orderly whorls and parallel 
arrays of cells typical of normal fibroblast cultures, but 
grow in a totally disorderly manner. There have been 
numerous reports that agents which reverse the transformed 
phenotype , such as cyclic AMP and butyric acid, cause the 
cells to be flatter and adopt more orderly patterns (8 , 83,
205, 243) . Only a few studies have reported that interferon 
has such an effect on morphology (78, 89, 201) . A series 
of experiments was therefore conducted to assess whether 
interferon could affect the morphology of these cells, after
treatment for varying periods up to one week.
Figure 13 illustrates that in the presence of 10 units/ml 
of interferon cells were enlarged. In this figure the 
morphologies of six cell types with or without interferon and/ 
or butyric acid are presented. These cell types are NIH MEF, 
C3H MEF, C3H10T*5, MSV C3H2, MSV C3H£, MSV MEF2 and MSV MEF4 .
For each cell type there are four photographs: i) control,
4ii) with 10 units/ml interferon, iii) with 0.5 mM butyric
4acid and iv) with 0.5 mM butyric acid and 10 units/ml of 
interferon.
As with the growth curves, the NIH MEF cells appeared 
to be resistant to the interferon, remaining at about 200- 
400 tim long (Fig. 13b (i) and (ii)) .while the C3H MEF cells 
increased in size from about 100-200 urn long to 250-400 jim 
in length (Fig. 13a (i) and (ii) ) . The CSHIOT^ cells, in 
the absence of interferon were approximately the same size 
as untreated C3H MEF cells, but in its presence they appeared 
to respond less dramatically than did the primary embryonic 
fibroblasts, increasing in length to only about 300 p.m (fig.
13c (i) and (ii) ) . Cells of the different transformed clones 
shown in figure 13d-g clearly became flattened and more 
orderly, except for MSV MEF4 cells which appeared to be quite 
insensitive to interferon (fig. 13g (i) and (ii) ). This 
insensitivity of MSV MEF4 cells correlates with their 
resistance to interferon's growth inhibition. MSV C3H2 and 6 
and MSV MEF2 cells all increased their sizes from 50-100 nm
1LBSBiD TO KICURK 13
The e f fe c t s  o f  in te r fe ro n  and b u ty r ic  acid  on c e l l  
and cu ltu re  morphology.
C e lls  grown on p la s t ic  p e t r i  d ish es  w ith or w ithout 
104 U/ml in te r fe ro n  and O^mM b u ty ric  a c id ; f ix e d  w ith  
3»^o formaldehyde in  PBS and stained w ith  c ry s ta l v io l e t .  
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( i )  C ontro ls ( i f )  10^ U/mlIFN
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in length to yield a heterogeneous mixture of cells ranging 
from 80 (im to 200 (im long, the largest cells only being 
found frequently in the interferon-treated MSV MEF2 cultures 
(fig. 13f (ii) ). In addition, at the time that the cultures 
were fixed and stained, the interferon-treated cultures were 
close to their maximum density, while the untreated controls 
were still growing rapidly, and still sparse enough to be 
able to identify individual cells. NIH 3T3 4E, CC1 and cA12 
cells, like MSV MEF4, were relatively insensitive, though 
some flattening could be seen (results not shown), paralleling 
their insensitivity to interferon's saturation density 
reducing effect seen in chapter two.
Increased spreading of cells could be seen with as little 
as 10 units/ml of interferon on MSV C3H6 and MSV MEF2 cells, 
but not MSV C3H2 cells (results not shown), which parallels 
the results of the growth curves in chapter two which showed 
MSV C3H6 and MSV MEF2 cells to be the most sensitive to 
interferon of the clones studied.
Butyric acid (0.5 mM) clearly had a combined action 
with interferon on the transformed cells (fig. 13), exqept 
MSV MEF4 cells which once again were resistant to both butyric 
acid and interferon (fig. 13g (iii) and (iv) ). With MSV C3H2 
and 6 and MSV MEF2 cells butyric acid treatment alone had a 
roughly similar effect to interferon alone, but the two 
together increased further the cells' size to 150-200 nm long 
with some MSV MEF2 cells reaching up to 400 nm long, with an
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appearance very similar to untreated NIH MEF cells (fig. 13d-f). 
Furthermore, the cultures became very much more orderly, 
with the parallel arrays and whorls, typical of normal 
cultures, becoming prominent.
The combined effects of interferon and butyric acid 
were evident at interferon doses as low as 10 units/ml with 
MSV C3H6 and MSV MEF2, and the degree of cell flattening 
when in the presence of 100 units/ml interferon plus 0.5 mM 
butyric acid was quite similar to that observed in cultures
4treated with 10 units/ml interferon alone (results not shown).
With the normal cells (fig. 13a-c) there was less 
evidence of combined effects . There appeared to be very 
little effect on the morphology of NIH MEF cells by butyric 
acid alone or in conjunction with interferon. C3H MEF cells, 
on the other hand, did become enlarged by butyric acid alone,
4to roughly the same size as when treated with 10 units/ml 
interferon alone, but butyric and interferon together appeared 
to have little additional effect. Similar observations were 
made with C3H10T*s cells, though possibly interferon and 
butyric acid together did show a small combined effect (fig. 13c) 
The main result of butyric acid treatment of these 
normal cells seems to have been a great inhibition of growth, 
which was more severe than in cultures of transformed cells.
C) Microfilament System
Reversion of rounded transformed morphology to a more
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normal flattened state may be accompanied by at least a 
partial re-establishment of the microfilament system of the 
cytoskeleton. This possibility was studied by staining some 
cell types, grown with or without interferon, with FITC-DNase I. 
DNase I binds specifically to actin, in addition to DNA, and 
FITC or rhodamine-conjugated DNase has been reported to be 
an effective agent with which to stain microfilaments for 
visualisation under an ultraviolet fluorescent microscope 
(260, 261) .
Figure 14 shows the results of experiments in which
4cells were grown on glass coverslips with or without 10 units/ml 
of interferon for three days before being fixed with 3.5% 
formaldehyde in PBS and stained with FITC-DNase I .
As expected, NIH MEF cells showed little change (fig. 14a 
and b) . CSHIOT^ cells showed a microfilament system poorly, 
but interferon treatment did appear to stimulate the establish­
ment of a more organised system, though the observations were 
not unequivocal (fig. 14c and d) . MSV C3H2 and MSV MEF2 
cells, in the absence of interferon, generally showed few 
signs of microfilaments, but in its presence these became 
quite visible. Figure 14e shows MSV C3H2 cells without 
interferon, and in this picture microfilaments could only 
faintly be seen in one cell, while in the interferon-treated 
culture (fig. 14f) all cells showed microfilaments.
With MSV MEF2 cells the effect was less clear-cut.
There were obviously no microfilaments in the absence of
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m ;  m u  TU Fl G UH E 14
The effects of interferon on the microfilament system of 
normal and transformed cells. Cells were grown on glass 
cover slips with or without interferon, fixed with 3*5?b 
formaldehyde in P3S, treated with cold methanol (-20°c) 
and stained with FITC-DNase I.
Plates;
a, c, e, g, i : No interferon (controls).
b, d, f, h, j i 10^ U/ml interferon.
a & b :  N IH  MEF
S'" -«>,•
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FIGURE 14
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The effects of interferon on the microfilament system of 
normal and transformed cells. Cells were prown on plass 
coverslip* with or without interferon, fixed with 
forT.aldeli.vdo in P3S, treated with cold methanol (-20°c) 
and stained with FITC-DHase I.
Plates;
a, °» e, g, i ; No interferon (controls).
b, d, f ,  h, j  : 10 ' li/ml in te r fe ro n .
L6Q
FIGURE 14
c & d : C3H IO T -2a & b :  N IH  MEF
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interferon (fig. 14g) , whilst they could be seen in the 
flattened cells in the presence of interferon, but not in 
the more rounded cells (fig. 14h).
Microfilaments are just visible in a few MSV C3H6 cells 
in control cultures, but they are rather more apparent in 
the cells of interferon-treated cultures.
Overall, figure 14 illustrates clearly the increase in 
cell size following interferon treatment, but gives rather 
equivocal evidence to support the reconstitution of the 
microfilament bundles . Attempts were made to quantitate 
the degree of polymerisation of actin within cells using a 
method devised by Blikstad et al^ . (32) which measured the 
inhibition of DNase I activity by monomeric actin, but not 
polymerised actin. Unfortunately this assay could not be 
made to function reliably and so was abandoned.
D) Cell Surface Fibronectin
Since fibronectin is a cell surface protein which in 
normal cells appears to play a major role in cell spreading 
and adhesion, but is usually lost or greatly reduced upon 
transformation, it is possible that any agent that reverses 
the transformed phenotype might in so doing increase the 
amount of cell surface fibronectin. This seems all the more 
likely since some agents, such as cyclic AMP or butyric acid, 
stimulate the reconstruction of the intracellular microfilament 
system, the presence of which usually parallels that of surface 
fibronectin (131, 230) .
In experiments with C3H MEF cells, two distinct patterns 
were obtained when they were stained with antiserum to 
fibronectin, depending on how the cells were treated before 
staining. Fixation and staining of intact confluent cells 
revealed a complex intercellular branching matrix running 
across the upper surfaces of the cells (figure 15a). Extrac­
tion of live cells with 1% NP40 prior to fixation left a 
footprint representing the subcellular matrix which when 
stained with fibronectin antiserum revealed a fine branching 
meshwork not unlike the microfilament system (figure 16a).
These observations are similar to those of Mautner and 
Hynes (177) who studied the fibronectin distribution on the 
surfaces of hamster NIL 8 fibroblasts .
Further observations of the matrix of the upper surface 
of intact ClHlOT^s and transformed cells are shown in figure 
15b-d, while the subcellular matrix of NP40-extracted C3H10T*s 
cells only is shown in figure 16b. Butyric acid treatment 
of C3H MEF cells was not recorded, but its treatment of the 
other cell types was. The layout of photographs in figure 
15b-d and figure 16b is the same as that described for figure 
13, i.e. for each cell type there are four photographs:-
4i) control, ii) with 10 units/ml interferon, iii) with 0.5 nM 4
4butyric acid, and iv) with 0.5 mM butyric acid and 10 units/ml 
interferon.
Confluent ClHlOT^ cells showed two distinct patterns, 
but in both cases the fibronectin matrix was much less
LEGEND TO FIGURE 15
Effects of interferon and butyric acid on fibronectin 
distribution. Coverslips were fixed in 3*5^ formaldehyde 
in PBS.
Plate a) arranged as follows:- 
(i) control
Plates b-d arranged as follows!»
(i) control (ii) 104 U/ml ITO
( i i i )  0*5mM BA ( i v )  104 U/ml IiU
& 0-3mM BA
a ) C3H MEF; b) C3H lOTJt; c ) MSV C3H6; 
d ) MSV MEF2
Plates«
LEGEND TO FIGURE 15
Effects of interferon and butyric acid on fibronectin 
distribution. Coverslips were fixed in 3*5/, formaldehyd 
in PBS.
Plate a) arranged as follows:- 
(i) control
Plates b-d arranged as follows:-
(i) control ( i i )  104 U/ml IFH
( i i i )  0-5mH BA ( i v )  IO4 U/ml ira  
& 0*5raM BA
P la te s : a ) C3H KEF; b) C3H IOTA; c ) MSV C3H6; 
d ) MSV MEF2
Scale:
100pn
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Effects of interferon and butyric acid on distribution 
of fibronectin in subcellular matrix. Cells were grown on 
glass coverslips, treated with 1% NP40, fixed with 3*5^ 
formaldehyde in PBS and then stained with antiserum to 
fibronectin.
Plates: a) C3H MKF; b) C3H lOT*
Treatments: a(i) and b(i) controls;
a(ii) and b(ii) 104 U/ml IFN.
b(iii) Û*3mK BA
b(iv) 0*5mM BA à 104 U/ml IFN.
Scale:
I---------------1100pm
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FIGURE 16 a
«1GKND TO FIGURE 16
Effects of interferon and butyric acid on distribution 
of fibronectin in subcellular matrix. Cells were grown on 
glass coverslips, treated with 1;X- NP40, fixed with 
forma]denyde in PBS and then stained with antiserum to 
fibronectin.
Plates: a) CÎH MKF; b) C3H 10T*
Treatments: a(.i) and b(i) controls;
a(ii) and b(ii) 104 U/ml IFN.
b(iii) O^mK BA
b(iv) 0*5mM BA & 104 U/ml IFN.
Scale:
I---------------f
100>uu
■■
¡■
■■
i
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extensive than on C3H MEF cells, (figures 15b and 16b).
On intact cells (figure 15b) the fluorescent matrix could be 
seen only in discrete patches which were quite widely dispersed, 
up to 0.5 mm apart, with occasionally a few fibres connecting 
adjacent patches. The subcellular matrix seen in NP40 
extracted cells (fig. 16b) was found on all cells, but the 
filamentous network was greatly reduced and less orderly.
The transformed cells showed very little fluorescence 
after NP40 extraction (results not shown) , suggesting poor 
cell-substrate adhesion. Intact cells showed a matrix of 
fine fibres which appeared to run between cells, suggesting 
cell-cell adhesion, but only occasionally across the cells' 
upper surfaces. Though the fibronectin present on the 
surfaces of these transformed cells is clearly reduced when 
compared with CSHIOT^ cells, the presence of any is quite 
unusual. Of the transformed clones examined, only observations 
with MSV C3H6 and MSV MEF2 cells are shown in figure 15, since 
they are representative of observations made on other clones 
(figure 15c-d) .
410 units/ml interferon appeared to have no obvious 
effect on the fibronectin pattern of any of the cell types 
(figures 15a-d (ii) and 16a (ii) and b (ii) ). Butyric acid 
(0.5 mM) did alter the fibronectin distribution in the sub- 
cellular matrix of CSHIOT^ cells (fig 16b (iii) and (iv) ) , 
which became organised into a fibrillar network similar to 
that seen under C3H MEF cells (fig. 16a (i) and (ii) ) .
In ClHlOT^s cells butyric acid and interferon together 
appeared to have no additional action (figs 15b (iv) and 
16 (iv) ) .
Butyric acid did not alter the fibronectin distribution 
of any of the transformed clones (fig. 15c (iii) and d (iii) 
for MSV C3H6 and MSV MEF2 cells respectively) . However, 
butyric acid and interferon together did greatly enhance the 
intercellular matrix on MSV C3H6 cells (fig. 15c (iv) ) . 
Observations with MSV C3H2 and MSV MEF2 cells were less clear. 
There may have been an increased fibronectin matrix, but in 
both clones the intensity and clarity of stainingwere reduced 
(see fig. 15d (iv) for MSV MEF2) . On the other hand, with 
MSV MEF4 cells it was quite clear that the fibronectin 
distribution remained unchanged (results not shown).
E) Adhesion to Glass Surfaces
The observations that interferon has little effect on the 
fibronectin distribution would suggest that either interferon- 
treated cells are no more or less adherent to the substratum, 
or fibronectin is not involved in adhesion, contrary to 
current ideas .
To test this, suspended radioactive cells were allowed to 
adsorb at 37°C to the base of glass scintillation vials which 
had previously been soaked with PBS or fibronectin purified 
from new-born calf serum. Serum contains fibronectin which 
when in contact with a substratum at 37 C, such as glass, will
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attach to it and may subsequently affect the ability of cells 
to adsorb to the glass (126, 199) .
The results in figure 17 show only small and inconsistent 
changes in cell adsorption which suggest that interferon had 
little effect on the adhesiveness of ¿¡ells .
F) Polyacrylamide Gel Electrophoresis
The photographs in figures 14 and 15 suggested that 
interferon alone or in conjunction with butyric acid could 
alter the intra- and extracellular distributions of actin and 
fibronectin respectively. Figure 15c (iv) which recorded the 
effects of butyric acid and interferon together on MSV C3H6 
suggested that the total amount of fibronectin may be increased.
To assess whether interferon and butyric acid could alter 
the total quantities of these proteins cultures were labelled 
with "^S-methionine, lysed and resolved on 8% polyacrylamide 
gels. As can be seen from the gels in figure 18, ClHlOT^ cells 
possessed considerably more fibronectin than the transformed 
clones, but little difference could be seen in the levels of 
total actin. Neither interferon, nor butyric acid treatment had 
any clear effect on levels of fibronectin or actin, even in 
MSV C3H6 cells treated with both agents .
Quantitation of these two proteins was attempted by 
excising the respective bands from the gels, dissolving the 
proteins in scintillant and then counting the radioactivity.
The histograms in figures 19 and 20 show the counts per
LEGEND TO FIGURE 18
SDS polyacrylamide gel electrophoresis of whole cell 
lysates taken from cells grown with or without interferon
(104 U/ml) and/or butyric acid (0*5mM), and labelled with 
55S-methionme.
Cells used! C3H lOTjt (tracks 1 -  4 ); MSV C5H2 (tracks 
5 - 8 ) ;  MSV MEF2 (tracks 9 - 1 2 ) ;  MSV C3H6 
(tracks 15 -16) « MSV M m  (tracks 17 -  20)
Treatments for each cell type are in the order shown for
C5H 10T^ cells (tracks 1 -  4 ). Thus;
Tracks; 1, 5» 9, 15* 17 -  ce lls grown w ithout IFN or BA,
2, 6, 10, 14,, 18 -  " it with 0*5mM BA,
5, 7, 11, 15,, 19 -  " it h 104 U/ml IFN.
4, 8, 12, 16,, 20 -  " it it It  I I  I I
& 0-5mM BA, FI
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SDS polyacrylamide gel electrophoresis of wnole cell 
lysates taken from cells  grown with or without interferon 
(10A U/ml) and/or butyric acid (O^rr'K), and labelled with 
"l'>S-methionine.
Cells used: C3H IOTA (tracks 1 - 4 ) ;  MSV C3H2 (tracks 
5 - 8 ) ;  MSV MEF2 (tracks 9 - 1 2 ) ;  MSV CJII6 
(tracks 13 -16); MSV MEF’4 (tracks 17 -  20)
Treatment:; for each ce1! type are in the order shown for
C3H 10T; cel 1 s (track s 1 - 4). Thu s ;
1 ; 1. 3, 9, 13, 17 - cells ^rown without 1FN or .
2, 6, 10,, 14, 18 __ It tt wi th
3, 7, 11,, 15, 19 __ It it I I 104 U/ml IFN.
4, 0, 12,, 16, 20 __ It i i I I It  II I I
Sc O-pmM BA. FI
GU
RE
 1
8
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minute in each band represented as a percentage of the total 
cpm applied to each track . They show quite clearly the large 
difference in fibronectin possessed by C3H10Tls and transformed 
cells (fig. 20) and also a two to five fold difference in 
total actin is revealed (fig. 19) .
These histograms also demonstrate quite clearly that no 
consistent changes in actin or fibronectin levels were initiated 
by interferon or butyric acid treatment. This obviously 
contradicts the observed increase in fibronectin matrix in 
MSV C3H6 cells treated with interferon and butyric acid.
Possible explanations will be put forward in the Discussion.
G) Conclusions
The data presented in this chapter show that interferon
clearly gives transformed cells a more normal morphology,1
appears to restore the microfilament system, but has little 
effect on cell surface fibronectin distribution. Butyric acid 
can cause further flattening when added jointly with interferon. 
Curiously, either treatment alone appears to have little effect 
on cell surface fibronectin, but the two together, at least 
on MSV C3H6 cells, greatly increase, its organisation.
FIGURE 19
% cpm per gel present 
in actin band
Levels of Actin in Cells Treated with Butyric Acid and 
Interferon for Up to One Week
Key for Fias 19 & 20
O  IF N ; O  BA 
O IF N ;  0 -5  mM BA 
104U/ml IF N ; O  BA 
lO ^U^m l IF N j-O ^ m M  BA
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FIGURE 20
% cpm per gel
Levels of Fibronectin in Celia Treated with Butyric Acid and 
Interferon
Key -  As for Fig 19
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CHAPTER FIVE
EFFECTS OF INTERFERON ON p21 LEVELS
One possible route for interferon to exert a transformation>
reversion would be for it to inhibit either the synthesis or 
the action of the protein(s) responsible for transformation.
In KiSV-transformed cells a 21000 dalton molecular weight 
protein (p21) is the only virus-coded protein so far detected, 
and it may be this protein which is responsible for trans­
formation (129, 227, 228) .
A) Electrophoresis
To test this possibility, cells grown with or without
interferon were labelled with 35S-methionine, lysed and immuno-
\
precipitated with antisera to p21. The immunoprecipitates
were than subjected to polyacrylamide gel electrophoresis.
Figure 21 shows the gels for the five cell types examined.
No p21 could be detected in ClHlOTh cells (gel 1, tracks
1-4), but all the transformed cells contained quantities which
could be seen when immunoprecipitated, but not when treated
with control sera (gel 1 tracks 2, 4, 6 , 8 , 10, 12; gel 2
tracks 2, 4, 6 , 8) . The densities of the p21 bands suggest
that interferon treatment did decrease the amounts of p21
present, but since the interferon-treated samples incorporated 
35generally less S-methionine than controls, this may not be
a real change.
LEGEND TO FIGURE 21
SDS polyacrylamide gel electrophoresis of cell lysates 
precipitated with antisera to p21. Cells grown with or 
without interferon (l(/4 U/ml) and labelled with ^S-methionine 
before lysis and immunoprécipitation.
Cel 1 :
Tracks: 1 - 4 C3H lOTjt; 5 - 0  MSV C3H2; 9 - 1 2  MSV C3H6;
Treatments: 1, 2, 5t 6* 9» 10 - cells grown with 10^ U/ml
IFN.
3, 4( 7* 0* 11, 12 - cells grown with no IFN. 
Immunoprécipitation:
2, 4, 6, 6, 10, 12 - cell lysates treated with 
control sera.
1» 3, 5» 7, 9* 11 - cell lysates treated with 
anti-p21 sera.
Gel 2;
Tracks; 1 - 4  MSV M1Î’ 2; 5 - 8  MSV MEF4.
Treatments: 1, 2, 5* 6 - cells grown with 10^ U/ml IFN.
3» 4, 5» 8 - " " " no interferon.
Immunoprécipitation:
2, 4, 6, 8 - cell lysates treated with control sera.
1, 5, 5, 7 - " " " " anti-p21 sera.
Bands labelled 1, 2, 3 are the proteins which were cut 
out and cpm determined for comparison with cpm of p21 in 
samples from interferon-treated and control cultures.
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SÛS polyacrylamide pel electrophoresis of cell lysates 
precipitated with antisera to p21. Cells grown with or 
without interferon (l(/‘ U/ml.) and labelled with '^’¿-methionine 
before lysis and immunoprécipitation.
Gel 1 ;
Tracts: 1 - 4 C3ii lOTjs; 5 - 8  MSV C3H2; 9 - 1 2  MSV C3H6;
Treatments» 1, 2, 5* 8, 9* 10 - cells grown with 10** u/ml
IFN.
3, 4, 7» 8, llf 12 - cells crown with no IFN. 
Immunoprécipitation:
2, 4, 6, 8, 10, 12 - cell lysates treat»! with 
control sera.
1» 3* 5, 7» 9, 11 - cell lysates treated with 
anti-p21 sera.
Gel 2;
Tracks;  1 - 4  MSV Mi» ’ 2; 5 - 8  MSV MKF4.
Treatments; 1, 2, 5» 6 - cells grown with 10** U/ml IFW.
3» 4, 5» 8 - " " " no interferon.
Immunoprécipitation»
2, 4, 6, 8 - cell lysates treated with control sera,
1* 3» 5» 7 -  " " " " anti-p21 sera.
Bands labelled 1, 2, 3 are the proteins which were cut 
out and cpm determined for comparison with cpm of p21 in 
samples from interferon-treated and control cultures.
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B) Quantitiation
Quantitation was attempted as described in Materials and
Methods, and the results are summarised in Table 10. The
data show only very small changes in p21 levels, which,
considering the large number of variables which could affect
35these figures such as how much S-methionine was incorporated 
into each sample, the efficiency of extraction of protein from 
the gel to measure the cpm in a single protein and the accuracy 
or such a procedure, do not permit firm conclusions to be 
drawn. However, it is interesting that the relative size of 
the change between the different clones corresponds fairly 
well with their observed sensitivities towards interferon’s
cellular activities .
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TABLE 10
Cell
Line
Change in p21 Levels in IFN- 
Treated Cells Relative to Levels 
in Controls, as measured by -
Total 
Protein 
[Lowry)
Total
cpm
Relative 
to proteins 
1, 2, 3.
MSV C3H2 -5x -4x -2x
MSV C3H6 -6x -6x -4x
MSV MEF2 -2x -2x -2x
MSV MEF4 +2x + 2x + 2x
Comparison of p21 Levels in Interferon-Treated and Control 
Cell Cultures
+ ;- indicates that interferon treatment resulted in 
an increase in p21 levels.
- indicates that interferon treatment resulted in 
a decrease in p21 levels, 
x means ' fold change'.
Thus , - 3 * ' means 'a three fold reduction' in le v e ls
of p21
DISCUSSION
This Discussion will be divided into several sections.
The first will consider the quality of the interferon used, 
as regards its suitability, purity and doses used in these 
studies in relation to interferon preparations used by 
others . The second section will consider in sequence the 
experiments described in chapters 2 to 5 to assess the 
conclusions that may be drawn from the results obtained and 
how such conclusions may be related to data that have been 
obtained by others . The final section will summarise these 
conclusions to give an overall view. The significance of 
the conclusions and how closely they fulfil the aims of this 
thesis will also be assessed, and some proposals for further 
work will be given.
I . Use of Interferon 
1. Interferon Purity
Recent studies with pure interferon (58, 82, 134) have
shown that the inhibition of cell growth is a property of
interferon itself, and not some contaminant in the impure
material often used. The majority of studies still use
impure interferon, and this study is no exception. The
experiments described in chapter one succeeded in raising
0the specific activity of purified interferon to 2 x 10 units/mg 
protein, still only 10% pure, but the two-step procedure
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employed was quick, simple and gave high yields. To raise 
the specific activity further would have required further 
purification steps, probably resulting in low final yields, 
which would have severely limited the supply of interferon 
for studies of its cell growth and morphological effects.
Thus, higher purity was sacrificed in order to ensure large 
yields of semi-pure interferon. Use of an antibody-agarose 
column, such as that described by De Maeyer-Guignard et al. 
(58) may have greatly improved purity. However, no antiserum 
was available, and it did not seem appropriate to commit 
large amounts of interferon to attempting to raise antisera.
The specific activity of interferon used in studies on
7 8cell growth and morphology varied between 5 x 10 and 2 x 10 
units/mg protein, which compared very favourably with the 
activities of interferons employed by others. However, 
without pure interferon it is not possible to be absolutely 
certain that observed effects are not due to contaminants, 
even though cell growth inhibition is known to be a property 
of pure interferon. Confidence that other observations, such 
as reduced saturation density and morphological effects, were 
due to interferon is justified by its stability even after 
pH 2 treatment and inactivity on heterologous species.
2. Interferon Doses
One of the most striking features of the studies reported 
over the past few years is the vast range of interferon doses
used, anything from less than 10 units/ml to 10 units/ml.
The majority of studies have been on the growth inhibitory 
activity, and most have indicated that maximal inhibition 
occurs at interferon doses of 100-1000 units/ml (43, 8 6 , 201), 
considerably lower than the dose for maximum inhibition seen 
here. It is clear, therefore, that cell types used in many 
other studies were much more sensitive to interferon than 
the cells used by myself (5, 82, 119, 143, 201) . One human 
lymphoblastoid line, Daudi, has been shown to be sensitive 
to as little as 1 unit/ml (5).
Of the cell types used in this study, DNA synthesis in 
some (MSV C3H2 and MSV MEF 4) was reduced a little by 100 
units/ml (see Figure 12) after 24 hours treatment, while 
from dose-response curves in Figure 6 , the doses for half 
maximal inhibition after 72 hours of interferon treatment 
(Table 5) suggest that growth of all cell types tested was 
sensitive to 100 units/ml. These latter data are, however, 
difficult to interpret due to the additional complication of 
reduced cell numbers in interferon-treated cultures. This 
will be discussed in greater detail later.
The effects of interferon on cloning of single cells on 
plastic illustrate very clearly the great differences in 
sensitivity between the cell types used here and those used 
in other experiments. The data presented in Table 7 show that 
cloning was inhibited by at the most three fold (0311101*5) , 
while some actually apparently showed a small increase in
4
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cloning efficiency (MSV C3H 2 and NIH 3T3) . This should be 
contrasted with Glasgow et al. (86), for instance, where
300 units/ml greatly reduced cloning efficiency of murine
. 3 4osteogenic sarcoma cells, and 3 x 10 to 3 x 10 units/ml
completely abolished cloning. Similarly O 1Shaughnessey et al.
(194) found that 1 unit/ml inhibited by 50% cloning of L
cells, while 100 units/ml caused 90% inhibition, and Buffett
et al. (43) achieved 90% inhibition of cloning of BALB/c 3T3
4cells with 10 units/ml.
II . The Effects of Interferon
1. Antiviral and Cell Growth Inhibitory Activities
a) Interpretation of results The dose-response curves 
for cell growth inhibition, shown in figure 6 , suggest that 
a three day treatment with interferon at high doses quite
3
considerably inhibited DNA synthesis, an observation which 
clearly conflicts with findings made later (Table 6), which 
indicated that a 24 hour interferon treatment of cells at 
different densities had little effect on growth rate of 
0311101*5 cells at all densities tested, and only affected 
transformed cells when at high density. This apparent 
conflict is probably due to a combination of two factors - 
i) a 24 hour treatment may not exert maximal inhibition 
of DNA synthesis, and ii) inhibition of 3H-thymidine incorp­
oration following a three day interferon treatment is probably
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due not just to inhibition of DNA synthesis but also to 
reduced cell numbers . The data in Figure 7 show that 
interferon-treated transformed cells may grow to a much 
lower saturation density than controls . It seems quite 
likely that after the three day incubation period, cells 
grown in the presence of large doses of interferon had reached 
that saturation density and stopped growing, while those with 
little or no interferon continued to grow rapidly. This would 
have been reflected by the large dose response curves seen 
in Figure 6 . It also explains why a 24 hour interferon 
treatment only inhibited growth of transformed cells seeded 
at high density.
Furthermore, unpublished data of Dr. Alan Morris showed 
very shallow dose-response curves for a range of murine 
cell lines that had been treated with interferon for just 
24 hours, the maximum observed inhibition being less than 
20%. This adds further support to the above suggestions 
that interferon, after only 24 hour treatment, actually had 
only a small effect on DNA synthesis.
b) Experimental techniques The above discussion centred 
solely on assessing whether the method used to measure cell 
growth inhibition by interferon was actually valid for the 
question under study. To study interferon's antiviral 
activity a routine assay procedure was employed which is 
known to give an accurate measure of a preparation’s potency,
so its validity has already been established (286) . The
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principal aim of these experiments, however, was to compare 
interferon’s antiviral and cell growth inhibitory activities. 
For this to be possible, the two assays should use similar 
techniques so that cells are grown, receive interferon and 
its affect assessed under similar conditions. However, in 
these experiments there were some differences. For instance 
antiviral activity was measured with cells grown in glass 
vial inserts with interferon treatment, virus infection and 
3H-uridine labelling conducted in medium containing only 
2% new-born calf serum - standard procedure for our interferon 
assays on L cells. Cell growth inhibition was measured in 
microtitre trays using medium containing 10% new-born calf 
serum throughout. More reliable, comparable results would 
have been obtained if the procedures for the two measurements 
had been standardised.
2 . Growth and Saturation Densities
a) Cell division and DNA synthesis The growth curves in 
Figure 7 show quite clearly that normal and transformed cells 
responded quite differently to interferon. The imposition 
of quite a low saturation density on some transformed clones 
suggests the reacquisition of density dependent growth control
3by these cells. However, H-thymidine labelling data in 
Table 6 suggest that even in such density-inhibited cells 
the level of DNA synthesis remained quite high . This could 
be due to several reasons - (i) even at the highest cell
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2 . Growth and Saturation Densities
a) Cell division and DNA synthesis The growth curves in 
Figure 7 show quite clearly that normal and transformed cells 
responded quite differently to interferon. The imposition 
of quite a low saturation density on some transformed clones 
suggests the reacquisition of density dependent growth control 
by these cells. However, "^H-thymidine labelling data in 
Table 6 suggest that even in such density-inhibited cells 
the level of DNA synthesis remained quite high . This could 
be due to several reasons - (i) even at the highest cell
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density in Table 6 the interferon-imposed saturation density 
had not been reached; (ii) the plateau in cell numbers in 
Figure 7 was not due to density dependent growth inhibition, 
but due to establishment of an equilibrium between growth of 
new cells and shedding of necrotic cells into the medium;
(iii) cell division may have been inhibited but DNA synthesis
I
continued, resulting in polyploid and multinucleate cells;
(iv) interferon had less effect on cells seeded at high than 
those seeded at low density; (v) a 24 hour interferon treat­
ment may be insufficient time to cause maximal inhibition of 
DNA synthesis .
The first possibility may be responsible but is unlikely
2since the highest density recorded in Table 6 (40000 cells/cm ) 
was higher than the saturation densities of any of the 
interferon-treated transformed clones recorded in Figure 7 .
The second possibility also seems unlikely since dead 
cells were not seen in the medium. 3
There is experimental evidence to support the possibility 
that both (iii) and (iv) may be involved. Support for 
continued DNA synthesis but inhibited division has been 
produced by Pfeffer et al. (201) who found that normal human 
fibroblasts treated with beta interferon increased in volume, 
surface area, protein and DNA content, but cell division 
ceased. In addition the number of binucleate cells increased 
five-fold. However, there are no reports which have extended 
these observations to transformed mouse cells.
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Evidence that cell growth may become less sensitive
to interferon as cell density increased was produced by
Kuwata et al. (151) and Gresser et al. (100) who used human
RSb cells and mouse L1210 cells respectively. Horoszewicz
et al. (121) suggested that this may be related more to growth
rate of the cells at the time of interferon addition, rather
than density; i .e. fresh sparsely-seeded stationary cells
being more sensitive than rapidly growing dense cells. Thus,
a 24 hour interferon treatment may have been less effective
at shutting off DNA synthesis in transformed cells seeded at 
4 24 x 10 cells/cm , than in cells that had grown up to that
density in the constant presence of interferon. This could
be tested by trypsinising cells that had grown to their
maximum density in the presence of interferon, and then
reseeding these and control cells, in wells of microtitre 
4 2trays at 4 x 10 cells/cm in the presence or absence of
interferon for 24 hours before feeding with ^H-thymidine.
Though it is possible that (iii) and (iv) may be partially
responsible for there appearing to be a high DNA synthesis
rate in transformed cells, whose growth has been density
inhibited due to interferon treatment, the most probable
explanation is simply that interferon takes more than 24 hours
to exert its maximal effect on DNA synthesis. Thus 48 or 72
hours may be required to completely halt DNA synthesis in
4 2cells seeded at 4 x 10 cells/cm . Certainly, in the morpho­
logical studies observed changes in cells shape were much
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greater after 72 hours treatment than just 24 hours. Due 
to the effect that interferon has on cell numbers when 
treatment is continued for several days, it would be difficult 
to test whether interferon does take several days to exert 
maximal inhibition of DNA synthesis, except by the use of a 
chemostat. In this the cell concentration could be maintained 
at a constant level so that ^H-thymidine incorporation would 
be a true measure of the rate of DNA synthesis.
b) Comparison with other studies on saturation density The 
reductions in saturation density observed by various workers 
appear to have varied greatly depending on cell type used, 
interferon dose, length of experiment and whether or not the 
medium was changed during the experiment. Many early studies 
used suspension cells (especially L1210 and L929 cells), which 
do not possess a 1 saturation density' in the sense of density 
dependent inhibition of growth. Their growth can be propagated 
indefinitely if the cells are regularly diluted with fresh 
medium. However, if the medium is not replenished and the 
cells grow to a high concentration, after a few days growth 
will halt and cell numbers start to decline. Initial studies 
on interferon's growth inhibitory activity were conducted 
without the addition of fresh medium and thus were able to 
continue for only 3 to 4 days. Macieira-Coelho et al. (172) 
found that suspension L1210 control cells increased in 
density by about ten fold over three days and then started 
to decline, whilst interferon-treated cultures grew to half
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this density in four days before starting a similar decline.
Had the medium been changed on the third day, both control 
and interferon-treated cultures may have continued growing. 
Paucker ^t al. (198) found that continuous interferon treat­
ment, under conditions where cells were diluted in fresh 
. 5medium to a density of 10 /ml every 2-3 days, resulted in
complete inhibition of growth after 13 days.
Similarly, experiments with monolayer cultures have
been conducted for a week or more with no media changes (151,
170, 190) . My experience showed that growth of sparsely
seeded cells was restricted after three to four days unless
the medium was replenished, and with transformed cells which 
5 2had reached 10 cells/cm or more, the medium had to be 
renewed every day. In my experiments the medium was, therefore, 
changed every day to ensure that growth was not nutrient 
limited.
The data presented in Figure 7 show that both the 
growth rates and the maximum densities of transformed cells 
and those normal cells sensitive to interferon could be reduced 
by interferon treatment. The growth curves for MSV MEF2,
MSV C3H6 and MSV C3H2 in late passage are similar to those 
presented by Knight (143) for SV40 and polyoma virus-transformed 
3T3 cells . Furthermore the growth curves for NIH MEF and 
NIH 3T3 4E cells are very similar to Knight's curves for 
embryonic and 3T3 fibroblasts, showing them to be quite in­
sensitive relative to the transformed cells. However, the
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data with C3H MEF and C3H10TJ5 cells agree more closely with 
work by others, such as Pfeffer et al. (201), Lindahl- 
Magnusson et al. (166) and Ohwaki and Kawade (190), that 
growth rate of normal cells can be greatly slowed.
The experiments by Tovey and Brouty-Boye (254) which 
showed that the viability of L1210 cells grown in a chemostat 
decreased at low growth rates and that interferon's growth 
inhibition could thus cause cell death may be a possible 
explanation for the very slow growth seen in interferon- 
treated C3H MEF and CSHlOT^ cultures. As already discussed 
this seems unlikely since cell debris was not observed in 
the media of such cultures, though because viabilities were 
not determined this cannot be definitely resolved. However, 
the majority of studies on growth inhibition in batch cultures 
have found that interferon does not decrease cell viability 
(54, 100, 143, 166, 190) .
c) Role of serum concentration Clearly serum levels had a 
profound effect on cells' responses to interferon, 50% serum 
virtually eliminating the growth inhibition and greatly 
reducing the effect on saturation density in CSHIOT^ and 
MSV C3H6 cells (Figure 10). This raised the problem of what 
serum level is appropriate for these experiments, especially 
when one considers that in vivo serum levels are very high.
Whether inhibition of interferon action by 50% serum was 
general for all the clones was not tested, but clearly at 
10% serum the different nontransformed types and transformed
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clones varied greatly in their sensitivity towards interferon, 
both as regards inhibition of growth rate and reduction of 
saturation density. This variation may be related to 
differences in serum dependence of the different cell types, 
though this was not tested.
Several reports have suggested that growth inhibition 
by interferon may be exerted by making cells more sensitive 
to an existing growth control mechanism (121, 172, 201) .
That this control mechanism may be serum-linked is supported 
by these observations and similar studies by Gresser et al. 
(100) . Pfeffer <it al. (201) , on the other hand, found that 
serum concentrations in the range 5-20% had no effect on 
interferon's inhibition of growth of human fibroblasts, which 
concurs with my findings for cloning of single cells in liquid 
medium (Table 8), though they contradict those of Kading et al. 
(138) . This possible growth control mechanism, and its 
relationship to transformation is discussed in more detail 
1 ater.
d) Passage level The growth curves of Figure 7 showed that 
the growth of MSV-transformed CSHIOT^ and NIH MEF cells could 
be inhibited in a very different manner from the growth of 
the non-transformed parents. When C3H10T*5 cells continued 
through many passages and started to lose growth control, 
their response to interferon eventually became very similar 
to that of the MSV-transformed cells (Figure 8). This suggests
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that interferon affects the growth of cells by modulating 
a cellular growth control mechanism and that the differential 
effect on the growth of transformed cells was not due to MSV 
infection itself. At no time, however, did the CSHIOT^ cells 
take on the range of transformed characteristics. Though the 
cells became smaller, they still retained a microfilament 
stress fibre system and cells remained in orderly arrays 
(results not shown) . Furthermore, unlike the MSV-transformed 
cells, they remained non-tumourigenic (292) .
e) Experiments with butyric acid The experiments which 
have been presented in this thesis employed only one dose of 
butyric acid, 0.5 mM, when perhaps a range of doses should 
have been applied to allow for different dose-dependent effects. 
Some preliminary tests with a range of butyric acid concen­
trations led to the conclusion that 0.5 mM gave clearly 
measurable effects without limiting the metabolic activity 
of the cells too severely. Butyric acid at 2.5 mM completely 
halted the growth of cells and was actually toxic towards them. 
Concentrations of 1-1.5 mM did allow cell growth, but only 
very slowly, whereas 0.5 mM inhibited cell growth to a clearly 
measurable degree, but did permit growth to continue at such 
a rate that full growth curves could be obtained on a similar 
time scale to untreated controls and interferon-treated 
cultures (see Figure 11) .
The observed effects of butyric acid on cells were similar
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to those described by others - flattening of cells, inhibition 
of growth but no return to density dependent growth control 
( 8 ,  8 3 ,  85 )  . The data concerning the interaction of butyrate 
and interferon (Figures 11 and 12), however, conflict a little 
with those of Bourgeade and Chany ( 35 )  . They found that 
butyrate and interferon together were more potent growth 
inhibitors than the sum of the two separate agents when added 
to transformed cells. Butyrate was totally ineffective on 
normal cells and there was no synergistic effect on them.
My data (Figures 11 and 12), on the other hand, show that no 
synergism existed in any of the cell types, rather the effects 
of butyrate and interferon were simply additive in all cell 
types, both normal and transformed.
Butyric acid inhibited growth of transformed and normal 
cells in much the same way. Initial growth of newly seeded 
cells was delayed, but logarithmic phase growth was largely 
unaffected, and there was minimal change in saturation density. 
This, coupled with the additivity, rather than synergism, of 
interferon and butyric acid suggests that interferon and 
butyric acid act by independent mechanisms.
3. Transformation-Specific Growth Parameters
Though the growth curves recorded in Figures 7-10 and the 
DNA synthesis data in Table 6 indicate that growth of normal 
and transformed cells may be inhibited by interferon in 
different ways, they alone do not confirm the existence of a
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transformation-specific effect. More evidence for such an 
effect was obtained by studying several phenotypes character­
istic of the transformed state, viz. loss of contact 
inhibition, anchorage dependence, raised agglutinability, 
rounded cell morphology and loss of microfilaments and cell 
surface fibronectin. This section will discuss only the 
first two properties and relate them to the data obtained to 
the effects of interferon on cloning in liquid media.
a) Focus formation All previous studies which have looked 
at focus formation have considered only the ability of 
interferon to prevent the formation of transformed foci 
following tumour virus infection of normal cells (71, 185). 
The inhibition is presumably due to the antiviral activity. 
This study is the first to consider interferon's ability to 
prevent previously transformed cells growing, due to their 
density independent growth, on top of a monolayer of normal 
cells. If MSV/MLV producer clones were used in these experi­
ments foci could grow by virus particles spreading from the 
transformed cells, and infecting and transforming cells of 
the normal monolayer. Inhibition of focus formation by inter­
feron under such conditions could be attributed to its anti­
viral activity. Non-producer clones, however, could form foci 
only by growth and division of the input transformed cells. 
Inhibition of focus formation by interferon under these 
conditions must be due to inhibition of cell growth.
For these reasons only non-producer clones were used in
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this study. The data presented in Table 7 show quite clearly 
that interferon could greatly inhibit focus formation, and 
coupled to the data regarding cloning in liquid media suggest 
that this inhibition was due to a combination of interferon's 
antiproliferative activity and a transformation-specific 
effect.
b) Growth in agar Macpherson and Montagnier (173) first 
developed this technique to isolate transformed clones from 
polyoma virus-infected cells, but it was later adapted as 
a quantitative measure of the degree of anchorage independence 
of transformed clones. Gresser et al. (104) were the first 
to use it to measure interferon's effects on growth in agar, 
and since then many workers have used this technique to study 
interferon's antiproliferative activity (8 6, 103, 107, 180).
Inevitably this technique has a number of problems, 
principally concerning the way one measures colony number 
and size. Few transformed clones form colonies with 100% 
efficiency, and many clones form only very small colonies. 
There is then the problem of defining how big a group of 
cells must be before it can be called a colony, and defining 
how many colonies, as a proportion of the total number of 
input cells, must grow before a cell type may be called 
• anchorage .independent' . This was particularly crucial with 
most of the transformed lines used in this study since most 
only gradually developed anchorage independence 15-20 
passages after transformation (292) . There seem to be no 
universal criteria for defining an anchorage independent
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line, and every laboratory has slightly different definitions. 
The ones adopted by myself, in line with others in this 
laboratory, were that 0.5% of the input cells should form 
colonies, and that a colony should be at least 0.1 mm in 
diameter to be recorded.
The variability in size of colonies created another 
problem when it came to recording colony numbers, particularly 
when comparing interferon-treated and control cultures . In
I
cultures with large colonies it was possible to overlook 
very small ones whereas, in cultures with only small colonies, 
they were all counted. Interferon treatment greatly reduced 
the average colony size, and so it is conceivable that this 
could have led to an underestimate of interferon's inhibitory 
activity.
c) Cloning in liquid medium The measurement of interferon's 
effect on cloning in liquid medium was necessary in order 
to try to distinguish between growth inhibition and a trans­
formation-specific activity during its inhibition of focus 
formation and growth in agar. Whilst it is difficult to 
envisage a better method to make this distinction, the belief 
that it is a viable method for cells in agar does rest on at 
least one basic assumption, namely that interferon's cell 
growth inhibitory activity is as effective against cells 
suspended in agar as against those attached to plastic in 
liquid medium. Bearing in mind that cells in agar and on 
plastic are in very different environments, and have very
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different shapes which may or may not affect sensitivity to 
outside influences, this maybe a real problem.
The effect that interferon had on colony size in agar 
has already been mentioned. The sizes of colonies on plastic 
were also reduced, in some clones (for instance MSV MEF4) 
quite drastically. This reduction in colony size, like 
colony number, was presumably due to growth inhibition, but 
the size reduction seen in agar colonies may in addition be 
due to a transformation-specific activity. These size changes 
were not quantitated, however, so it is not possible to 
fully assess their significance. Foci did not appear to vary 
in size - they were either present or absent.
Clearly the techniques of focus formation, growth in agar 
and cloning in liquid medium suffer from a number of problems 
as regards defining exactly what each is measuring and dis­
tinguishing between growth inhibition by interferon and a 
transformation-specific activity, so the exact data presented 
in Table 7 may be subject to some subjective bias. However, 
the general trends shown by the ratios of focus formation 
and growth in agar to efficiencies of cloning in liquid 
medium definitely indicate some kind of transformation-specific 
activity in addition to the growth inhibiton.
All previous studies of interferon's effects on growth 
in agar did not attempt to identify a transformation-specific
activity, but assumed that the inhibition of colony formation/
was due solely to interferon's antiproliferative activity.
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Glasgow et al. (86) conducted growth in agar and cloning in 
liquid medium together, but because no quantitative data were 
provided, only photographs of the Petri dishes, it was not 
possible to compare the two experiments. My study of growth 
in agar and focus formation is the first to distinguish a 
transformation-specific activity from interferon's growth 
inhibitory activity.
Firmer data about an effect on the transformed phenotype 
could be acquired by the study of transformation specific 
phenomena which may be independent of growth and thus not 
subject to interference by interferon's growth inhibition. 
Studies on agglutinability of transformed cells were early 
attempts to acquire such data.
4. Agglutinability
The technical problems involved in these experiments were 
never quite overcome. For instance, even though cell sus­
pensions were agitated constantly and the glass walls of the 
vessels were treated with 'repelcote' many cells still attached 
to them. It was very difficult to obtain consistent results, 
not just because of the tendency for cells to attach to the 
glass, but also because an aliquot removed from one part of 
the suspension often contained widely differing concentrations 
of aggregated cells from those in an aliquot removed from 
another part of the suspension.
Although a reduction in agglutinability in interferon-
treated cultures was observed on several occasions, these 
results were very variable, and so should be treated with 
caution. Nevertheless, these studies could be improved and 
firmer data obtained.
5. Adhesiveness
The studies on adhesiveness of cells show quite clearly 
that interferon had no significant effect on this parameter.
The aims of these experiments were to assess interferon's 
effect on cell adhesivity per se, and the ability of the cells 
to respond to serum in the medium (which contains fibronectin). 
Other workers have found that presoaking the substratum with 
serum or fibronectin aids the adhesion of cells which do not 
produce their own fibronectin when a cell suspension is 
subsequently added to the substratum (126, 199). Thus in my 
experiments glass vials were presoaked with PBS or fibronectin, 
and cell suspensions were kept free of serum. Perhaps it 
would have been more consistent with the rest of this study 
had serum been present in or absent from the cell suspension 
and prior soaking of the glass omitted.
6 . Morphology and Fluorescence
a) Experimental technique
(i) Microscopy Microscopical studies can give mis­
leading results due to the large degree of subjective judge­
ment that is required, and the difficulty in making quantitative
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measurements. The problem of subjectivity is especially 
acute at high magnifications where such a limited field of 
view is visible at any one time that it is very easy to select 
fields that are not representative of the culture as a whole. 
Studies with crystal violet-stained cultures were generally 
free of this problem since very low magnification was used 
to provide an overall image of cell and culture morphology.
With fluorescence microscopy, however, it was a problem, 
and there was often a temptation to photograph fields which 
contained especially striking patterns, even though they may 
not have been entirely representative of the culture as a 
whole. Nevertheless this temptation was always avoided and 
the photographs presented in Figures 13 to 16 are representative.
Coupled to this problem of representativeness is the 
problem of quantitation of observations. In Figure 13, 
interferon-treated cells are quite clearly flatter than 
control cells, but the methods that were available for 
assessing what proportion of cells in the entire culture 
responded in that way, and by how much cell spreading was 
increased could give only partial answers. A rough guide, 
used in this study, was to measure the range between minimum 
and maximum lengths of the longest dimension of a large number 
of cells in each culture. A more satisfactory method may 
have been to trace the outlines of cells onto graph paper and 
record the number of squares each cell covered. Such a 
determination might give a more accurate indication of the
extent of increased cell size, but would add little more to 
the obvious observations from Figure 13 that interferon 
treatment has enlarged the cells .
Quantitation could yield useful additonal data when 
high magnification microscopy is used, due to the limited 
field of view.
(ii) FITC-DNase staining Quantitation was attempted 
with FITC-DNase stained cultures of MSV C3H2, where cells 
in different fields were scored for presence or absence of 
microfilament bundles . This was not attempted with MSV MEF2 
since, due to the high background staining, it was quite 
difficult to be certain whether or not cells contained 
microfilament bundles .
Whilst background staining varied between different cell 
types for any one batch of FITC-DNase, the ability to stain 
microfilament bundles also appeared to vary for different 
batches on the same cell type, thus calling into question 
the efficacy of this staining method . In general this 
technique did appear to be a satisfactory alternative to the 
use of antiserum to actin (which had proved difficult to 
prepare due to poor antigenicity of actin), and in a study 
to compare the efficiency of anti-actin, DNase I plus anti­
serum to DNase I, and FITC-DNase I for staining microfilaments, 
Wang and Goldberg (260, 261) found that FITC-DNase I compared 
quite favourably, even with anti-actin. The variability I 
experienced with different batches may have been due to
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contamination with unconjugated FITC, despite gel filtration 
to remove unbound FITC. Free FITC and DNase could be generated 
in a batch of FITC-DNase during storage if the bond were 
unstable at -20°C. This was not assessed, but it is known to 
be unstable at 4°C.
(iii) Anti-fibronectin staining The studies conducted 
on distribution of cell surface fibronectin showed that 
interferon had no effect, unless butyric acid was also present. 
These studies are, however, incomplete since the effects of 
interferon on fibronectin beneath the transformed cells were 
not looked at, only the distribution across the upper cell 
surfaces .
The main difficulty that arose with these experiments 
was that on a number of occasions there was some variation in 
cell density at the time of fixation, which could influence 
differences in fibronectin patterns in a way similar to those 
observed by Mautner and Hynes (177) . They found that the 
intercellular matrix of fibronectin fibres developed and 
became increasingly complex as cultures of normal cells 
approached and attained confluence. Furthermore, multiple 
layers of cells in transformed cultures sometimes made it 
difficult to focus on the interwoven mesh,of fibronectin fibres. 1.
(iv) Quantitation of actin and fibronectin in cells 
Initially, attempts were made to assess not only the total 
quantity of actin present within cells, but also the percentage 
polymerised into microfilaments. This was studied using an
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assay developed by Blikstad et al. (32) which took advantage 
of the fact that monomeric actin would inactivate DNase I 
whereas polymerised actin would not. Unfortunately in my 
hands this assay method would not work reliably. There have 
also been no more studies published which have used this assay.
The polyacrylamide gel electrophoresis subsequently 
employed was able to give an indication of total actin present
in cells, but of course would not distinguish between monomeric
35and polymerised actin. The use of S-methionine meant that 
only proteins containing this amino acid were visible on 
autoradiographs, and the short labelling period (45 minutes) 
tended to measure rate of synthesis of methionine-containing 
proteins rather than the actual amount of protein present.
This may explain the contradiction between Figure 20c and 
Figure 15c (iv) where butyric acid and interferon treatment 
together appeared to have little effect on MSV C3H5 cellular 
fibronectin levels, according to gel electrophoresis, but 
clearly greatly increased its organisation and probably total 
amount present on the cell surfaces, according to immuno­
fluorescence. This apparent conflict could be reconciled if 
butyric acid and interferon had no effect on rate of fibro­
nectin synthesis, but was able to stabilise fibronectin at 
the cell surface, reducing its turnover and loss to the medium.
b) interpretation of microscopy studies The main question 
mark over these morphological studies is whether the observed
effects were a manifestation of a transformation-specific 
property of interferon. Clearly interferon-treated trans­
formed cells looked more normal, especially if butyric acid 
was also present. However, if the morphological changes were 
a reverse transformation, why were the morphologies of C3H10T*5 
and C3H MEF also affected? For C3H10T*j it could be that, 
being an established line, it was already partially transformed, 
i.e. in a pre-malignant state, which was also reversed by 
interferon. This explanation is unsatisfactory for C3H MEF 
cells, however, since these cells were completely normal, 
having been freshly taken from embryos. Pfeffer et al. (201) 
also observed that interferon treatment of human embryonic 
fibroblasts resulted in increased cell spreading and an 
increase in cell volume and surface area. They noted that 
decreased growth rate often correlated with these morphological 
changes, and they drew parallels between interferon-treated 
early passage fibroblasts and late passage senescent fibro­
blasts . They suggested that interferon may render the cells 
more sensitive to a normal growth control mechanism. Certainly 
C3H MEF fibroblasts also increased their size and degree of 
spreading during senescence. The lack of change of NIH MEF 
cell morphology in response to interferon may have been due 
to general insensitivity towards interferon, or perhaps these 
cells may have already entered senescence when treated with 
interferon, rendering them resistant to interferon, or masking 
any effects that interferon might have had. (It is quite
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possible that NIH MEF cells were entering senescence during 
these experiments since secondary cultures were generally 
used, and cells at the third passage clearly were senescent) .
Fuse and Kuwata (78) also linked morphological changes 
with decreased growth rate with their suggestion that 
transformed human RSb cells, treated with interferon changed 
from a fibroblastic to an epithelial morphology due to the 
cells being halted in S phase. The interferon-treated trans­
formed cells in Figure 3d (ii), e (ii) and f (ii) are indeed 
more epithelial in appearance than the controls in Figure 
13 d (i) , e (i) and f (i) , but the explanation proposed by 
Fuse and Kuwata for this morphology change seems unlikely.
They claimed that growth of interferon-treated cells was 
blocked in S phase, but many studies have indicated that at 
least the main block for both normal and transformed cells is 
in G^ (170, 194, 231, 264), though some have found an additional 
block in S+G2 (18, 54, 79, 175) .
Subsequent studies by Pfeffer et ad. (202) found that 
the interferon-treated human fibroblasts showed an increase 
in intracellular microfilament bundles and cell surface 
fibronectin fibres. My studies, on the other hand, indicated 
that interferon had no effect on C3H MEF fibronectin distribution. 
Others (174, 247) have recently found that interferon may 
increase the microfilament bundles in transformed cells, in 
agreement with the results presented here (Figure 14) . Whilst 
it is conceivable that the changes observed by Pfeffer et al.
209
210
(202) were the result of a slower growth rate, this is unlikely 
to be the explanation with the transformed cells, at least 
in this study, due to the limited effect that interferon had 
on growth rate of subconfluent cells (Figure 7) .
The decrease in total cellular actin (Figure 19) and 
fibronectin (Figure 20) upon transformation concur with the 
findings of a number of studies (70, 215, 274), though others 
have found that actin content may remain unaffected by 
transformation (ref 128 p88) . Despite the increases in 
frequency of microfilament bundles, no consistent changes in 
total cellular actin or fibronectin in interferon - or butyrate- 
treated transformed cells were observed. If interferon did 
cause reverse transformation it might be thought that it may 
be accompanied by a return of actin levels towards those 
seen in the CSHlOT^ cells, but this does not necessarily need 
to be so. As already mentioned, the apparent conflict between 
the immunofluorescence results of MSV C3H6 cells treated with 
interferon and butyrate together, and the gel electrophoresis 
results may be reconciled, by proposing that this treatment 
has no effect on rate of synthesis of fibronectin, but decreases 
its turnover.
It is perhaps surprising that though interferon treatment 
appeared to increase the frequency of microfilaments, there 
seemed to be little change in the fibronectin pattern.
Virtually all studies to date that have studied both micro­
filaments and fibronectin have found that changes in one
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result in parallel changes in the other (128, 131, 177, 274). 
Since both appear to be important in controlling cell shape 
and adhesion, the increased cell flattening presumably should 
require increases in levels of extracellular matrix as well 
as the intracellular microfilament system. The lack of change 
in the fibronectin matrix could be explained if another 
protein, such as collagen, were involved in the spreading of 
these cells. One point against this possibility is the 
findings by Chen et al_. (49) that the extracellular matrix of 
chick embryo fibroblasts and myoblasts normally consists 
almost entirely of fibronectin and no collagen. However, 
these studies were not extended to include transformed mouse 
fibroblasts, and the possibility cannot be ruled out that 
synthesis of a new cell surface protein may be activated, 
though the polyacrylamide gels (Figure 18) argue against such 
a possibility.
The fact that the transformed cells studied did possess 
a little fibronectin, may mean that enough matrix existed for 
the cells to spread out to the degree stimulated by butyrate 
or interferon alone, without the need for new matrix to be 
laid down. The increased fibronectin on the surfaces of 
transformed cells under the influence of the two agents to­
gether may have been a response to a demand for the cells to 
flatten to a much greater degree than the existing matrix 
could allow. On the other hand, the increased flattening 
could be due to some cooperative activity between butyric acid
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and interferon, despite their diverse effects on growth rate; 
e.g. increased intercellular communication and contact 
inhibition. This might then enable the transformed cells to 
lay down and retain a more complex matrix.
c) Possible role for interferon in control of growth rate 
by cell shape Some correlations between interferon-induced 
morphological changes and decreased growth rate have already 
been mentioned. The field of morphology and growth control 
has been most closely studied by Folkman and his colleagues 
(72, 73, 41). They proposed that in normal cells growth rate 
and cell shape were closely linked. Thus growth could be 
maintained only if the cells remained flattened. As a result, 
at confluence, as cell crowding increases and each cell 
becomes more rounded, DNA synthesis slows and eventually stops. 
Such control may in part be a result of a limitation of 
intracellular supply of nutrients. Increased flattening of 
serum-starved and senescent cells may be due to increased 
sensitivity to this control process. This growth control 
mechanism may be the same as that proposed by Pfeffer et al. 
(201, 202) to explain the inhibition of growth and increased 
cell size of human fibroblasts by interferon. This too would 
explain the increased flattening of C3H MEF and C3H10T*5 cells. 
In this respect it is interesting that increasing the serum 
supply can induce cell rounding and overcome growth inhibition 
induced as a result of cell crowding, serum starvation,
senescence (though only initially) and interferon treatment, 
suggesting that serum can at least partially ease restrictions 
of the control process.
Folkman and Moscona (73) proposed that the reason that 
transformed cells were able to grow regardless of their shape 
may be due to loss of sensitivity to this control mechanism.
If this is so then the data presented in this thesis go some 
way to suggesting that interferon may at least partially 
recouple growth control and cell shape, thus explaining both 
reduced saturation density and cell flattening. On the other 
hand it is conceivable that interferon could impose a sub­
stitute control mechanism to compensate for the breakdown of 
the normal process .
My data would also suggest that loss of sensitivity to 
this growth control mechanism may not correlate fully with MSV 
transformation. For instance, MSV C3H2 cells appeared to 
retain the control for several passages after transformation 
(Figure 7), while C3HlOT*s started to lose this sensitivity at 
later passages (Figure 8). These two examples also clearly 
illustrate how interferon's effect changed depending on 
whether or not they were sensitive to growth control.
Recently Brouty-Boye et al. (40, 41) were able to 
stimulate transformed C3H10T** cells (transformed by X-irradi- 
ation) to revert to the normal phenotype by prolonged culturing 
at very low density on plastic on which they were able to 
maintain a well-spread form. These revertants also showed
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morphology-linked growth control as demonstrated by growth 
on various thicknesses of poly(HEMA) (41). These experiments 
raise the possibility that prolonged interferon treatment of 
transformed cells, which show increased flattening as a 
response to interferon, may eventually result in formation of 
stable transformation revertants. This has, in fact, been 
shown to be the case by Chany and Vignal (48) who found that 
interferon treatment for 200 passages of a producer clone of 
MSV-transformed BALB/c 3T3 cells eventually resulted in the 
formation of stable revertants. It is possible, however, 
that such an effect may have been due, at least partly, to an 
antiviral activity.
7. Effects of Interferon on p21 Levels
a) Experimental techniques The experiments to measure levels 
of intracellular p2 1, the putative transforming protein of 
KiSV, suggest that interferon treatment might have lowered 
them somewhat, by degrees roughly in line with the observed 
relative sensitivities of each transformed clone towards inter­
feron. However, the techniques used to quantitate the amount 
of p21 in gel bands are subject to so many variables that it 
would be difficult to draw firm conclusion from changes which 
were after all, relatively small. Such variables include the 
losses during the preparation of cell extracts, accuracy of 
locating and cutting out the p21 protein on the gel, the 
efficiency with which the gel scintillant solubolised the
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protein, the variability of methionine and total protein 
content of control and interferon-treated cultures, and the 
variability of amounts of proteins 1 , 2 and 3 (with which p21 
was compared) in control and interferon-treated cultures.
The variability of total protein was partly overcome by 
relating the cpm of p21 to the total protein per culture dish 
as determined by the Lowry assay. However, perhaps a more 
meaningful comparison may have been to relate the p21 cpm to 
the total protein content of the number of cells applied to 
the gel.
b) Relevance to other studies It has been proposed that 
S2TCpp60 of Rous Sarcoma Virus may transform cells by acting 
directly on the cytoskeleton (66, 178, 179) or some cell
S JTCsurface components (129, 154) . Indeed since pp60 is now
known to be concentrated in the plasma membrane (129), it
raises the possibility that it may be ideally located to
somehow induce the severance of the putative links between
intracellular microfilaments and extracellular fibronectin.
One possible means may be to activate a proteolytic enzyme
by phosphorylation. This could cause the disaggregation of
the microfilaments and shedding of the fibronectin, resulting
in at least some properties of the transformed phenotype
srcbecoming manifest. In additon, or alternatively, pp60 's 
location may alter in some other way cellular communications 
between the internal and external environments, which may 
hinder growth control, for instance. The cellular equivalent
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. sarc . . . .ppbO , which is produced in normal cells in much lower 
quantities than is pp60Src in transformed cells, is thought 
to be a normal growth regulator (see Introduction), so it may 
well be that large amounts of pp60Src may upset growth control. 
It is much less clear how the cellular activities and location 
of p21 of Kirsten Sarcoma Virus-transformed cells compare wtih 
those of pp60SrC (89), nor even if it is actually the trans­
forming protein of KiSV and HaSV. If p21 is the transforming 
protein, then reverse transformation may be induced by inter­
feron by a number of effects on it. The data presented in 
these experiments indicate that interferon probably did not 
inhibit the synthesis of p21, but it may still block its 
activity or have some effect on the target of p21 activity, 
e.g. growth control.
Ill. General Conclusions
The aim of this thesis was to establish whether or not 
interferon could revert the phenotype of transformed cells 
towards more normal behaviour. Of the data presented no 
single experiment has proved the existence of such a reverse 
transformation activity for interferon. However, overall the 
evidence argues very strongly in its favour (118) . The 
strongest evidence comes from the studies on focus formation 
and growth in agar. Interferon clearly inhibited these trans^ 
formation-specific phenomena to a much greater degree than
the antiproliferative activity inhibited cloning in liquid 
media.
The growth curves (Figure 7) provide slightly less 
convincing evidence since other explanations for the reduced 
saturation density of transformed cultures were possible. 
However, increased density dependent growth control is still 
the most likely explanation.
The morphological studies showed that interferon treatment 
did increase cell spreading, and could instigate at least a 
partial restoration of the microfilament bundles of transformed 
cells. These observations are consistent with reversion of 
the transformed phenotype, though since C3H MEF cells also 
spread out further, there must be some doubt.
There is evidence that growth rate and cell morphologyl
are closely linked in normal cells by a common control mechanism 
from which transformed cells may have escaped. Interferon’s 
effect on normal cells may be to increase their sensitivity 
to this regulatory mechanism, perhaps in a similar way to 
serum starvation, density dependent growth control and sen­
escence. Its effects on transformed cells may be to reimpose 
this control mechanism, so that growth rate and morphology 
are once again linked. If this is so, then interferon’s growth 
inhibitory activity and reverse transformation activity may 
not be so very different. The former would make normal cells 
more sensitive to the control, and the latter reimpose that 
control on transformed cells.
How interferon might exert this effect on transformed 
cells is not known. It appears that, in these KiSV-transformed 
cells at least, it does not act by inhibiting the synthesis 
of the putative transforming protein, p2 1 .
Obviously these proposals must be backed up by firmer 
experimental data, for instance by conducting studies into 
interferon's effects on growth of different shaped cells on 
poly(HEMA), as described by Folkman and Moscona (73).
Further data to characterise the reverse transformation 
activity could be obtained by studies on phenomena which are 
not growth-related, such as secretion of proteases (note the 
inhibition of secretion of plasminogen activator (223) ) and 
other transformation-specific proteins (8 8 , 226). The 
preliminary studies on agglutinability conducted should also 
be improved and extended.
Of more immediate significance to clinical application 
are the questions of just what degree of reversion may be 
possible, and how stable it may be after cessation of a pro­
longed interferon treatment.
Studies over the past few years established that inter­
feron probably could exert its antitumour activity in vivo 
by two mechanisms - firstly by a direct effect that inhibited 
the growth of the tumour cells, and secondly by an indirect 
effect which stimulated the activity of the immune system, 
particularly macrophages, T-lymphocytes and Natural Killer 
cells (84,94, 103, 105, 112, 114, 183, 184) . A number of studies
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have been undertaken to determine whether one of these 
activities in general plays the dominant role in vivo (93,
103, 105, 246, 281) . Most experiments that have studied the 
effects on interferon on the growth of tumour and transformed 
cells, both in vivo, and iji vitro, have considered that only 
the antiproliferative activity is responsible for inhibiting 
tumour and transformed cells' growth (8 6 , 151, 190, 194, 201, 
254) . The experiments conducted in this project have shown, 
however, that interferon can prevent growth of transformed 
cells by an activity which reverts the behaviour of the cells 
towards a more normal phenotype.
The identification of this third possible antitumour 
mechanism underlines the diversity of interferon's metabolic 
activities, and increases the likelihood that a direct effect 
on tumour cell behaviour plays an important role in interferon's 
antitumour activity. Thus, this project has increased our 
understanding of the way in which interferon exerts some of 
its cellular effects, and has greatly strengthened interferon's 
position as a potentially powerful antitumour agent.
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